| Ident. | Authors (with country if any) | Title |
|---|
| 000577 |
Julie Messier [Canada] ; Sergei Adamovich [États-Unis] ; David Jack [États-Unis] ; Wayne Hening [États-Unis] ; Jacob Sage [États-Unis] ; Howard Poizner [États-Unis] | Visuomotor learning in immersive 3D virtual reality in Parkinson's disease and in aging |
| 000578 |
Asha Kishore [Canada] ; Alberto J. Espay [Canada] ; Connie Marras [Canada] ; Thamer Al-Khairalla [Canada] ; Tamara Arenovich [Canada] ; Abena Asante [Canada] ; Janis Miyasaki [Canada] ; Anthony E. Lang [Canada] | Unilateral versus bilateral tasks in early asymmetric Parkinson's disease : Differential effects on bradykinesia |
| 000579 |
Joseph Jankovic [États-Unis] ; Ray L. Watts [États-Unis] ; Wayne Martin [Canada] ; Babak Boroojerdi [États-Unis] | Transdermal rotigotine : Double-blind, placebo-controlled trial in parkinson disease |
| 000580 |
Edith G. Mcgeer [Canada] ; Patrick L. Mcgeer [Canada] | The role of anti-inflammatory agents in Parkinson's disease |
| 000581 |
Edith G. Mcgeer [Canada] ; Patrick L. Mcgeer [Canada] | The role of anti-inflammatory agents in Parkinson's disease |
| 000582 |
Anthony E. Lang [Canada] | The progression of Parkinson disease : A hypothesis |
| 000584 |
Sarah Lemieux [Canada] ; Mehrdad Ghassemi [Canada] ; Mandar Jog [Canada] ; Roderick Edwards [Canada] ; Christian Duval [Canada] | The influence of levodopa-induced dyskinesias on manual tracking in patients with Parkinson's disease |
| 000585 |
B. Ravina [États-Unis] ; R. Camicioli [Canada] ; P. G. Como [États-Unis] ; L. Marsh [États-Unis] ; Joseph Jankovic [États-Unis] ; D. Weintraub [États-Unis] ; J. Elm [États-Unis] | The impact of depressive symptoms in early Parkinson disease |
| 000586 |
Philippe Huot [Canada] ; Martin Levesque [Canada] ; André Parent [Canada] | The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea |
| 000587 |
Irene Litvan [États-Unis] ; Marie-Francoise Chesselet [États-Unis] ; Thomas Gasser [Allemagne] ; Donato A. Di Monte [États-Unis] ; Davis Jr Parker [États-Unis] ; Theo Hagg [États-Unis] ; John Hardy [États-Unis] ; Peter Jenner [Royaume-Uni] ; Richard H. Myers [États-Unis] ; Donald Price [États-Unis] ; Mark Hallett [États-Unis] ; William J. Langston [États-Unis] ; Anthony E. Lang [Canada] ; Glenda Halliday [Australie] ; Walter Rocca [États-Unis] ; Charles Duyckaerts [France] ; Dennis W. Dickson [États-Unis] ; Yoav Ben-Shlomo [Royaume-Uni] ; Christopher G. Goetz [États-Unis] ; Eldad Melamed [Israël] | The etiopathogenesis of parkinson disease and suggestions for future research. Part II |
| 000588 |
Irene Litvan [États-Unis] ; Glenda Halliday [Australie] ; Mark Hallett [États-Unis] ; Christopher G. Goetz [États-Unis] ; Walter Rocca [États-Unis] ; Charles Duyckaerts [France] ; Yoav Ben-Shlomo [Royaume-Uni] ; Dennis W. Dickson [États-Unis] ; Anthony E. Lang [Canada] ; Marie-Francoise Chesselet [États-Unis] ; William J. Langston [États-Unis] ; Donato A. Di Monte [États-Unis] ; Thomas Gasser [Allemagne] ; Theo Hagg [États-Unis] ; John Hardy [États-Unis] ; Peter Jenner [Royaume-Uni] ; Eldad Melamed [Israël] ; Richard H. Myers [États-Unis] ; Davis Jr Parker [États-Unis] ; Donald L. Price [États-Unis] | The etiopathogenesis of parkinson disease and suggestions for future research. Part I |
| 000589 |
Brigitte Stemmer [Canada] ; Sidney J. Segalowitz [Canada] ; Jane Dywan [Canada] ; Michel Panisset [Canada] ; Calvin Melmed [Canada] | The error negativity in nonmedicated and medicated patients with Parkinson's disease |
| 000591 |
Moigan Hodaie [Canada] ; Joseph S. Neimat [États-Unis] ; Andres M. Lozano [Canada] ; Erik C. Parker ; Patrick J. Kelly ; Philip A. Starr ; Julie G. Pilitsis ; Roy A. E. Bakay | The dopaminergic nigrostriatal system and Parkinson's disease : Molecular events in development, disease, and cell death, and new therapeutic strategies. Commentary |
| 000593 |
M. M. Lewis [États-Unis] ; C. G. Slagle [États-Unis] ; A. B. Smith [États-Unis] ; Y. Truong [États-Unis] ; P. Bai [États-Unis] ; M. J. Mckeown [Canada] ; R. B. Mailman [États-Unis] ; A. Belger [États-Unis] ; X. Huang [États-Unis] | Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries |
| 000594 |
Mélanie Bourque [Canada] ; BIN LIU [États-Unis] ; Dean E. Dluzen [États-Unis] ; Therese Di Paolo [Canada] | Tamoxifen protects male mice nigrostriatal dopamine against methamphetamine-induced toxicity |
| 000595 |
Brian N. Mathur [États-Unis] ; M. Diana Neely [États-Unis] ; Melanie Dyllick-Brenzinger [Canada] ; Anurag Tandon [Canada] ; Ariel Y. Deutch [États-Unis] | Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration |
| 000596 |
Brian N. Mathur [États-Unis] ; M. Diana Neely [États-Unis] ; Melanie Dyllick-Brenzinger [Canada] ; Anurag Tandon [Canada] ; Ariel Y. Deutch [États-Unis] | Systemic administration of a proteasome inhibitor does not cause nigrostriatal dopamine degeneration |
| 000597 |
A. Sailer [Canada, Suède] ; D. I. Cunic [Canada] ; G. O. Paradiso [Canada] ; C. A. Gunraj [Canada] ; A. Wagle-Shukla [Canada] ; E. Moro [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] ; R. Chen [Canada] | Subthalamic nucleus stimulation modulates afferent inhibition in Parkinson disease |
| 000599 |
Penelope J. Hallett [États-Unis] ; J. M. Brotchie [Canada] | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia |
| 000601 |
Dominique Guehl [France] ; Roderick Edwards [Canada] ; Emmanuel Cuny [France] ; Pierre Burbaud [France] ; Alain Rougier [France] ; Julien Modolo [France] ; Anne Beuter [France] | Statistical determination of the optimal subthalamic nucleus stimulation site in patients with Parkinson disease |
| 000603 |
Jennifer E. Tobin [États-Unis] ; JING CUI [États-Unis] ; Jemma B. Wilk [États-Unis] ; Jeanne C. Latourelle [États-Unis] ; Jason M. Laramie [États-Unis] ; Ann C. Mckee [États-Unis] ; Mark Guttman [Canada] ; Samer Karamohamed [États-Unis] ; Anita L. Destefano [États-Unis] ; Richard H. Myers [États-Unis] | Sepiapterin reductase expression is increased in Parkinson's disease brain tissue |
| 000604 |
A. Jon Stoessl [Canada] ; Michael G. Kaplitt [États-Unis] ; Andrew Feigin [États-Unis] ; Chengke Tang [États-Unis] ; Helen L. Fitzsimons ; Paul Mattis [États-Unis] ; Patricia A. Lawlor [Nouvelle-Zélande] ; Ross J. Bland ; Deborah Young [Nouvelle-Zélande] ; Kristin Strybing [États-Unis] ; David Eidelberg [États-Unis] ; Matthew J. During [États-Unis, Nouvelle-Zélande] | Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease : an open label, phase I trial. Commentary |
| 000605 |
Adrian P. Fawcett [Canada] ; Daniel Cunic [Canada] ; Clement Hamani [Canada] ; Mojgan Hodaie [Canada] ; Andres M. Lozano [Canada] ; Robert Chen [Canada] ; William D. Hutchison [Canada] | Saccade-related potentials recorded from human subthalamic nucleus |
| 000607 |
S. Wang [Royaume-Uni] ; Y. Chen [États-Unis] ; M. Ding [États-Unis] ; J. Feng [Royaume-Uni] ; J. F. Stein [Royaume-Uni] ; T. Z. Aziz [Royaume-Uni] ; X. Liu [Royaume-Uni] | Revealing the dynamic causal interdependence between neural and muscular signals in Parkinsonian tremor |
| 000608 |
Ana Djarmati [Allemagne] ; Miodrag Guzvic [Allemagne, Serbie] ; Anne Grünewald [Allemagne] ; Anthony E. Lang [Canada] ; Peter P. Pramstaller [Italie] ; David K. Simon [États-Unis] ; Angela M. Kaindl [Allemagne] ; Peter Vieregge [Allemagne] ; Anders O. H. Nygren [Pays-Bas] ; Christian Beetz [Allemagne] ; Katja Hedrich [Allemagne] ; Christine Klein [Allemagne] | Rapid and reliable detection of exon rearrangements in various movement disorders genes by multiplex ligation-dependent probe amplification |
| 000609 |
R. L. Watts [États-Unis] ; Joseph Jankovic [États-Unis] ; C. Waters [États-Unis] ; A. Rajput [Canada] ; B. Boroojerdi [Allemagne] ; J. Rao [États-Unis] | Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease |
| 000611 |
Michelle R. Ciucci [États-Unis] ; Sean T. Ma [États-Unis] ; Cynthia Fox [États-Unis] ; Jacqueline R. Kane [États-Unis] ; Lorraine O. Ramig [États-Unis] ; Timothy Schallert [États-Unis] | Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol : A preliminary study |
| 000612 |
Janis M. Miyasaki [Canada] ; Khalid Al Hassan [Canada] ; Anthony E. Lang [Canada] ; Valerie Voon [Canada] | Punding prevalence in Parkinson's disease |
| 000614 |
Anne M. Landau [Canada] ; Edouard Kouassi [Canada] ; Rosmarie Siegrist-Johnstone [Canada] ; Julie Desbarats [Canada] | Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle |
| 000618 |
Lesley A. Brown [Canada] ; Jon B. Doan [Canada] ; Ian Q. Whishaw [Canada] ; Oksana Suchowersky [Canada] | Parkinsonian deficits in context-dependent regulation of standing postural control |
| 000619 |
Nikolaos Yiannakoulias [Canada] ; Donald P. Schopflocher [Canada] ; Sharon A. Warren [Canada] ; Lawrence W. Svenson [Canada] | Parkinson's disease, multiple sclerosis and changes of residence in Alberta |
| 000621 |
Daniel Levesque [Canada] ; Claude Rouillard [Canada] | Nur77 and retinoid X receptors : crucial factors in dopamine-related neuroadaptation |
| 000623 |
Rohita Sharma [Canada] ; Catherine R. Mcmillan [Canada] ; Lennard P. Niles [Canada] | Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease |
| 000625 |
Christopher G. Goetz [États-Unis] ; Stanley Fahn [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Werner Poewe [Autriche] ; Cristina Sampaio [Portugal] ; Glenn T. Stebbins [États-Unis] ; Matthew B. Stern [États-Unis] ; Barbara C. Tilley [États-Unis] ; Richard Dodel [Allemagne] ; Bruno Dubois [France] ; Robert Holloway [États-Unis] ; Joseph Jankovic [États-Unis] ; Jaime Kulisevsky [Espagne] ; Anthony E. Lang [Canada] ; Andrew Lees [Royaume-Uni] ; Sue Leurgans [États-Unis] ; Peter A. Lewitt [États-Unis] ; David Nyenhuis [États-Unis] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Anette Schrag [Royaume-Uni] ; Jeanne A. Teresi [États-Unis] ; Jacobus J. Van Hilten [Pays-Bas] ; Nancy Lapelle [États-Unis] | Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS) : Process, format, and clinimetric testing plan |
| 000626 |
Alexandre Berney [Canada, Suisse] ; Michel Panisset [Canada] ; Abbas F. Sadikot [Canada] ; Alain Ptito [Canada] ; Alain Dagher [Canada] ; Maria Fraraccio [Canada] ; Ghislaine Savard [Canada] ; Marc Pell [Canada] ; Chawki Benkelfat [Canada] | Mood Stability during Acute Stimulator Challenge in Parkinson's Disease Patients Under Long-Term Treatment with Subthalamic Deep Brain Stimulation |
| 000629 |
Valerie Voon [États-Unis, Canada] ; Susan H. Fox [Canada] | Medication-related impulse control and repetitive behaviors in parkinson disease |
| 000631 |
Richard M. Camicioli [Canada] ; Christopher C. Hanstock [Canada] ; Thomas P. Bouchard [Canada] ; Myrlene Gee [Canada] ; Nancy J. Fisher [Canada] ; W. R. Wayne Martin [Canada] | Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease |
| 000632 |
Jessica M. Castellano [Canada] ; Jody Batrynchuk [Canada] ; Kristine Dolbeare [États-Unis] ; Vaneeta Verma [Canada] ; Amandeep Mann [Canada] ; Kevin J. Skoblenick [Canada] ; Rodney L. Johnson [États-Unis] ; Ram K. Mishra [Canada] | MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats |
| 000633 |
Jessica M. Castellano [Canada] ; Jody Batrynchuk [Canada] ; Kristine Dolbeare [États-Unis] ; Vaneeta Verma [Canada] ; Amandeep Mann [Canada] ; Kevin J. Skoblenick [Canada] ; Rodney L. Johnson [États-Unis] ; Ram K. Mishra [Canada] | MIF-1 and its peptidomimetic analogs attenuate haloperidol-induced vacuous chewing movements and modulate apomorphine-induced rotational behavior in 6-hydroxydopamine-lesioned rats |
| 000634 |
Nicolas Dupre [Canada] ; Jean-Baptiste Riviere [Canada] ; Richard H. Myers [États-Unis] ; Pierre Provencher [Canada] ; Emmanuelle Pourcher [Canada] ; Francois Emond [Canada] ; Guy A. Rouleau [Canada] | Lrrk2 is not a significant cause of parkinson's disease in French-Canadians |
| 000635 |
Panida Piboolnurak [Canada, Thaïlande] ; Anthony E. Lang [Canada] ; Andres M. Lozano [Canada] ; Janis M. Miyasaki [Canada] ; Jean A. Saint-Cyr [Canada] ; Yu-Yan W. Poon [Canada] ; William D. Hutchison [Canada] ; Jonathan O. Dostrovsky [Canada] ; Elena Moro [Canada] | Levodopa response in long-term bilateral Subthalamic stimulation for Parkinson's disease |
| 000636 |
J. M. B. Wilson [Canada] ; C. A. Shaw [Canada] | Late appearance of glutamate transporter defects in a murine model of ALS-parkinsonism dementia complex |
| 000637 |
D. A. Grimes [Canada] ; L. Racacho [Canada] ; F. Han [Canada] ; M. Panisset [Canada] ; D. E. Bulman [Canada] | LRRK2 screening in a Canadian Parkinson's disease cohort |
| 000639 |
Ronald B. Postuma [Canada] ; Christina Wolfson [Canada] ; Ali Rajput [Canada] ; A. Jon Stoessl [Canada] ; W. R. Wayne Martin [Canada] ; Oksana Suchowersky [Canada] ; Sylvain Chouinard [Canada] ; Michel Panisset [Canada] ; Mandar S. Jog [Royaume-Uni] ; David A. Grimes [Canada] ; Connie Marras [Canada] ; Anthony E. Lang [Canada] | Is there seasonal variation in risk of Parkinson's disease? |
| 000641 |
Cindy M. De Frias [Canada] ; Roger A. Dixon [Canada] ; Nancy Fisher [Canada] ; Richard Camicioli [Canada] | Intraindividual variability in neurocognitive speed: A comparison of Parkinson's disease and normal older adults |
| 000642 |
A. Y. Alemdar [Canada] ; D. Sadi [Canada] ; V. Mcalister [Canada] ; I. Mendez [Canada] | Intracerebral Co-transplantation of liposomal tacrolimus improves xenograft survival and reduces graft rejection in the hemiparkinsonian rat |
| 000643 |
Jie-Yuan Li [Canada, Taïwan] ; Alberto J. Espay [Canada] ; Carolyn A. Gunraj [Canada] ; Pramod K. Pal [Canada] ; Danny I. Cunic [Canada] ; Anthony E. Lang [Canada] ; Robert Chen [Canada] | Interhemispheric and ipsilateral connections in Parkinson's disease : Relation to mirror movements |
| 000645 |
Henri Cohen [Canada] ; Emmanuelle Pourcher [Canada] | Intact encoding, impaired consolidation in procedural learning in Parkinson's disease |
| 000647 |
Ivan L. Cepeda [Canada] ; Joseph Flores [Canada] ; Michael L. Cornfeldt [États-Unis] ; John R. O'Kusky [Canada] ; Doris J. Doudet [Canada] | Human retinal pigment epithelial cell implants ameliorate motor deficits in two rat models of parkinson disease |
| 000650 |
Valerie Voon [États-Unis] ; Teri Thomsen [Canada] ; Janis M. Miyasaki [Canada] ; Minella De Souza [Canada] ; Ariel Shafro [Canada] ; Susan H. Fox [Canada] ; Sarah Duff-Canning [Canada] ; Anthony E. Lang [Canada] ; Mateusz Zurowski [Canada] | Factors associated with dopaminergic drug-related pathological gambling in parkinson disease |
| 000652 |
Laura Monetta [Canada] ; Marc D. Pell [Canada] | Effects of verbal working memory deficits on metaphor comprehension in patients with Parkinson's disease |
| 000654 |
Philippe Huot [Canada] ; André Parent [Canada] | Dopaminergic neurons intrinsic to the striatum |
| 000655 |
Quincy J. Almeida [Canada] ; James S. Frank [Canada] ; Eric A. Roy [Canada] ; Aftab E. Patla [Canada] ; Mandar S. Jog [Canada] | Dopaminergic modulation of timing control and variability in the gait of parkinson's disease |
| 000662 |
Sylvie Raoul [France] ; Dominique Leduc [France] ; Thomas Vegas [France] ; Paul Sauleau [France] ; Andres M. Lozano [Canada] ; Marc Verin [France] ; Philippe Damier [France] ; Youenn Lajat [France] | Deep brain stimulation electrodes used for staged lesion within the basal ganglia: experimental studies for parameter validation : Laboratory investigation |
| 000663 |
Oury Monchi [Canada] ; Michael Petrides [Canada] ; Beatriz Mejia-Constain [Canada] ; Antonio P. Strafella [Canada] | Cortical activity in Parkinson's disease during executive processing depends on striatal involvement |
| 000664 |
Richard Camicioli [Canada] ; Serge Gauthier [Canada] | Clinical trials in Parkinson's disease dementia and dementia with lewy bodies |
| 000666 |
Murat Emre [Turquie] ; Dag Aarsland [Norvège] ; Richard Brown [Royaume-Uni] ; David J. Burn [Royaume-Uni] ; Charles Duyckaerts [France] ; Yoshikino Mizuno [Japon] ; Gerald Anthony Broe [Australie] ; Jeffrey Cummings [États-Unis] ; Dennis W. Dickson [États-Unis] ; Serge Gauthier [Canada] ; Jennifer Goldman [États-Unis] ; Christopher Goetz [États-Unis] ; Amos Korczyn [Israël] ; Andrew Lees [Royaume-Uni] ; Richard Levy [France] ; Irene Litvan [États-Unis] ; Ian Mckeith [Royaume-Uni] ; Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; Christina Sampaio [Portugal] ; Eduardo Tolosa [Espagne] ; Bruno Dubois [France] | Clinical diagnostic criteria for dementia associated with parkinson's disease |
| 000668 |
Joseph Flores [Canada] ; Ivan L. Cepeda [Canada] ; Michael L. Comfeldt [États-Unis] ; John R. O'Kusky [Canada] ; Doris J. Doudet [Canada] | Characterization and survival of long-term implants of human retinal pigment epithelial cells attached to gelatin microcarriers in a model of parkinson disease |
| 000671 |
Alessandro Stefani [Italie] ; Andres M. Lozano [Canada] ; Antonella Peppe [Italie] ; Paolo Stanzione [Italie] ; Salvatore Galati [Italie] ; Domenicantonio Tropepi [Italie] ; Mariangela Pierantozzi [Italie] ; Livia Brusa [Italie] ; Eugenio Scarnati [Italie] ; Paolo Mazzone [Italie] | Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease |
| 000672 |
Hernish J. Acharya [Canada] ; Thomas P. Bouchard [Canada] ; Derek J. Emery [Canada] ; Richard M. Camicioli [Canada] | Axial signs and magnetic resonance imaging correlates in Parkinson's disease |
| 000673 |
XUEMEI HUANG [États-Unis] ; Yueh Z. Lee [États-Unis] ; Martin Mckeown [Canada] ; Guido Gerig [États-Unis] ; HONGBIN GU [États-Unis] ; WEILI LIN [États-Unis] ; Mechelle M. Lewis [États-Unis] ; Sutapa Ford [États-Unis] ; Alexander I. Troster [États-Unis] ; Daniel R. Weinberger [États-Unis] ; Martin Styner [États-Unis] | Asymmetrical ventricular enlargement in Parkinson's disease |
| 000674 |
Connie Marras [Canada] ; Alexander Kopp [Canada] ; FENG QIU [Canada] ; Anthony E. Lang [Canada] ; Kathy Sykora [Canada] ; Kenneth I. Shulman [Canada] ; Paula A. Rochon [Canada] | Antipsychotic use in older adults with parkinson's disease |
| 000675 |
Valerie Voon [États-Unis, Canada] ; Susan Fox [Canada] ; Tracy R. Butler [États-Unis] ; Anthony E. Lang [Canada] | Antidepressants and psychosis in Parkinson disease: a case series |
| 000676 |
Murray M. Finkelstein [Canada] ; Michael Jerrett [États-Unis] | A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities |
| 000680 |
James Scozzafava [Canada] ; Jennifer Takahashi [Canada] ; Wendy Johnston [Canada] ; Lakshmi Puttagunta [Canada] ; W. R. Wayne Martin [Canada] | Valvular heart disease in pergolide- treated Parkinson's disease |
| 000681 |
Yuri Ishida [Japon] ; Atsushi Nagai [Japon] ; Shotai Kobayashi [Japon] ; Seung U. Kim [Corée du Sud, Canada] | Upregulation of protease-activated receptor-1 in astrocytes in parkinson disease : Astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase |
| 000682 |
R. H. Kim [Canada] ; T. W. Mak [Canada] | Tumours and tremors : how PTEN regulation underlies both |
| 000683 |
Susan H. Fox [Canada] ; Anthony E. Lang [Canada] ; Jonathan M. Brotchie [Canada] | Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies : Keys to success and roads to failure |
| 000684 |
David A. Grimes [Canada] ; FABIN HAN [Canada] ; Michel Panisset [Canada] ; Lemuel Racacho [Canada] ; FENGXIA XIAO [Canada] ; RUOBING ZOU [Canada] ; Kelly Westaff [Canada] ; Dennis E. Bulman [Canada] | Translated mutation in the Nurr1 gene as a cause for Parkinson's disease |
| 000686 |
Ysbrand D. Van Der Werf [Canada] ; Abbas F. Sadikot [Canada] ; Antonio P. Strafella [Canada] ; Tomas Paus [Canada, Royaume-Uni] | The neural response to transcranial magnetic stimulation of the human motor cortex. II. Thalamocortical contributions |
| 000687 |
Clement Hamani [Canada] ; Jonathan O. Dostrovsky [Canada] ; Andres M. Lozano [Canada] ; Alon Mogilner ; Ali R. Rezai ; Patrick J. Kelly ; Chihiro Ohye | The motor thalamus in neurosurgery. Commentary |
| 000688 |
Christian Duval [Canada] ; Michel Panisset [Canada] ; Antonio P. Strafella [Canada] ; Abbas F. Sadikot [Canada] | The impact of ventrolateral thalamotomy on tremor and voluntary motor behavior in patients with Parkinson's disease |
| 000689 |
Marc D. Pell [Canada] ; Henry S. Cheang [Canada] ; Carol L. Leonard [Canada] | The impact of parkinson's disease on vocal-prosodic communication from the perspective of listeners |
| 000690 |
Martine Saint-Pierre [Canada] ; Marie-Eve Tremblay [Canada] ; Attila Sik [Canada] ; Robert E. Gross [États-Unis] ; Francesca Cicchetti [Canada] | Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats |
| 000691 |
Muhammad A. Chishti [Arabie saoudite] ; Saeed Bohlega [Arabie saoudite] ; Maqbool Ahmed [Arabie saoudite] ; Arslan Loualich [Arabie saoudite] ; Pamela Carroll [Arabie saoudite] ; Christine Sato [Canada] ; Peter St George-Hyslop [Canada] ; David Westaway [Canada] ; Ekaterina Rogaeva [Canada] | T313M PINK1 mutation in an extended highly consanguineous saudi family with early-onset parkinson disease |
| 000693 |
Galit Kleiner-Fisman [États-Unis] ; Jan Herzog [Allemagne] ; David N. Fisman [États-Unis] ; Filippo Tamma [Italie] ; Kelly E. Lyons [États-Unis] ; Rajesh Pahwa [États-Unis] ; Anthony E. Lang [Canada] ; Günther Deuschl [Allemagne] | Subthalamic nucleus deep brain stimulation : Summary and meta-analysis of outcomes |
| 000694 |
Pepijn Van Den Munckhof [Canada] ; Francois Gilbert [Canada] ; Michel Chamberland [Canada] ; Daniel Levesque [Canada] ; Jacques Drouin [Canada] | Striatal neuroadaptation and rescue of locomotor deficit by L-dopa in aphakia mice, a model of parkinson's disease |
| 000695 |
Evelyn F. Field [Canada] ; Gerlinde A. Metz [Canada] ; Sergio M. Pellis [Canada] ; Ian Q. Whishaw [Canada] | Sexually dimorphic postural adjustments during vertical behaviour are altered in a unilateral 6-OHDA rat model of Parkinson's disease |
| 000697 |
J. Miklossy [Canada] ; D. D. Doudet [Canada] ; C. Schwab [Canada] ; S. Yu [Canada] ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Role of ICAM-1 in persisting inflammation in parkinson disease and MPTP monkeys |
| 000699 |
Anthony E. Lang [Canada] ; Steven Gill [Royaume-Uni] ; Nik K. Patel [Royaume-Uni] ; Andres Lozano [Canada] ; John G. Nutt [États-Unis] ; Richard Penn [États-Unis] ; David J. Brooks [Royaume-Uni] ; Gary Hotton [Royaume-Uni] ; Elena Moro [Canada] ; Peter Heywood [Canada] ; Matthew A. Brodsky [États-Unis] ; Kim Burchiel [États-Unis] ; Patrick Kelly [États-Unis] ; Arif Dalvi [États-Unis] ; Burton Scott [États-Unis] ; Mark Stacy [États-Unis] ; Dennis Turner [États-Unis] ; V. G. Frederich Wooten [États-Unis] ; William J. Elias [Canada] ; Edward R. Laws [États-Unis] ; Vijay Dhawan [États-Unis] ; A. Jon Stoessl [Canada] ; James Matcham [Royaume-Uni] ; Robert J. Coffey [États-Unis] ; Michael Traub [États-Unis] | Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease |
| 000700 |
V. Voon [États-Unis, Canada] ; K. Hassan [Canada] ; M. Zurowski [Canada] ; S. Duff-Canning [Canada] ; M. De Souza [Canada] ; S. Fox [Canada] ; A. E. Lang [Canada] ; J. Miyasaki [Canada] | Prospective prevalence of pathologic gambling and medication association in Parkinson disease |
| 000701 |
Marc Morissette [Canada] ; Mehdi Dridi [Canada] ; Frédéric Calon [Canada] ; Abdallah Hadj Tahar [Canada] ; Leonard T. Meltzer [États-Unis] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in Parkinsonian monkeys : Implication of preproenkephalin |
| 000702 |
V. Voon [États-Unis, Canada] ; K. Hassan [Canada] ; M. Zurowski [Canada] ; M. De Souza [Canada] ; T. Thomsen [Canada] ; S. Fox [Canada] ; A. E. Lang [Canada] ; J. Miyasaki [Canada] | Prevalence of repetitive and reward-seeking behaviors in Parkinson disease |
| 000703 |
R. Pahwa [États-Unis] ; S. A. Factor [États-Unis] ; K. E. Lyons [États-Unis] ; W. G. Ondo [États-Unis] ; G. Gronseth [États-Unis] ; H. Bronte-Stewart [États-Unis] ; M. Hallett [États-Unis] ; J. Miyasaki [Canada] ; J. Stevens [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter:Treatment of parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology |
| 000704 |
O. Suchowersky [Canada] ; G. Gronseth [États-Unis] ; J. Perlmutter [États-Unis] ; S. Reich [États-Unis] ; T. Zesiewicz [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter:Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology |
| 000706 |
O. Suchowersky [Canada] ; S. Reich [États-Unis] ; J. Perlmutter [États-Unis] ; T. Zesiewicz [États-Unis] ; G. Gronseth [États-Unis] ; W. J. Weiner [États-Unis] | Practice Parameter:Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) : Report of the quality standards subcommittee of the american academy of neurology |
| 000707 |
Ronald B. Postuma [Canada] ; Anthony E. Lang [Canada] ; Jessica Massicotte-Marquez [Canada] ; Jacques Montplaisir [Canada] | Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder |
| 000708 |
Carl Julien [Canada] ; Line Berthiaume [Canada] ; Abdallah Hadj-Tahar [Canada] ; Ali H. Rajput [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] ; Pierre Julien [Canada] ; Frédéric Calon [Canada] | Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys |
| 000709 |
Rohita Sharma [Canada] ; Catherine R. Mcmillan [Canada] ; Catherine C. Tenn [Canada] ; Lennard P. Niles [Canada] | Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease |
| 000710 |
Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada] | Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease |
| 000711 |
Claire Ardouin [France] ; Valerie Voon [Canada] ; Yulia Worbe [France] ; Nehman Abouazar [France] ; Virginie Czernecki [France] ; Hassan Hosseini [France] ; Antoine Pelissolo [France] ; Elena Moro [Canada] ; Eugénie Lhommee [France] ; Anthony E. Lang [Canada] ; Yves Agid [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France] ; Luc Mallet [France] ; Paul Krack [France] | Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation |
| 000712 |
Kaveh M. Koochesfahani [Canada] ; Raul De La Fuente-Fernandez [Canada, Espagne] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Lakshmi N. Yatham [Canada] ; Thomas J. Ruth [Canada] ; Stephan Blinder [Canada] ; A. Jon Stoessl [Canada] | Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients : Positron emission tomographic studies |
| 000713 |
Jon Doan [Canada] ; Ian Q. Whishaw [Canada] ; Sergio M. Pellis [Canada] ; Oksana Suchowersky [Canada] ; Lesley A. Brown [Canada] | Motor deficits in parkinsonian reaching : Dopa-sensitivity influenced by real-world task constraint |
| 000714 |
Francesca Morgante [Canada, Italie] ; Alberto J. Espay [Canada] ; Carolyn Gunraj [Canada] ; Anthony E. Lang [Canada] ; Robert Chen [Canada] | Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias |
| 000717 |
Judith Miklossy [Canada] ; Tetsuaki Arai [Japon] ; Jian-Ping Guo [Canada] ; Andis Klegeris [Canada] ; SHENG YU [Canada] ; Edith G. Mcgeer [Canada] ; Patrick L. Mcgeer [Canada] | LRRK2 expression in normal and pathologic human brain and in human cell lines |
| 000718 |
JUNCHAO TONG [Canada] ; Oleh Hornykiewicz [Autriche] ; Stephen J. Kish [Canada] | Inverse relationship between brain noradrenaline level and dopamine loss in parkinson disease : A possible neuroprotective role for noradrenaline |
| 000719 |
Catherine L. Burton [Canada] ; Esther Strauss [Canada] ; David F. Hultsch [Canada] ; Alex Moll [Canada] ; Michael A. Hunter [Canada] | Intraindividual variability as a marker of neurological dysfunction : A comparison of Alzheimer's disease and Parkinson's disease |
| 000721 |
MEI SUN [États-Unis] ; Jeanne C. Latourelle [États-Unis] ; G. Frederick Wooten [États-Unis] ; Mark F. Low [États-Unis] ; Christine Klein [Allemagne] ; Holly A. Shill [États-Unis] ; Lawrence I. Golbe [États-Unis] ; Margery H. Mark [États-Unis] ; Brad A. Racette [États-Unis] ; Joel S. Perlmutter [États-Unis] ; Abbas Parsian [États-Unis] ; Mark Guttman [Canada] ; Garth Nicholson [Australie] ; GANG XU [États-Unis] ; Jemma B. Wilk [États-Unis] ; Made H. Saint-Hilaire [États-Unis] ; Anita L. Destefano [États-Unis] ; Ranjana Prakash [États-Unis] ; Sally Williamson [États-Unis] ; Oksana Suchowersky [États-Unis] ; Nancy Labelle [États-Unis] ; John H. Growdon [États-Unis] ; Carlos Singer [États-Unis] ; Ray L. Watts [États-Unis] ; Stefano Goldwurm [Italie] ; Gianni Pezzoli [Italie] ; Kenneth B. Baker [États-Unis] ; Peter P. Pramstaller [Italie] ; David J. Burn [Royaume-Uni] ; Patrick F. Chinnery [Royaume-Uni] ; Scott Sherman [États-Unis] ; Peter Vieregge [Allemagne] ; Irene Litvan [États-Unis] ; Tammy Gillis [États-Unis] ; Marcy E. Macdonald [États-Unis] ; Richard H. Myers [États-Unis] ; James F. Gusella [États-Unis] | Influence of heterozygosity for Parkin mutation on onset age in familial parkinson disease : The genepd study |
| 000723 |
Cindy Zadikoff [Canada] ; Ekaterina Rogaeva [Canada] ; Ana Djarmati [Allemagne] ; Christine Sato [Canada] ; Shabnam Salehi-Rad [Canada] ; Peter St. George-Hyslop [Canada] ; Christine Klein [Canada, Allemagne] ; Anthony E. Lang [Canada] | Homozygous and heterozygous PINK1 mutations : Considerations for diagnosis and care of parkinson's disease patients |
| 000724 |
Zoran Todorovic [Serbie] ; Eleonora Dzoljic [Serbie] ; Ivana Novakovic [Serbie] ; Dusko Mirkovic [Serbie] ; Radan Stojanovic [Serbie] ; Zorica Nesic [Serbie] ; Maja Krajinovic [Canada] ; Milica Prostran [Serbie] ; Vladimir Kostic [Serbie] | Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy |
| 000725 |
Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease |
| 000728 |
G. Rasouli [Canada] ; M. Rasouli [Canada] ; F. A. Lenz [États-Unis] ; L. Verhagen [États-Unis] ; D. S. Borrett [Canada] ; H. C. Kwan [Canada] | Fractal characteristics of human parkinsonian neuronal spike trains |
| 000729 |
Patrick S. R. Davidson [Canada] ; David Anaki [Canada] ; Jean A. Saint-Cyr [Canada] ; Tiffany W. Chow [Canada] ; Morris Moscovitch [Canada] | Exploring the recognition memory deficit in Parkinson's disease : estimates of recollection versus familiarity |
| 000730 |
Rodrigo Mercado [Canada] ; Constantine Constantoyannis [Canada] ; Tomasz Mandat [Canada] ; Ajit Kumar [Canada] ; Michael Schulzer [Canada] ; A. Jon Stoessl [Canada] ; Christopher R. Honey [Canada] | Expectation and the placebo effect in parkinson's disease patients with subthalamic nucleus deep brain stimulation |
| 000733 |
Robert E. Gross [États-Unis] ; Paul Krack [France] ; Maria C. Rodriguez-Oroz [Espagne] ; Ali R. Rezai [États-Unis] ; Alim-Louis Benabid [France] | Electrophysiological mapping for the implantation of deep brain stimulators for Parkinson's disease and tremor |
| 000734 |
Andrew R. Willan [Canada] ; Ron Goeree [Canada] ; Eleanor M. Pullenayegum [Canada] ; Christopher Mcburney [États-Unis] ; Gordon Blackhouse [Canada] | Economic evaluation of rivastigmine in patients with parkinson's disease dementia |
| 000738 |
Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni] | Development of dyskinesias in a 5-year trial of ropinirole and L-dopa |
| 000739 |
Andre Machado [États-Unis] ; Ali R. Rezai [États-Unis] ; Brian H. Kopell [États-Unis] ; Robert E. Gross [États-Unis] ; Ashwini D. Sharan [États-Unis] ; Alim-Louis Benabid [France] | Deep brain stimulation for Parkinson's disease : Surgical technique and perioperative management |
| 000740 |
Ali R. Rezai [États-Unis] ; Brian H. Kopell [États-Unis] ; Robert E. Gross [États-Unis] ; Jerrold L. Vitek [États-Unis] ; Ashwini D. Sharan [États-Unis] ; Patricia Limousin [Royaume-Uni] ; Alim-Louis Benabid [France] | Deep brain stimulation for Parkinson's disease : Surgical issues |
| 000741 |
Anthony E. Lang [Canada] ; Jean-Luc Houeto [France] ; Paul Krack [France] ; Cynthia Kubu [États-Unis] ; Kelly E. Lyons [États-Unis] ; Elena Moro [Canada] ; William Ondo [États-Unis] ; Rajesh Pahwa [États-Unis] ; Werner Poewe [Autriche] ; Alexander I. Tröster [États-Unis] ; Ryan Uitti [États-Unis] ; Valerie Voon [Canada, États-Unis] | Deep brain stimulation : Preoperative issues |
| 000742 |
Günther Deuschl [Allemagne] ; Jan Herzog [Allemagne] ; Galit Kleiner-Fisman [États-Unis] ; Cynthia Kubu [États-Unis] ; Andres M. Lozano [Canada] ; Kelly E. Lyons [États-Unis] ; Maria C. Rodriguez-Oroz [Espagne] ; Filippo Tamma [Italie] ; Alexander I. Tröster [États-Unis] ; Jerrold L. Vitek [États-Unis] ; Jens Volkmann [Allemagne] ; Valerie Voon [États-Unis] | Deep brain stimulation : Postoperative issues |
| 000743 |
Valerie Voon [Canada, États-Unis] ; Cynthia Kubu [États-Unis] ; Paul Krack [France] ; Jean-Luc Houeto [France] ; Alexander I. Tröster [États-Unis] | Deep brain stimulation : Neuropsychological and neuropsychiatric issues |
| 000744 |
Todd B. Sherer [États-Unis] ; Brian K. Fiske [États-Unis] ; Clive N. Svendsen [États-Unis] ; Anthony E. Lang [Canada] ; J. William Langston [États-Unis] | Crossroads in GDNF therapy for Parkinson's disease |
| 000747 |
Maryka Quik [États-Unis] ; Neeraja Parameswaran [États-Unis] ; Sarah E. Mccallum [États-Unis] ; Tanuja Bordia [États-Unis] ; SHANSHAN BAO [États-Unis] ; Alison Mccormack [États-Unis] ; Amy Kim [États-Unis] ; Rachel F. Tyndale [Canada] ; J. William Langston [États-Unis] ; Donato A. Di Monte [États-Unis] | Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates |
| 000750 |
Jens Volkmann [Allemagne] ; Elena Moro [Canada] ; Rajesh Pahwa [États-Unis] | Basic algorithms for the programming of deep brain stimulation in Parkinson's disease |
| 000752 |
Brian H. Kopell [États-Unis] ; Ali R. Rezai [États-Unis] ; JIN WOO CHANG [Corée du Sud] ; Jerrold L. Vitek [États-Unis] | Anatomy and physiology of the basal Ganglia : Implications for deep brain stimulation for Parkinson's disease |
| 000757 |
Naomi P. Visanji [Canada] ; Mark J. Millan [France] ; Jonathan M. Brotchie [Canada] | Actions at sites other than D3 receptors mediate the effects of BP897 on L-DOPA-induced hyperactivity in monoamine-depleted rats |
| 000758 |
J. Lewis [États-Unis] ; G. Bench [États-Unis] ; O. Myers [États-Unis] ; B. Tinner [Canada] ; W. Staines [Canada] ; E. Barr [États-Unis] ; K. K. Divine [États-Unis] ; W. Barrington [États-Unis] ; J. Karlsson [États-Unis] | Trigeminal uptake and clearance of inhaled manganese chloride in rats and mice |
| 000760 |
Monty A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Canada] | Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of parkinson's disease |
| 000761 |
B. Ravina [États-Unis] ; D. Eidelberg [États-Unis] ; J. E. Ahlskog [États-Unis] ; R. L. Albin [États-Unis] ; D. J. Brooks [Royaume-Uni] ; M. Carbon [États-Unis] ; V. Dhawan [États-Unis] ; A. Feigin [États-Unis] ; S. Fahn [États-Unis] ; M. Guttman [Canada] ; K. Gwinn-Hardy [États-Unis] ; H. Mcfarland [États-Unis] ; R. Innis [États-Unis] ; R. G. Katz [États-Unis] ; K. Kieburtz [États-Unis] ; S. J. Kish [Canada] ; N. Lange [États-Unis] ; J. W. Langston [États-Unis] ; K. Marek [États-Unis] ; L. Morin [États-Unis] ; C. Moy [États-Unis] ; D. Murphy [États-Unis] ; W. H. Oertel [Allemagne] ; G. Oliver [États-Unis] ; Y. Palesch [États-Unis] ; W. Powers [États-Unis] ; J. Seibyl [États-Unis] ; K. D. Sethi [États-Unis] ; C. W. Shults [États-Unis] ; P. Sheehy [États-Unis] ; A. J. Stoessl [Canada] ; R. Holloway [États-Unis] | The role of radiotracer imaging in Parkinson disease |
| 000763 |
Christian Duval [Canada] ; Antonio P. Strafella [Canada] ; Abbas F. Sadikot [Canada] | The impact of ventrolateral thalamotomy on high-frequency components of tremor |
| 000764 |
Christopher P. Bertram [Canada] ; Martin Lemay [Canada] ; George E. Stelmach [États-Unis] | The effect of Parkinson's disease on the control of multi-segmental coordination |
| 000765 |
C. Marras [Canada] ; M. P. Mcdermott [États-Unis] ; P. A. Rochon [Canada] ; C. M. Tanner [États-Unis] ; G. Naglie [Canada] ; A. Rudolph [États-Unis] ; A. E. Lang [Canada] | Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort |
| 000767 |
Brigitte Gilbert [Canada] ; Louis Bherer [Canada] ; Sylvie Belleville [Canada] ; Sylvain Chouinard [Canada] | Study of verbal working memory in patients with Parkinson's disease |
| 000769 |
Melisa Proulx [Canada] ; Francois P. De Courval [Canada] ; Michael A. Wiseman [Canada] ; Michel Panisset [Canada] | Salivary production in Parkinson's disease |
| 000771 |
Valerie Voon [Canada] ; Jean Saint-Cyr ; Andres M. Lozano ; Elena Moro ; YU YAN POON ; Anthony E. Lang | Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery |
| 000772 |
Anthony E. Lang [Canada] ; Janis Miyasaki [Canada] ; C. Warren Olanow [Canada] ; A. Jon Stoessl [Canada] ; Oksana Suchowersky [Canada] | Progress in clinical neurosciences : A forum on the early management of Parkinson's disease |
| 000774 |
Andrew Nataraj [Canada] ; Ali H. Rajput [Canada] | Parkinson's disease, stroke, and related epidemiology |
| 000775 |
WING LOK AU [Canada] ; John R. Adams [Canada] ; André R. Troiano [Canada] ; A. Jon Stoessl [Canada] | Parkinson's disease : in vivo assessment of disease progression using positron emission tomography |
| 000776 |
Kyle G. Melvin [Canada] ; Jon Doan [Canada] ; Sergio M. Pellis [Canada] ; Lesley Brown [Canada] ; Ian Q. Whishaw [Canada] ; Oksana Suchowersky [Canada] | Pallidal deep brain stimulation and L-dopa do not improve qualitative aspects of skilled reaching in parkinson's disease |
| 000777 |
John R. Adams [Canada] ; Hinke Van Netten [Canada] ; Michael Schulzer [Canada] ; Edwin Mak [Canada] ; Jessamyn Mckenzie [Canada] ; Audrey Strongosky [États-Unis] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; Chong S. Lee [Canada] ; Matthew Farrer [États-Unis] ; Thomas Gasser [Allemagne] ; Ryan J. Uitti [États-Unis] ; Donald B. Calne [Canada] ; Zbigniew K. Wszolek [États-Unis] ; A. Jon Stoessl [Canada] | PET in LRRK2 mutations : comparison to sporadic parkinson's disease and evidence for presymptomatic compensation |
| 000780 |
V. F. Rafuse [Canada] ; P. Soundararajan [Canada] ; C. Leopold [Canada] ; H. A. Robertson [Canada] | Neuroprotective properties of cultured neural progenitor cells are associated with the production of sonic hedgehog |
| 000781 |
F. Han [Canada] ; D. E. Bulman [Canada] ; M. Panisset [Canada] ; D. A. Grimes [Canada] | Neurofilament M gene in a french-canadian population with Parkinson's disease |
| 000782 |
Shawn Hayley [Canada] ; Hymie Anisman [Canada] | Multiple mechanisms of cytokine action in neurodegenerative and psychiatric states: Neurochemical and molecular substrates : The role of cytokines in neurodegeneration and psychiatric conditions: Multiple mechanisms of action |
| 000784 |
Sarah A. Baker [États-Unis] ; Lianne E. Stanford [Canada] ; Richard E. Brown [Canada] ; Theo Hagg [États-Unis] | Maturation but not survival of dopaminergic nigrostriatal neurons is affected in developing and aging BDNF-deficient mice |
| 000786 |
Wiplove Lamba [Canada] ; Wendy Prichett [Canada] ; David Munoz [Canada] ; David S. Park [Canada] ; John M. Woulfe [Canada] | MPTP induces intranuclear rodlet formation in midbrain dopaminergic neurons |
| 000787 |
C. Paisan-Ruiz [États-Unis, Espagne] ; A. E. Lang [Canada] ; T. Kawarai [Canada] ; C. Sato [Canada] ; S. Salehi-Rad [Canada] ; G. K. Fisman [Canada] ; T. Al-Khairallah [Canada] ; P. St George-Hyslop [Canada] ; A. Singleton [États-Unis] ; E. Rogaeva [Canada] | LRRK2 gene in parkinson disease : Mutation analysis and case control association study |
| 000788 |
Edith G. Mcgeer [Canada] ; Andis Klegeris [Canada] ; Patrick L. Mcgeer [Canada] | Inflammation, the complement system and the diseases of aging |
| 000789 |
Anthony O'Hagan [Royaume-Uni] ; Christopher Mccabe [Royaume-Uni] ; Ron Akehurst [Royaume-Uni] ; Alan Brennan [Royaume-Uni] ; Andrew Briggs [Royaume-Uni] ; Karl Claxton [Royaume-Uni] ; Elisabeth Fenwick [Royaume-Uni] ; Dennis Fryback [États-Unis] ; Mark Sculpher [Royaume-Uni] ; David Spiegelhalter [Royaume-Uni] ; Andrew Willan [Canada] | Incorporation of uncertainty in health economic modelling studies |
| 000790 |
Ned Jenkinson [Royaume-Uni] ; Dipankar Nandi [Royaume-Uni] ; Tipu Z. Aziz [Royaume-Uni] ; John F. Stein [Royaume-Uni] ; Paolo Mazzone [Italie] ; Andres Lozano [Canada] ; Paolo Stanzione [Italie] ; Salvatore Galati [Italie] ; Eugenio Scarnati [Italie] ; Antonella Peppe [Italie] ; Alessandro Stefani [Italie] | Implantation of human pedunculopontine nucleus : a safe and clinically relevant target in Parkinson's disease. Commentary |
| 000791 |
Mark Stacy [États-Unis] ; Annette Bowron [Royaume-Uni] ; Mark Guttman [Canada] ; Robert Hauser [États-Unis] ; Kim Hughes [Royaume-Uni] ; Jan Petter Larsen [Norvège] ; Peter Lewitt [États-Unis] ; Wolfgang Oertel [Allemagne] ; Niall Quinn [Royaume-Uni] ; Kapil Sethi [États-Unis] ; Fabrizio Stocchi [Italie] | Identification of motor and nonmotor wearing-off in Parkinson's disease : Comparison of a patient questionnaire versus a clinician assessment |
| 000793 |
Bianca Marchetti [Italie] ; Pier Andrea Serra [Italie] ; Cataldo Tirolo [Italie] ; Francesca L'Episcopo [Italie] ; Salvo Caniglia [Italie] ; Florinda Gennuso [Italie] ; Nuccio Testa [Italie] ; Egidio Miele [Italie] ; Speranza Desole [Italie] ; Nicholas Barden [Canada] ; Maria Concetta Morale [Italie] | Glucocorticoid receptor-nitric oxide crosstalk and vulnerability to experimental parkinsonism : pivotal role for glia-neuron interactions |
| 000795 |
Joyce K. H. Tang [Canada] ; Elena Moro [Canada] ; Andres M. Lozano [Canada] ; Anthony E. Lang [Canada] ; William D. Hutchison [Canada] ; Neil Mahant [Canada] ; Jonathan O. Dostrovsky [Canada] | Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients |
| 000796 |
Marc D. Pell [Canada] ; Carol L. Leonard [Canada] | Facial expression decoding in early Parkinson's disease |
| 000797 |
Adrian P. Fawcett [Canada] ; Jonathan O. Dostrovsky [Canada] ; Andres M. Lozano [Canada] ; William D. Hutchison [Canada] | Eye movement-related responses of neurons in human subthalamic nucleus |
| 000799 |
James G. Perretta [Canada] ; Giovanna Pari [Canada] ; Richard J. Beninger [Canada] | Effects of parkinson disease on two putative nondeclarative learning tasks : Probabilistic classification and gambling |
| 000800 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada] | Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys |
| 000802 |
Ronald B. Postuma [Canada] ; Tamara Arenovich [Canada] ; Anthony E. Lang [Canada] | Does severity of Parkinson's disease vary according to season? |
| 000803 |
Katerina Venderov [Canada] ; Timothy M. Brown [Royaume-Uni] ; Jonathan M. Brotchie [Canada] | Differential effects of endocannabinoids on [3H]-GABA uptake in the rat globus pallidus |
| 000805 |
Florence Chan [Canada] ; Irene T. Armstrong [Canada] ; Giovanna Pari [Canada] ; Richard J. Riopelle [Canada] ; Douglas P. Munoz [Canada] | Deficits in saccadic eye-movement control in Parkinson's disease |
| 000807 |
Clement Hamani [Canada] ; Erich O. Richter [États-Unis] ; Yuri Andrade-Souza [Canada] ; William Hutchison [Canada] ; Jean A. Saint-Cyr [Canada] ; Andres M. Lozano [Canada] ; Kim J. Burchiel [États-Unis] ; Christopher J. Winfree [États-Unis] | Correspondence of microelectrode mapping with magnetic resonance imaging for subthalamic nucleus procedures. Commentary |
| 000808 |
Katie Wiltshire [Canada] ; Sheri Foster [Canada] ; Jeffrey A. Kaye [États-Unis] ; Brent J. Small [États-Unis] ; Richard Camicioli [Canada] | Corpus callosum in neurodegenerative diseases : Findings in Parkinson's disease |
| 000810 |
Victor Lun [Canada] ; Nancy Pullan [Canada] ; Nancy Labelle [Canada] ; Corey Adams [Canada] ; Oksana Suchowersky [Canada] | Comparison of the effects of a self-supervised home exercise program with a physiotherapist-supervised exercise program on the motor symptoms of Parkinson's disease |
| 000811 |
Yuri M. Andrade-Souza [Canada] ; Jason M. Schwalb [Canada] ; Clement Hamani [Canada] ; Tasnuva Hoque [Canada] ; Jean Saint-Cyr [Canada] ; Andres M. Lozano [Canada] ; Kim J. Burchiel [États-Unis] ; Christopher J. Winfree [États-Unis] ; Konstantin Slavin [États-Unis] | Comparison of 2-dimensional magnetic resonance imaging and 3-planar reconstruction methods for targeting the subthalamic nucleus in parkinson disease |
| 000813 |
Anne Beuter [France] ; Emilie Barbo [Canada] ; Robert Rigal [Canada] ; Pierre J. Blanchet [Canada] | Characterization of subclinical tremor in Parkinson's disease |
| 000814 |
A. Nagano-Saito [Japon, Canada] ; Y. Washimi [Japon] ; Y. Arahata [Japon] ; T. Kachi [Japon] ; J. P. Lerch [Canada] ; A. C. Evans [Canada] ; A. Dagher [Canada] ; K. Ito [Japon] | Cerebral atrophy and its relation to cognitive impairment in Parkinson disease |
| 000815 |
Deniz Kirik [Suède] ; Anders Björklund [Suède] ; Ivar Mendez [Canada] ; Rosario Sanchez-Pernaute [États-Unis] ; Oliver Cooper [États-Unis] ; Angel Vinuela [États-Unis] ; Daniela Ferrari [États-Unis] ; Lars Björklund [États-Unis] ; Alain Dagher [Canada] ; Ole Isacson [États-Unis] | Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Commentary |
| 000816 |
Marguerite Wieler [Canada] ; Richard Camicioli [Canada] ; C. Allyson Jones [Canada] ; W. R. Wayne Martin [Canada] | Botulinum toxin injections do not improve freezing of gait in Parkinson disease |
| 000817 |
Clement Hamani [Canada] ; Erich Richter [Canada] ; Jason M. Schwalb [Canada] ; Andres M. Lozano ; Alim-Louis Benabid ; Hilip A. Starr ; Brian H. Kopell ; Ali R. Rezai ; Giovanni Broggi ; Angelo Franzini | Bilateral subthalamic nucleus stimulation for Parkinson's disease : A systematic review of the clinical literature |
| 000818 |
Hans-Joachim Freund [Allemagne] ; M. C. Rodriguez-Oroz [Espagne] ; J. A. Obeso [Espagne] ; A. E. Lang [Canada] ; J.-L. Houeto [France] ; P. Pollak [France] ; S. Rehncrona [France] ; J. Kulisevsky [Espagne] ; A. Albanese [Italie] ; J. Volkmann [Allemagne] ; M. I. Hariz [Royaume-Uni] ; N. P. Quinn [Royaume-Uni] ; J. D. Speelman [Pays-Bas] ; J. Guridi [Espagne] ; I. Zamarbide [Espagne] ; A. Gironell [Espagne] ; J. Molet [Espagne] ; B. Pascual-Sedano [Espagne] ; B. Pidoux [France] ; A. M. Bonnet [France] ; Yves Agid [France] ; J. Xie [France] ; A.-L. Benabid [France] ; A. M. Lozano [Canada] ; J. Saint-Cyr [Canada] ; L. Romito [Italie] ; M. F. Contarino [Italie] ; M. Scerrati [Italie] ; V. Fraix [France] ; N. Van Blercom [France] | Bilateral deep brain stimulation in Parkinson's disease : a multicentre study with 4 years follow-up. Commentary |
| 000819 |
S. Karamohamed [États-Unis] ; J. C. Latourelle [États-Unis] ; B. A. Racette [États-Unis] ; J. S. Perlmutter [États-Unis] ; G. F. Wooten [États-Unis] ; M. Lew [États-Unis] ; C. Klein [Allemagne] ; H. Shill [États-Unis] ; L. I. Golbe [États-Unis] ; M. H. Mark [États-Unis] ; M. Guttman [Canada] ; G. Nicholson [Australie] ; J. B. Wilk [États-Unis] ; M. Saint-Hilaire [États-Unis] ; A. L. Destefano [États-Unis] ; R. Prakash [États-Unis] ; S. Tobin [États-Unis] ; J. Williamson [États-Unis] ; O. Suchowersky [Canada] ; N. Labell [Canada] ; B. N. J. Growdon [États-Unis] ; C. Singer [États-Unis] ; R. Watts [États-Unis] ; S. Goldwurm [Italie] ; G. Pezzoli [Italie] ; K. B. Baker [États-Unis] ; M. L. Giroux [États-Unis] ; P. P. Pramstaller [Italie] ; D. J. Burn [Royaume-Uni] ; P. Chinnery [Royaume-Uni] ; S. Sherman [États-Unis] ; P. Vieregge [Allemagne] ; I. Litvan [États-Unis] ; J. F. Gusella [États-Unis] ; R. H. Myers [États-Unis] ; A. Parsian [États-Unis] | BDNF genetic variants are associated with onset age of familial Parkinson disease : GenePD Study |
| 000820 |
Cindy Zadikoff [Canada] ; Anthony E. Lang [Canada] | Apraxia in movement disorders |
| 000821 |
Richard Camicioli [Canada] ; Ali Rajput [Canada] ; Michelle Rajput [Canada] ; Christian Reece [Canada] ; Haydeh Payami [États-Unis] ; CHUNHAI HAO [Canada] ; Alex Rajput [Canada] | Apolipoprotein E ε4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease : Relationship to dementia and hallucinations |
| 000822 |
Brad Hagen [Canada] ; Chris Armstrong Esther [Canada] ; Roland Ikuto [Canada] ; Robert J. Williams [Canada] ; Carole-Lynne Le Navenec [Canada] ; Morgan Aho | Antipsychotic drug use in Canadian long-term care facilities : prevalence, and patterns following resident relocation |
| 000823 |
Q. J. Almeida [Canada] ; J. S. Frank [Canada] ; E. A. Roy [Canada] ; M. E. Jenkins [Canada] ; S. Spaulding [Canada] ; A. E. Patla [Canada] ; M. S. Jog [Canada] | An evaluation of sensorimotor integration during locomotion toward a target in Parkinson's disease |
| 000825 |
Samer Karamohamed [États-Unis] ; L. I. Golbe [États-Unis] ; M. H. Mark [États-Unis] ; A. M. Lazzarini [États-Unis] ; O. Suchowersky [Canada] ; N. Labelle [Canada] ; Mark Guttman [Canada] ; L. J. Currie [États-Unis] ; G. F. Wooten [États-Unis] ; M. Stacy [États-Unis] ; M. Saint-Hilaire [États-Unis] ; R. G. Feldman [États-Unis] ; J. Liu [États-Unis] ; C. M. Shoemaker [États-Unis] ; J. B. Wilk [États-Unis] ; A. L. Destefano [États-Unis] ; J. C. Latourelle [États-Unis] ; G. Xu [États-Unis] ; R. Watts [États-Unis] ; J. Growdon [États-Unis] ; M. Lew [États-Unis] ; C. Waters [États-Unis] ; P. Vieregge [Allemagne] ; P. P. Pramstaller [Italie] ; C. Klein [Allemagne] ; B. A. Racette [États-Unis] ; J. S. Perlmutter [États-Unis] ; A. Parsian [États-Unis] ; Carlos Singer [États-Unis] ; E. Montgomery [États-Unis] ; K. Baker [États-Unis] ; J. F. Gusella [États-Unis] ; A. Herbert [États-Unis] ; R. H. Myers [États-Unis] | Absence of previously reported variants in the SCNA (G88c and G209A), NR4A2 (T291D and T245G) and the DJ-1 (T497C) genes in familial parkinson's disease from the GenePD study |
| 000826 |
Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease |
| 000827 |
| Abstracts of the 12th World Congress of Psychophysiology the Olympics of the Brain of the International Organization of Psychophysiology (I.O.P.) associated with the United Nations, Thessaloniki, Porto Carras, Halkidiki, Greece, September 18-23, 2004 |
| 000828 |
Anna Moszczynska [Canada] ; Paul Fitzmaurice [Canada] ; Lee Ang [Canada] ; Kathryn S. Kalasinsky [États-Unis] ; Gregory A. Schmunk [États-Unis] ; Frank J. Peretti [États-Unis] ; Sally S. Aiken [États-Unis] ; Dennis J. Wickham [États-Unis] ; Stephen J. Kish [Canada] | Why is parkinsonism not a feature of human methamphetamine users? |
| 000829 |
Andrew M. Johnson [Canada] ; Quincy J. Almeida [Canada] ; Con Stough [Australie] ; James C. Thompson [Australie] ; Rene Singarayer [Canada] ; Mandar S. Jog [Canada] | Visual inspection time in Parkinson's disease: deficits in early stages of cognitive processing |
| 000831 |
Brian Harel [États-Unis] ; Michael Cannizzaro [États-Unis] ; Peter J. Snyder [États-Unis, Canada] | Variability in fundamental frequency during speech in prodromal and incipient Parkinson's disease: A longitudinal case study |
| 000832 |
Jason A. Brodkey [Canada] ; Ronald R. Tasker ; Clement Hamani ; Mary Pat Mcandrews ; Jonathan O. Dostrovsky ; Andres M. Lozano | Tremor cells in the human thalamus: differences among neurological disorders |
| 000833 |
Clement Hamani [Canada] ; Jean A. Saint-Cyr [Canada] ; Justin Fraser [États-Unis] ; Michael Kaplitt [États-Unis] ; Andres M. Lozano [Canada] | The subthalamic nucleus in the context of movement disorders |
| 000834 |
L. Clark [Royaume-Uni] ; R. Cools [Royaume-Uni] ; T. W. Robbins [Royaume-Uni] | The neuropsychology of ventral prefrontal cortex: Decision-making and reversal learning |
| 000836 |
Christian Duval [Canada] ; Abbas F. Sadikot [Canada] ; Michel Panisset [Canada] | The detection of tremor during slow alternating movements performed by patients with early Parkinson's disease |
| 000838 |
J. E. Nash [Canada] ; P. Ravenscroft [Royaume-Uni] ; S. Mcguire [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; F. S. Menniti [États-Unis] ; J. M. Brotchie [Canada] | The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease |
| 000841 |
K. Dujardin [France] ; S. Blairy [Belgique] ; L. Defebvre [France] ; P. Krystkowiak [France] ; U. Hess [Canada] ; S. Blond [France] ; A. Destee [France] | Subthalamic nucleus stimulation induces deficits in decoding emotional facial expressions in Parkinson's disease |
| 000842 |
Galit Kleiner-Fisman [Canada] ; David N. Fisman [Canada] ; Orit Zamir [Canada] ; Jonathan O. Dostrovsky [Canada] ; Elspeth Sime [Canada] ; Jean A. Saint-Cyr [Canada] ; Andres M. Lozano [Canada] ; Anthony E. Lang [Canada] | Subthalamic nucleus deep brain stimulation for Parkinson's disease after successful pallidotomy: Clinical and electrophysiological observations |
| 000843 |
Mohammed Filali [Canada] ; William D. Hutchison [Canada] ; Vanessa N. Palter [Canada] ; Andres M. Lozano [Canada] ; Jonathan O. Dostrovsky [Canada] | Stimulation-induced inhibition of neuronal firing in human subthalamic nucleus |
| 000844 |
Ritsuko Hanajima [Canada] ; Jonathan O. Dostrovsky [Canada] ; Andres M. Lozano [Canada] ; William D. Hutchison [Canada] ; Karen D. Davis [Canada] ; Robert Chen [Canada] ; Peter Ashby [Canada] | Somatosensory evoked potentials (SEPs) recorded from deep brain stimulation (DBS) electrodes in the thalamus and subthalamic nucleus (STN) |
| 000847 |
M. A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; P. Ravenscroft [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; M. J. Millan [France] ; J. M. Brotchie [Canada] | Selective blockade of D3 dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate |
| 000848 |
Murat Emre [Turquie] ; Dag Aarsland [Norvège] ; Albeao Albanese [Italie] ; E. Jane Byrne [Royaume-Uni] ; Günther Deuschl [Allemagne] ; Peter P. De Deyn [Belgique] ; Franck Durif [France] ; Jaime Kulisevsky [Espagne] ; Teus Van Laar [Pays-Bas] ; Andrew Lees [Royaume-Uni] ; Werner Poewe [Autriche] ; Alain Robillard [Canada] ; Mario M. Rosa [Portugal] ; Erik Wolters [Pays-Bas] ; Peter Quarg [Suisse] ; Sibel Tekin [États-Unis] ; Roger Lane [États-Unis] | Rivastigmine for dementia associated with Parkinson's disease |
| 000849 |
Connie Marras [Canada] ; Anthony Lang [Canada] ; Murray Krahn [Canada] ; George Tomlinson [Canada] ; Gary Naglie [Canada] | Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations |
| 000850 |
Howard T. J. Mount [Canada] ; Jean-Claude Martel [France] ; Paul Fluit [Canada] ; YINGJI WU [Canada] ; Eleanor Gallo-Hendrikx [Canada] ; Cristina Cosi [France] ; Marc R. Marien [France] | Progressive sensorimotor impairment is not associated with reduced dopamine and high energy phosphate donors in a model of ataxia-telangiectasia |
| 000852 |
Raul De La Fuente-Fernandez [Canada, Espagne] ; Michael Schulzer [Canada] ; Edwin Mak [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model |
| 000853 |
Gerlinde A. Metz [Canada] ; Dionne M. Piecharka [Canada] ; Jeffrey A. Kleim [Canada] ; Ian Q. Whishaw [Canada] | Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease |
| 000854 |
Ajmal Razmy [Canada] ; Anthony E. Lang [Canada] ; Colin M. Shapiro [Canada] | Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists |
| 000855 |
Lisa M. Inkster [Canada] ; Janice J. Eng [Canada] | Postural control during a sit-to-stand task in individuals with mild Parkinson's disease |
| 000856 |
M. G. Carpenter [Suisse, Canada] ; J. H. J. Allum [Suisse] ; F. Honegger [Suisse] ; A. L. Adkin [Suisse, Canada] ; B. R. Bloem [Pays-Bas] | Postural abnormalities to multidirectional stance perturbations in Parkinson's disease |
| 000857 |
R. M. Camicioli [Canada] ; J. R. Korzan [Canada] ; S. L. Foster [Canada] ; N. J. Fisher [Canada] ; D. J. Emery [Canada] ; A. C. Bastos [Canada] ; C. C. Hanstock [Canada] | Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia |
| 000858 |
Raul De La Fuente-Fernandez [Canada, Espagne] ; Michael Schulzer [Canada] ; A. Jon Stoessl [Canada] | Placebo mechanisms and reward circuitry: Clues from Parkinson's disease |
| 000859 |
Richard Camicioli [Canada] ; Nancy Fisher [Canada] | Parkinson's disease with dementia and dementia with Lewy bodies |
| 000861 |
D. J. Doudet [Canada] ; M. L. Cornfeldt [États-Unis] ; C. R. Honey [Canada] ; A. W. Schweikert [États-Unis] ; R. C. Allen [États-Unis] | PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of parkinson's disease |
| 000862 |
Yoanna K. Skrobik [Canada] ; Nicolas Bergeron [Canada] ; Marc Dumont [Canada] ; Stewart B. Gottfried [Canada] | Olanzapine vs haloperidol: treating delirium in a critical care setting |
| 000864 |
M. O. Poulter [Canada] ; K. B. Payne [Canada] ; J. P. Steiner [États-Unis] | Neuroimmunophilins: A novel drug therapy for the reversal of neurodegenerative disease? |
| 000867 |
Martin Zonenshayn [États-Unis] ; Djordje Sterio [États-Unis] ; Patrick J. Kelly [États-Unis] ; Ali R. Rezai [États-Unis] ; Aleksander Beric [États-Unis] ; Kim J. Burchiel [États-Unis] ; Ronald R. Tasker [Canada] | Location of the active contact within the subthalamic nucleus (STN) in the treatment of idiopathic Parkinson's disease. Commentary |
| 000868 |
Raul De La Fuente-Fernandez [Canada] ; Vesna Sossi [Canada] ; ZHIGAO HUANG [Canada] ; Sarah Furtado [Canada] ; Jian-Qiang Lu [Canada] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias |
| 000869 |
C. Warren Olanow [États-Unis] ; Yves Agid [France] ; Yoshi Mizuno [Japon] ; Alberto Albanese [Italie] ; U. Bonucelli [Italie] ; Philip Damier [France] ; Justo De Yebenes [Espagne] ; Oscar Gershanik [Argentine] ; Mark Guttman [Canada] ; F. Grandas [Espagne] ; Mark Hallett [États-Unis] ; Ole Hornykiewicz [Autriche] ; Peter Jenner [Royaume-Uni] ; R. Katzenschlager [Royaume-Uni] ; William J. Langston [États-Unis] ; Peter Lewitt [États-Unis] ; Eldad Melamed [Israël] ; M. A. Mena [Espagne] ; P. P. Michel [France] ; Catherine Mytilineou [États-Unis] ; Jose A. Obeso [Espagne] ; Werner Poewe [Autriche] ; Niall Quinn [Royaume-Uni] ; R. Raisman-Vozari [France] ; Ali H. Rajput [Canada] ; Olivier Rascol [France] ; Christina Sampaio ; Fabrizio Stocchi | Levodopa in the treatment of Parkinson's disease: Current controversies |
| 000870 |
Y. Kumakura [Danemark] ; E. H. Danielsen [Danemark] ; A. Reilhac [Canada] ; A. Gjedde [Danemark, Canada] ; P. Cumming [Danemark] | Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease |
| 000872 |
Chong S. Lee [Canada] ; Michael Schulzer [Canada] ; Raul De La Fuente-Fernandez [Canada] ; Edwin Mak [Canada] ; Lisa Kuramoto [Canada] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Lack of Regional selectivity during the progression of Parkinson disease: Implications for pathogenesis |
| 000873 |
Frédéric Calon [Canada] ; Mehdi Dridi [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Ali H. Rajput [Canada] ; Thérèse Di Paolo [Canada] | Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias |
| 000874 |
Ronald B. Postuma [Canada] ; Anthony E. Lang [Canada] | Homocysteine and levodopa: Should Parkinson disease patients receive preventative therapy? |
| 000878 |
Justus L. Groen [Canada] ; Toshitaka Kawarai [Canada] ; Anna Toulina [Canada] ; Chiara Rivoiro [Canada, Italie] ; Shabnam Salehi-Rad [Canada] ; Christine Sato [Canada] ; Angharad Morgan [Canada] ; YAN LIANG [Canada] ; Ronald B. Postuma [Canada] ; Peter St George-Hyslop [Canada] ; Anthony E. Lang [Canada] ; Ekaterina Rogaeva [Canada] | Genetic association study of PINK1 coding polymorphisms in Parkinson's disease |
| 000880 |
R. P. Munhoz [Canada] ; J.-Y. Li [Canada] ; M. Kurtinecz [Canada] ; P. Piboolnurak [États-Unis] ; A. Constantino [États-Unis] ; S. Fahn [États-Unis] ; A. E. Lang [Canada] | Evaluation of the pull test technique in assessing postural instability in Parkinson's disease |
| 000882 |
S. Kedia [États-Unis] ; E. Moro [Canada] ; M. Tagliati [États-Unis] ; A. E. Lang [Canada] ; R. Kumar [États-Unis] | Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease |
| 000884 |
Naila Ismayilova [Canada] ; Alan Crossman [Canada] ; Alexei Verkhratsky [Canada] ; Jonathan Brotchie [Canada] | Effects of adenosine A1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats |
| 000888 |
Eugene Tunik [États-Unis] ; Sergei V. Adamovich [États-Unis] ; Howard Poizner [États-Unis] ; Anatol G. Feldman [Canada] | Deficits in rapid adjustments of movements according to task constraints in Parkinson's disease |
| 000889 |
Kathy Dujardin [France] ; Sylvie Blairy [Belgique] ; Luc Defebvre [France] ; Stéphane Duhem [France] ; Yvonnick Noël [France] ; Ursula Hess [Canada] ; Alain Destée [France] | Deficits in decoding emotional facial expressions in Parkinson's disease |
| 000890 |
E. Tunik [États-Unis] ; H. Poizner [États-Unis] ; S. V. Adamovich [États-Unis] ; M. F. Levin [Canada] ; A. G. Feldman [Canada] | Deficits in adaptive upper limb control in response to trunk perturbations in Parkinson's disease |
| 000891 |
K. Hedrich [Allemagne] ; A. Djarmati [Allemagne, Serbie] ; N. Sch Fer [Allemagne] ; R. Hering [Allemagne] ; C. Wellenbrock [Allemagne] ; P. H. Weiss [Allemagne] ; R. Hilker [Allemagne] ; P. Vieregge [Allemagne] ; L. J. Ozelius [États-Unis] ; P. Heutink [Pays-Bas] ; V. Bonifati [Pays-Bas, Italie] ; E. Schwinger [Allemagne] ; A. E. Lang [Canada] ; J. Noth [Allemagne] ; S. B. Bressman [États-Unis] ; P. P. Pramstaller [Italie] ; O. Riess [Allemagne] ; C. Klein [Allemagne] | DJ-1 (PARK7) mutations are less frequent than Parkin (PARK2) mutations in early-onset Parkinson disease |
| 000892 |
Ajit Kumar [Canada] ; Susan M. Calne [Canada] ; Michael Schulzer [Canada] ; Edwin Mak [Canada] ; Zbigniew Wszolek [États-Unis] ; Chris Van Netten [Canada] ; Joseph K. C. Tsui [Canada] ; A. Jon Stoessl [Canada] ; Donald B. Calne [Canada] | Clustering of Parkinson disease: Shared cause or coincidence? |
| 000893 |
Vesna Sossi [Canada] ; Raul De La Fuente-Fernandez [Canada] ; James E. Holden [Canada] ; Michael Schulzer [Canada] ; Thomas J. Ruth [États-Unis] ; Jon Stoessl [Canada] | Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: Their relation to disease-compensatory mechanisms |
| 000895 |
Kerry B. Goralski [Canada] ; Kenneth W. Renton [Canada] | Brain inflammation enhances 1-methyl-4-phenylpyridinium-evoked neurotoxicity in rats |
| 000896 |
Junchao Tong [Canada] ; Paul S. Fitzmaurice [Canada] ; Lee Cyn Ang [Royaume-Uni] ; Yoshiaki Furukawa [Canada] ; Mark Gunman [Canada] ; Stephen J. Kish [Canada] | Brain dopamine-stimulated adenylyl cyclase activity in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy |
| 000900 |
Christine Sato [Canada] ; Angharad Morgan [Canada] ; Anthony E. Lang [Canada] ; Shabnam Salehi-Rad [Canada] ; Toshitaka Kawarai [Canada] ; YAN MENG [États-Unis] ; Peter N. Ray [Canada] ; Lindsay A. Farrer [États-Unis] ; Peter St George-Hyslop [Canada] ; Ekaterina Rogaeva [Canada] | Analysis of the glucocerebrosidase gene in Parkinson's disease |
| 000901 |
Ekaterina Rogaeva [Canada] ; Janel Johnson [États-Unis] ; Anthony E. Lang [Canada] ; Cindy Gulick [États-Unis] ; Katrina Gwinn-Hardy [États-Unis] ; Toshitaka Kawarai [Canada] ; Christine Sato [Canada] ; Angharad Morgan [Canada] ; John Werner [États-Unis] ; Robert Nussbaum [États-Unis] ; Agnes Petit [Canada] ; Michael S. Okun [États-Unis] ; Aideen Mcinerney [États-Unis] ; Ronald Mandel [États-Unis] ; Justus L. Groen [Canada] ; Hubert H. Fernandez [États-Unis] ; Ron Postuma [Canada] ; Kelly D. Foote [États-Unis] ; Shabnam Salehi-Rad [Canada] ; YAN LIANG [Canada] ; Sharon Reimsnider [États-Unis] ; Anurag Tandon [Canada] ; John Hardy [États-Unis] ; Peter St George-Hyslop [Canada] ; Andrew B. Singleton [États-Unis] | Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease |
| 000902 |
Victor Frak [Canada] ; Henri Cohen [Canada] ; Emmanuelle Pourcher [Canada] | A dissociation between real and simulated movements in Parkinson's disease |
| 000903 |
Ajit Kumar [Canada] ; Sharanpal Mann [Canada] ; Vesna Sossi [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] ; Michael Schulzer [Canada] ; Chong S. Lee [Canada] | [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease |
| 000904 |
Susan M. Calne [Canada] ; Edwin Mak [Canada] ; Jeanne Hall [Canada] ; Marie-Jose Fortin [Canada] ; Pamela King [Canada] ; Germaine Mcinnes [Canada] ; Linda Grantier [Canada] ; Sherree Trecartin [Canada] ; Michael Schulzer [Canada] | Validating a quality-of-life scale in caregivers of patients with Parkinson's disease: Parkinson's impact scale (PIMS) |
| 000907 |
Joseph King Ching Tsui [Canada] | Treatment of dystonia in Parkinson's disease |
| 000908 |
W. R. Wayne Martin [Canada] ; Marguerite Wieler [Canada] | Treatment of Parkinson's disease |
| 000910 |
Pierre J. Blanchet [Canada] | The fluctuating Parkinsonian patient: Clinical and pathophysiological aspects |
| 000911 |
Louis Bherer [États-Unis] ; Sylvie Belleville [Canada] ; Brigitte Gilbert [Canada] | Temporal preparation strategy may inflate RT deficit in patients with Parkinson's disease |
| 000912 |
Andres M. Lozano [Canada] | Surgery for Parkinson's disease, the five W's: Why, who, what, where, and when |
| 000913 |
Antonio P. Strafella [Canada] ; Abbas F. Sadikot [Canada] ; Alain Dagher [Canada] | Subthalamic deep brain stimulation does not induce striatal dopamine release in Parkinson's disease |
| 000914 |
Antonio P. Strafella [Canada] ; Tomas Paus [Canada] ; Maria Fraraccio [Canada] ; Alain Dagher [Canada] | Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex |
| 000915 |
Aviva Abosch [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada] ; Doug Hussey [Canada] ; Elspeth Sime [Canada] ; Janis Miyasaki [Canada] ; Svlvain Houle [Canada] ; Andres M. Lozano [Canada] ; Philip Starr ; Giovanni Broggi ; Roy A. E. Bakay ; Nicholas Boulis ; Ali R. Rezai | Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Commentary |
| 000916 |
Aviva Abosch [Canada] ; Andres Lozano [États-Unis] | Stereotactic neurosurgery for movement disorders |
| 000917 |
Alan L. Whone [Royaume-Uni] ; Ray L. Watts [États-Unis] ; A. Jon Stoessl [Canada] ; Margaret Davis [États-Unis] ; Sven Reske [Allemagne] ; Claude Nahmias [Canada] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Maria J. Ribeiro [France] ; Philippe Remy [France] ; Werner Poewe [Autriche] ; Robert A. Hauser [États-Unis] ; David J. Brooks [Royaume-Uni] | Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study |
| 000918 |
Basta Maria [Grèce] ; Schiza Sophia [Grèce] ; Mauridis Michalis [Grèce] ; Lydakis Charalampos [Grèce] ; Plaitakis Andreas [Grèce] ; Milic Emili John [Canada] ; Siafakas M. Nikolaos [Grèce] | Sleep breathing disorders in patients with idiopathic Parkinson's disease |
| 000919 |
Alexandra Sailer [Canada, Allemagne] ; Gregory F. Molnar [Canada] ; Guillermo Paradiso [Canada] ; Carolyn A. Gunraj [Canada] ; Anthony E. Lang [Canada] ; Robert Chen [Canada] | Short and long latency afferent inhibition in Parkinson's disease |
| 000920 |
Pierre J. Blanchet [États-Unis, Canada] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] | Renaissance of amantadine in the treatment of Parkinson's disease |
| 000921 |
K. Fuxe [Suède] ; L. F. Agnati [Italie] ; K. Jacobsen [Canada] ; J. Hillion [États-Unis] ; M. Canals [Espagne] ; M. Torvinen [Suède] ; B. Tinner-Staines [Canada] ; W. Staines [Canada] ; D. Rosin [États-Unis] ; A. Terasmaa [Suède] ; P. Popoli [Italie] ; G. Leo [Italie] ; V. Vergoni [Italie] ; C. Lluis [Espagne] ; F. Ciruela [Espagne] ; R. Franco [Espagne] ; S. Ferre [États-Unis] | Receptor heteromerization in adenosine A2A receptor signaling: Relevance for striatal function and Parkinson's disease |
| 000922 |
J. G. Nutt [États-Unis] ; K. J. Burchiel [États-Unis] ; C. L. Comella [États-Unis] ; Joseph Jankovic [États-Unis] ; A. E. Lang [Canada] ; E. R. Jr Laws [États-Unis] ; A. M. Lozano [Canada] ; R. D. Penn [États-Unis] ; R. K. Jr Simpson [États-Unis] ; M. Stacy [États-Unis] ; G. F. Wooten [États-Unis] | Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD |
| 000924 |
Marc D. Pell [Canada] ; Carol L. Leonard [Canada] | Processing emotional tone from speech in Parkinson's disease: A role for the basal ganglia |
| 000925 |
Erwan Bezard [France] ; Christian E. Gross [France] ; Jonathan M. Brotchie [Canada] | Presymptomatic compensation in Parkinson's disease is not dopamine-mediated |
| 000926 |
Patrick L. Mcgeer [Canada] ; Claudia Schwab [Canada] ; Andre Parent [Canada] ; Doris Doudet [Canada] | Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration |
| 000927 |
Simon Lemay [Canada] ; Pierre Blanchet [Canada] ; Sylvain Chouinard [Canada] ; Hélène Masson [Canada] ; Valérie Soland [Canada] ; Marc-André Bedard [Canada] | Poor tolerability of a transdermal nicotine treatment in Parkinson's disease |
| 000928 |
Sophie Vigouroux [France] ; Yoshiaki Furukawa [Canada] ; Luc Farout [France] ; Stephen J. Kish [Canada] ; Marièle Briand [France] ; Yves Briand [France] | Peptidase activities of the 20/26S proteasome and a novel protease in human brain |
| 000929 |
Richard Camicioli [États-Unis, Canada] ; M. Milar Moore [États-Unis] ; Anthony Kinney [États-Unis] ; Elizabeth Corbridge [États-Unis] ; Kathryn Glassberg [États-Unis] ; Jeffrey A. Kaye [États-Unis] | Parkinson's disease is associated with hippocampal atrophy |
| 000930 |
S. Lincoln [États-Unis] ; J. Wiley [Irlande (pays)] ; T. Lynch [Irlande (pays)] ; J. W. Langston [États-Unis] ; R. Chen [États-Unis] ; A. Lang [Canada] ; E. Rogaeva [Canada] ; D. S. Sa [Canada] ; R. P. Munhoz [Canada] ; J. Harris [États-Unis] ; K. Marder [États-Unis] ; C. Klein [Allemagne] ; G. Bisceglio [États-Unis] ; J. Hussey [États-Unis] ; A. West [États-Unis] ; M. Hulihan [États-Unis] ; J. Hardy [États-Unis] ; M. Farrer [États-Unis] | Parkin-proven disease: Common founders but divergent phenotypes |
| 000931 |
William D. Hutchison [Canada] ; Anthony E. Lang [Canada] ; Jonathan O. Dostrovsky [Canada] ; Andres M. Lozano [Canada] | Pallidal neuronal activity: Implications for models of dystonia |
| 000933 |
Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Paul J. Bedard [Canada] | Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems |
| 000934 |
Michael P. Hill [Royaume-Uni] ; Erwan Bezard [France] ; Steven G. Mcguire [Royaume-Uni] ; Alan R. Crossman [Royaume-Uni] ; Jonathan M. Brotchie [Canada] ; Ann Michel [Belgique] ; Renee Grimee [Belgique] ; Henrik Klitgaard [Belgique] | Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset |
| 000935 |
Paul S. Fitzmaurice [Canada] ; LEE ANG [Canada] ; Mark Guttman [Canada] ; Ali H. Rajput [Canada] ; Yoshiaki Furukawa [Canada] ; Stephen J. Kish [Canada] | Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease |
| 000936 |
S. Warby [Canada] | New mutations, new etiologies for Parkinson disease |
| 000937 |
A. Hadj Tahar [Canada] ; R. Grondin [Canada] ; L. Gregoire [Canada] ; F. Calon [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | New insights in Parkinson's disease therapy: Can levodopa-induced dyskinesia ever be manageable |
| 000938 |
Jackalina Van Kampen [Canada] ; Harold Robertson [Canada] ; Theo Hagg [Canada] ; Robert Drobitch [Canada] | Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease |
| 000939 |
Jeffrey A. Kleim [Canada] ; Theresa A. Jones [États-Unis] ; Timothy Schallert [États-Unis] | Motor enrichment and the induction of plasticity before or after brain injury |
| 000941 |
Ajit Kumar [Canada] ; ZHIGAO HUANG [Canada] ; Raul De La Fuente-Fernandez [Canada] | Mechanisms of motor complications in treatment of Parkinson's disease |
| 000942 |
Douglas Coyle [Canada] ; Martin J. Buxton [Royaume-Uni] ; Bernie J. O'Brien [Canada] | Measures of importance for economic analysis based on decision modeling |
| 000944 |
Rajeev Kumar [Canada, États-Unis] ; Andres M. Lozano [Canada] ; Elspeth Sime [Canada] ; Anthony E. Lang [Canada] | Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor |
| 000945 |
Galit Kleiner-Fisman [Canada] ; David N. Fisman ; Elspeth Sime ; Jean A. Saint-Cyr ; Andres M. Lozano ; Anthony E. Lang | Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease |
| 000946 |
Lisa M. Inkster [Canada] ; Janice J. Eng [Canada] ; Donna L. Macintyre [Canada] ; A. Jon Stoessl [Canada] | Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair |
| 000947 |
Z. H. T. Kiss [Canada] ; K. D. Davis [Canada] ; R. R. Tasker [Canada] ; A. M. Lozano [Canada] ; B. Hu [Canada] ; J. O. Dostrovsky [Canada] | Kinaesthetic neurons in thalamus of humans with and without tremor |
| 000948 |
G. Paradiso [Canada] ; J. A. Saint-Cyr [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] ; R. Chen [Canada] | Involvement of the human subthalamic nucleus in movement preparation |
| 000949 |
Richard A. Wennberg [Canada] ; Andres M. Lozano [Canada] | Intracranial volume conduction of cortical spikes and sleep potentials recorded with deep brain stimulating electrodes |
| 000950 |
LI LIU [Canada] ; Shu S. Hsu [Canada] ; Suneil K. Kalia [Canada] ; Andres M. Lozano [Canada] | Injury and strain-dependent dopaminergic neuronal degeneration in the substantia nigra of mice after axotomy or MPTP |
| 000951 |
Adam O. Hebb [Canada] ; Kari Hebb ; Arun C. Ramachandran ; Ivar Mendez | Glial cell line-derived neurotrophic factor-supplemented hibernation of fetal ventral mesencephalic neurons for transplantation in Parkinson disease: long-term storage |
| 000953 |
Allan L. Adkin [Canada] ; James S. Frank [Canada] ; Mandar S. Jog [Canada] | Fear of falling and postural control in Parkinson's disease |
| 000954 |
Kelly L. Jordan-Sciutto [États-Unis] ; Robert Dorsey [États-Unis] ; Elisabeth M. Chalovich [États-Unis] ; Robert R. Hammond [Canada] ; Cristian L. Achim [États-Unis] | Expression patterns of retinoblastoma protein in Parkinson disease |
| 000955 |
ZHIGAO HUANG [Canada] ; Raul De La Fuente-Fernandez [Canada] ; A. Jon Stoessl [Canada] | Etiology of Parkinson's disease |
| 000957 |
Alex Rajput [Canada] ; Michele Rajput [Canada] | Essential tremor and Parkinsonism |
| 000958 |
V. Sossi [Canada] ; J. E. Holden [États-Unis] ; R. De La Fuente-Fernandez [Canada] ; T. J. Ruth [Canada] ; A. J. Stoessl [Canada] | Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant KOCC and the [18F]fluorodopa plasma input uptake rate constant Ki |
| 000959 |
Benoit Melchior [France] ; Véronique Nerriere-Daguin [France] ; David-A. Laplaud [France] ; Séverine Remy [France] ; Sandrine Wiertlewski [France] ; Isabelle Neveu [France] ; Philippe Naveilhan [France] ; Susan O. Meakin [Canada] ; Philippe Brachet [France] | Ectopic expression of the TrkA receptor in adult dopaminergic mesencephalic neurons promotes retrograde axonal NGF transport and NGF-dependent neuroprotection |
| 000960 |
Stephen Hague [Canada] ; Ekaterina Rogaeva [Canada] ; Dena Hernandez [Canada] ; Cindy Gulick [Canada] ; Amanda Singleton [États-Unis] ; Melissa Hanson [États-Unis] ; Janel Johnson [Canada] ; Roberto Weiser [Venezuela] ; Marisol Gallardo [Venezuela] ; Bernard Ravina [États-Unis] ; Katrina Gwinn-Hardy [États-Unis] ; Anthony Crawley [États-Unis] ; Peter H. St. George-Hyslop [Canada] ; Anthony E. Lang [Canada] ; Peter Heutink [Pays-Bas] ; Vincenzo Bonifati [Pays-Bas, Italie] ; John Hardy [États-Unis] ; Andrew Singleton [Canada] | Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation |
| 000961 |
A. Jon Stoessl [Canada] ; Raul De La Fuente-Fernandez [Canada] | Dopamine receptors in Parkinson's disease: Imaging studies |
| 000964 |
Taresa Stefurak [Canada] ; David Mikulis [Canada] ; Helen Mayberg [Canada] ; Anthony E. Lang [Canada] ; Stephanie Hevenor [Canada] ; Peter Pahapill [États-Unis] ; Jean Saint-Cyr [Canada] ; Andres Lozano [Canada] | Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: A functional MRI case study |
| 000965 |
Michael Iskedjian [Canada] ; Thomas R. Einarson [Canada] | Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease |
| 000966 |
Pierre J. Blanchet [États-Unis, Canada] ; Spiros Konitsiotis [États-Unis, Grèce] ; Hideki Mochizuki [États-Unis, Japon] ; Ryszard Pluta [États-Unis] ; Dwaine F. Emerich [États-Unis] ; Thomas N. Chase [États-Unis] ; M. Maral Mouradian [États-Unis] | Complications of a trophic xenotransplant approach in parkinsonian monkeys |
| 000967 |
Mahyar Etminan [Canada] ; Sudeep Gill [Canada] ; Ali Samii [États-Unis] | Comparison of the risk of adverse events with Pramipexole and ropinirole in patients with Parkinson's disease a meta-analysis |
| 000968 |
G. V. Mcdonnell [Canada] ; J. Cabrera-Gomez [Canada] ; D. B. Calne [Canada] ; D. K. B. Li [Canada] ; J. Oger [Canada] | Clinical presentation of primary progressive multiple sclerosis 10 years after the incidental finding of typical magnetic resonance imaging brain lesions: The subclinical stage of primary progressive multiple sclerosis may last 10 years |
| 000969 |
Doug Everett Hobson [Canada] | Clinical manifestations of Parkinson's disease and parkinsonism |
| 000970 |
Nancy Belanger [Canada] ; Laurent Gregoire [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Paul J. Bedard [Canada] | Chronic treatment with small doses of cabergoline prevents Dopa-induced dyskinesias in Parkinsonian monkeys |
| 000971 |
Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications |
| 000972 |
Antonio P. Strafella [Canada] ; Alain Dagher [Canada] ; Abbas F. Sadikot [Canada] | Cerebral blood flow changes induced by subthalamic stimulation in Parkinson's disease |
| 000974 |
Stephen J. Kish [Canada] | Biochemistry of Parkinson's disease: Is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? |
| 000975 |
D. J. Brooks [Royaume-Uni] ; K. A. Frey [États-Unis] ; K. L. Marek [États-Unis] ; D. Cakes [États-Unis] ; D. Paty [Canada] ; R. Prentice [États-Unis] ; C. W. Shults [États-Unis] ; A. J. Stoessl [Canada] | Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease |
| 000976 |
Jason A. R. Carr [Canada] ; Christopher R. Honey ; Marci Sinden ; Anthony G. Phillips ; Jeffrey S. Martzke | A waitlist control-group study of cognitive, mood, and quality of life outcome after posteroventral pallidotomy in Parkinson disease |
| 000977 |
David K. Simon [États-Unis] ; Jennifer Friedman ; Xandra O. Breakefield [États-Unis] ; Joseph Jankovic [États-Unis] ; Mitchell F. Brin [États-Unis] ; John Provias [Canada] ; Susan B. Bressman [États-Unis] ; Michael E. Charness [États-Unis] ; Daniel Tarsy [États-Unis] ; Donald R. Johns [États-Unis] ; Mark A. Tarnopolsky [Canada] | A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia |
| 000978 |
S. Karamohamed [États-Unis] ; A. L. Destefano [États-Unis] ; J. B. Wilk [États-Unis] ; C. M. Shoemaker [États-Unis] ; L. I. Golbe [États-Unis] ; M. H. Mark [États-Unis] ; A. M. Lazzarini [États-Unis] ; O. Suchowersky [Canada] ; N. Labelle [Canada] ; M. Guttman [Canada] ; L. J. Currie [États-Unis] ; G. F. Wooten [États-Unis] ; M. Stacy [États-Unis] ; M. Saint-Hilaire [États-Unis] ; R. G. Feldman [États-Unis] ; K. M. Sullivan [États-Unis] ; G. Xu [États-Unis] ; R. Watts [États-Unis] ; J. Growdon [États-Unis] ; M. Lew [États-Unis] ; C. Waters [États-Unis] ; P. Vieregge [Allemagne] ; P. P. Pramstaller [Italie] ; C. Klein [Allemagne] ; B. A. Racette [États-Unis] ; J. S. Perlmutter [États-Unis] ; A. Parsian [États-Unis] ; C. Singer [États-Unis] ; E. Montgomery [États-Unis] ; K. Baker [États-Unis] ; J. F. Gusella [États-Unis] ; S. J. Fink [États-Unis] ; R. H. Myers [États-Unis] ; A. Herbert [États-Unis] | A haplotype at the PARK3 locus influences onset age for Parkinson's disease: The GenePD study |
| 000979 |
C. Warren Olanow [États-Unis] ; Christopher G. Goetz [États-Unis] ; Jeffrey H. Kordower [États-Unis] ; A. Jon Stoessl [Canada] ; Vesna Sossi [Canada] ; Mitchell F. Brin [États-Unis] ; Kathleen M. Shannon [États-Unis] ; G. Michael Nauert [États-Unis] ; Daniel P. Perl [États-Unis] ; James Godbold [États-Unis] ; Thomas B. Freeman [États-Unis] | A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's Disease |
| 000980 |
Robert Jr Laforce [Canada] | Revue des mécanismes d'apprentissage par lesquels le striatum participe à l'apprentissage implicite d'habiletés |
| 000981 |
J.-F. Gagnon [Canada] ; J. Montplaisir [Canada] ; M.-A. Bedard [Canada] | Les troubles du sommeil paradoxal dans la maladie de Parkinson |
| 000982 |
Anne-Geneviève Herbaut [Belgique] | Le plancher pelvien neurologique et le gastro-entérologue |
| 000983 |
A. Beuter [Canada] ; R. Edwards [Canada] | Caractérisation et discrimination du tremblement cinétique dans la maladie de Parkinson |
| 000984 |
Anette V. Nieves [Canada, États-Unis] ; Anthony E. Lang [Canada] | Treatment of excessive daytime sleepiness in patients with Parkinson's Disease with modafinil |
| 000985 |
B. D. Westerberg [Canada] ; J. B. Roberson [États-Unis] ; B. A. Stach [Canada] ; G. D. Silverberg [États-Unis] ; G. Heit [États-Unis] | The effects of posteroventral pallidotomy on balance function in patients with Parkinson's disease |
| 000986 |
Todd S. Woodward [Canada] ; Daniel N. Bub [Canada] ; Michael A. Hunter [Canada] | Task switching deficits associated with Parkinson's disease reflect depleted attentional resources |
| 000987 |
H. Christopher Hyson [Canada] ; Andrew M. Johnson [Canada] ; Mandar S. Jog [Canada] | Sublingual atropine for sialorrhea secondary to parkinsonism: A pilot study |
| 000988 |
J. Q. Lu [Canada] ; A. J. Stoessl [Canada] | Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats |
| 000989 |
H. Uri Saragovi [Canada] ; Maria Clara Zaccaro [Canada] | Small molecule peptidomimetic ligands of neurotrophin receptors, identifying binding sites, activation sites and regulatory sites |
| 000990 |
R. Levy [Canada] ; A. E. Lang [Canada] ; W. D. Hutchison [Canada] ; A. M. Lozano [Canada] ; J. O. Dostrovsky [Canada] | Simultaneous repetitive movements following pallidotomy or subthalamic deep brain stimulation in patients with Parkinson's disease |
| 000991 |
Ivar Mendez [Canada] ; Alain Dagher ; Murray Hong ; Paula Gaudet ; Swarna Weerasinghe ; Vivian Mcalister ; David King ; Jacques Desrosiers ; Sultan Darvesh ; Tanya Acorn ; Harold Robertson | Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study: Report of three cases |
| 000993 |
Vincenzo Di Matteo [Italie] ; Marisa Cacchio [Italie] ; Camillo Di Giulio [Italie] ; Ennio Esposito [Italie] | Role of serotonin2C receptors in the control of brain dopaminergic function |
| 000994 |
J.-F. Gagnon [Canada] ; M.-A. Bedard [Canada] ; M. L. Fantini [Canada] ; D. Petit [Canada] ; M. Panisset [Canada] ; S. Rompre [Canada] ; J. Carrier [Canada] ; J. Montplaisir [Canada] | REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease |
| 000995 |
Andrew J. Thompson [Royaume-Uni] ; Colin J. Barrow [Canada] | Protein conformational misfolding and amyloid formation: Characteristics of a new class of disorders that include Alzheimer's and Prion diseases |
| 000996 |
Connie Marras [Canada] ; Paula Rochon [Canada] ; Anthony E. Lang [Canada] | Predicting motor decline and disability in Parkinson disease: A systematic review |
| 000997 |
M. Guttman [Canada] ; P. M. Slaughter [Canada] ; M.-E. Theriault [Canada] ; D. P. Deboer [Canada] ; C. D. Naylor [Canada] | Parkinsonism in Ontario: Physician utilization |
| 000998 |
Anita L. Destefano [États-Unis] ; Mark F. Lew [États-Unis] ; Lawrence I. Golbe [États-Unis] ; Margery H. Mark [États-Unis] ; Alice M. Lazzarini [États-Unis] ; Mark Guttman [Canada] ; Erwin Montgomery [États-Unis] ; Cheryl H. Waters [États-Unis] ; Carlos Singer [États-Unis] ; Ray L. Watts [États-Unis] ; Lillian J. Currie [États-Unis] ; G. Frederick Wooten [États-Unis] ; Nancy E. Maher [États-Unis] ; Jemma B. Wilk [États-Unis] ; Kristin M. Sullivan [États-Unis] ; Karen M. Slater [États-Unis] ; Marie H. Saint-Hilaire [États-Unis] ; Robert G. Feldman [États-Unis] ; Oksana Suchowersky [Canada] ; Anne-Louise Lafontaine [Canada] ; Nancy Labelle [Canada] ; John H. Growdon [États-Unis] ; Peter Vieregge [Allemagne] ; Peter P. Pramstaller [Italie] ; Christine Klein [Allemagne] ; Jean P. Hubble [États-Unis] ; Carson R. Reider [États-Unis] ; Mark Stacy [États-Unis] ; Marcy E. Macdonald [États-Unis] ; James F. Gusella [États-Unis] ; Richard H. Myers [États-Unis] | PARK3 influences age at onset in parkinson disease: A genome scan in the GenePD study |
| 000A00 |
Alan Kingstone [Canada] ; Raymond Klein [Canada] ; Sharon Morein-Zamir [Canada] ; Amelia Hunt [Canada] ; John Fisk [Canada] ; Charles Maxner [Canada] | Orienting attention in aging and Parkinson's disease: Distinguishing modes of control |
| 000A01 |
Jeffrey D. Atkinson [Canada] ; D. Louis Collins ; Gilles Bertrand ; Terry M. Peters ; G. Bruce Pike ; Abbas F. Sadikot | Optimal location of thalamotomy lesions for tremor associated with Parkinson disease: a probabilistic analysis based on postoperative magnetic resonance imaging and an integrated digital atlas |
| 000A02 |
Z. H. T. Kiss [Canada] ; D. M. Mooney [Canada] ; L. Renaud [Canada] ; B. Hu [Canada] | Neuronal response to local electrical stimulation in rat thalamus: Physiological implications for mechanisms of deep brain stimulation |
| 000A03 |
Mohamed Shafiq [Canada] ; Anthony E. Lang [Canada] | Myoclonus in parkinsonian disorders |
| 000A04 |
Aviva Abosch [Canada] ; William D. Hutchison ; Jean A. Saint-Cyr ; Jonathan O. Dostrovsky ; Andres M. Lozano | Movement-related neurons of the subthalamic nucleus in patients with Parkinson disease |
| 000A08 |
Jean A. Saint-Cyr [Canada] ; Tasnuva Hoque ; Luiz C. M. Pereira ; Jonathan O. Dostrovsky ; William D. Hutchison ; David J. Mikulis ; Aviva Abosch ; Elspeth Sime ; Anthony E. Lang ; Andres M. Lozano | Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging |
| 000A09 |
David A. Grimes [Canada] ; J. David Grimes [Canada] ; Lem Racacho [Canada] ; Kylie A. Scoggan [Canada] ; Fabin Han [Canada] ; Betty Anne Schwarz [Canada] ; John Woulfe [Canada] ; Dennise Bulman [Canada] | Large French-Canadian family with Lewy body parkinsonism: Exclusion of known loci |
| 000A12 |
Kristen J. Armstrong [Canada] ; Lennard P. Niles [Canada] | Induction of GDNF mRNA expression by melatonin in rat C6 glioma cells |
| 000A13 |
Frédéric Calon [Canada] ; Sam Birdi [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias |
| 000A14 |
Vesna Sossi [Canada] ; Raul De La Fuente-Fernandez [Canada] ; James E. Holden [États-Unis] ; Doris J. Doudet [Canada] ; Jess Mckenzie [Canada] ; A. J. Stoessl [Canada] ; T. J. Ruth [Canada] | Increase in dopamine turnover occurs early in Parkinson's disease: Evidence from a new modeling approach to PET 18F-fluorodopa data |
| 000A15 |
James E. Holden [États-Unis] ; Salma Jivan [Canada] ; Thomas J. Ruth [Canada] ; Doris J. Doudet [Canada] | In vivo receptor assay with multiple ligand concentrations: An equilibrium approach |
| 000A16 |
Ian Q. Whishaw [Canada] ; Oksana Suchowersky [Canada] ; Leigh Davis [Canada] ; Justyna Sarna [Canada] ; Gerlinde A. Metz [Canada] ; Sergio M. Pellis [Canada] | Impairment of pronation, supination, and body co-ordination in reach-to-grasp tasks in human Parkinson's disease (PD) reveals homology to deficits in animal models |
| 000A17 |
Mary Jenkins [Canada] ; Dan Mendonca [Canada] ; Andrew Parrent [Canada] ; Mandar S. Jog [Canada] | Hemiparkinsonism-somatic hemiatrophy syndrome |
| 000A20 |
Douglas E. Hobson [Canada] ; Anthony E. Lang [Canada] ; W. R. Wayne Martin [Canada] ; Ajmal Razmy [Canada] ; Jean Rivest [Canada] ; Jonathan Fleming [Canada] | Excessive daytime Sleepiness and sudden-onset Sleep in Parkinson disease: A survey by the Canadian Movement Disorders Group |
| 000A21 |
Sophie Callier [France, Canada] ; Maryvonne Le Saux [France] ; Anne-Marie Lhiaubet [France] ; Thérèse Di Paolo [Canada] ; William Rostene [France] ; Didier Pelaprat [France] | Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture |
| 000A22 |
Michel Cyr [Canada] ; Frederic Calon [Canada] ; Marc Morissette [Canada] ; Thérèse Di Paolo [Canada] | Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease |
| 000A23 |
N. E. Maher [États-Unis, Canada, Allemagne, Italie] ; L. I. Golbe ; A. M. Lazzarini ; M. H. Mark ; L. J. Currie ; G. F. Wooten ; M. Saint-Hilaire ; J. B. Wilk ; J. Volcjak ; J. E. Maher ; R. G. Feldman ; M. Guttman ; M. Lew ; S. Schuman ; O. Suchowersky ; A. L. Lafontaine ; N. Labelle ; P. Vieregge ; P. P. Pramstaller ; C. Klein ; J. Hubble ; C. Reider ; J. Growdon ; R. Watts ; E. Montgomery ; K. Baker ; C. Singer ; M. Stacy ; R. H. Myers | Epidemiologic study of 203 sibling pairs with Parkinson's disease: The GenePD study |
| 000A24 |
D. Cunic [Canada] ; L. Roshan [Canada] ; F. I. Khan [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] ; R. Chen [Canada] | Effects of subthalamic nucleus stimulation on motor cortex excitability in Parkinson's disease |
| 000A26 |
A. Berney [Suisse, Canada] ; F. Vingerhoets [Suisse] ; A. Perrin [Suisse] ; P. Guex [Suisse] ; J.-G. Villemure [Suisse] ; P. R. Burkhard [Suisse] ; C. Benkelfat [Canada] ; J. Ghika [Suisse] | Effect on mood of subthalamic DBS for Parkinson's disease: A consecutive series of 24 patients |
| 000A27 |
G. A. Metz [Canada] ; I. Q. Whishaw [Canada] | Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance |
| 000A28 |
Raul De La Fuente-Fernandez [Canada] ; Anthony G. Phillips [Canada] ; Mariangela Zamburlini [Canada] ; Vesna Sossi [Canada] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Dopamine release in human ventral striatum and expectation of reward |
| 000A29 |
C. E. Clarke [Royaume-Uni] ; M. Guttman [Canada] | Dopamine agonist monotherapy in Parkinson's disease |
| 000A30 |
Janine F. Hay [Canada] ; Morris Moscovitch [Canada] ; Brian Levinc [Canada] | Dissociating habit and recollection: evidence from Parkinson's disease, amnesia and focal lesion patients |
| 000A31 |
Robert Jr Laforce [Canada] ; Julien Doyon [Canada] | Differential role for the striatum and cerebellum in response to novel movements using a motor learning paradigm |
| 000A32 |
Ron Levy [Canada] ; Peter Ashby [Canada] ; William D. Hutchison [Canada] ; Anthony E. Lang [Canada] ; Andres M. Lozano [Canada] ; Jonathan O. Dostrovsky [Canada] | Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease |
| 000A33 |
Anthony E. Lang [Canada] ; Hakan Widner [Suède] | Deep brain stimulation for Parkinson's disease: Patient selection and evaluation |
| 000A35 |
Francois Tremblay [Canada] ; Louis E. Tremblay [Canada] | Cortico-motor excitability of the lower limb motor representation: a comparative study in Parkinson's disease and healthy controls |
| 000A36 |
Yun J. Kim [Canada] ; Masanori Ichise [Canada] ; James R. Ballinger [Canada] ; Douglas Vines [Canada] ; Sean S. Erami [Canada] ; Tatsuro Tatschida [Canada] ; Anthony E. Lang [Canada] | Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP |
| 000A37 |
Nicole Duchesne [Canada] ; Jean-Paul Soucy [Canada] ; Hélène Masson [Canada] ; Sylvain Chouinard [Canada] ; Marc-André Bedard [Canada] | Cognitive deficits and striatal dopaminergic denervation in Parkinson's disease: A single photon emission computed tomography study using 123Iodine-β-CIT in patients on and OFF levodopa |
| 000A38 |
Azi H. Rajput [Canada] ; Mark E. Fenton [Canada] ; Sam Birdi [Canada] ; Rob Macaulay [Canada] ; David George [Canada] ; Bohdar Rozdilsky [Canada] ; Lee C. Ang [Canada] ; Ambikaipakan Senthilselvan [Canada] ; Oleh Hornykiewicz [Autriche] | Clinical-pathological study of levodopa complications |
| 000A39 |
Yoshiaki Furukawa [Canada] ; Sophie Vigouroux [France] ; Henry Wong [Canada] ; Mark Guttman [Canada] ; Ali H. Rajput [Canada] ; LEE ANG [Canada] ; Marièle Briand [France] ; Stephen J. Kish [Canada] ; Yves Briand [France] | Brain proteasomal function in sporadic Parkinson's disease and related disorders |
| 000A40 |
Quincy J. Almeida [Canada] ; Laurie R. Wishart [Canada] ; Timothy D. Lee [Canada] | Bimanual coordination deficits with Parkinson's disease: The influence of movement speed and external cueing |
| 000A41 |
Patrick L. Mcgeer [Canada] ; Koji Yasojima [Canada] ; Edith G. Mcgeer [Canada] | Association of interleukin-1β polymorphisms with idiopathic Parkinson's disease |
| 000A44 |
J. M. Woulfe [Canada] ; R. Duke [Canada] ; J. M. Middeldorp [Pays-Bas] ; S. Stevens [Pays-Bas] ; M. Vervoort [Pays-Bas] ; M. Hashimoto [États-Unis] ; E. Masliah [États-Unis] ; P. Chan ; D. A. Di Monte [États-Unis] ; J. W. Langston [États-Unis] ; G. Petzinger [États-Unis] ; H. Hoogendoorn [Canada] ; D. G. Munoz [Canada, Espagne] | Absence of elevated anti-α-synuclein and anti-EBV latent membrane protein antibodies in PD |
| 000A45 |
Rubia P. Meshack [Canada] ; Kathleen E. Norman [Canada] | A randomized controlled trial of the effects of weights on amplitude and frequency of postural hand tremor in people with Parkinson's disease |
| 000A46 |
Ravikant S. Palur [Canada] ; Caglar Berk ; Michael Schulzer ; Christopher R. Honey | A metaanalysis comparing the results of pallidotomy performed using microelectrode recording or macroelectrode stimulation |
| 000A48 |
| Parkinson's disease |
| 000A49 |
J. Thomas Hutton [États-Unis] ; Jerry L. Morris [États-Unis] | Vision in Parkinson's disease |
| 000A50 |
Wakako Maruyama [Japon] ; Yukihiro Akao [Japon] ; Moussa B. H. Youdim [Israël] ; Bruce A. Davis [Canada] ; Makoto Naoi [Japon] | Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol |
| 000A51 |
J. Thomas Hutton [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Thomas N. Chase [États-Unis] ; Jorge L. Juncos [États-Unis] ; William C. Koller [États-Unis] ; Rajesh Pahwa [États-Unis] ; Peter A. Lewitt [États-Unis] ; Ali Samii [Canada] ; Joseph K. C. Tsui [Canada] ; Donald B. Calne [Canada] ; Cheryl H. Waters [États-Unis] ; Vincent P. Calabrese [États-Unis] ; James P. Bennett [États-Unis] ; Richard Barrett [États-Unis] ; Jerry L. Morris [États-Unis] | Transdermal dopaminergic D2 receptor agonist therapy in Parkinson's disease with N-0923 TDS: A double-blind, placebo-controlled study |
| 000A52 |
Alain Dagher [Royaume-Uni, Canada] ; Adrian M. Owen [Royaume-Uni] ; Henning Boecker [Royaume-Uni] ; David J. Brooks [Royaume-Uni] | The role of the striatum and hippocampus in planning : A PET activation study in Parkinson's disease |
| 000A53 |
Ali H. Rajput [Canada] | The protective role of levodopa in the human substantia nigra |
| 000A54 |
Kurt A. Jellinger [Autriche] | The pathology of Parkinson's disease |
| 000A55 |
Serge Przedborski [États-Unis] ; Miquel Vila | The last decade in Parkinson's disease research: Basic sciences |
| 000A56 |
Stephen A. Marion [Canada] | The epidemiology of Parkinson's disease: Current issues |
| 000A57 |
Andrzej Friedman [Pologne] ; Jolanta Galazka-Friedman [Pologne] | The current state of free radicals in Parkinson's disease: Nigral iron as a trigger of oxidative stress |
| 000A58 |
Lauri V. Laitinen [Suède] | Surgical treatment for Parkinson's disease over the last decade |
| 000A59 |
C. Warren Olanow [États-Unis] ; Mitchell F. Brin [États-Unis] | Surgical therapies for Parkinson's disease: A physician's perspective |
| 000A60 |
J. F. Marsden [Royaume-Uni] ; P. Limousin-Dowsey [Royaume-Uni, France] ; P. Ashby [Canada] ; P. Pollak [France] ; P. Brown [Royaume-Uni] | Subthalamic nucleus, sensorimotor cortex and muscle interrelationships in Parkinson's disease |
| 000A61 |
Thomas N. Chase [États-Unis] ; Spiridon Konitsiotis [États-Unis] ; Justin D. Oh [États-Unis] | Striatal molecular mechanisms and motor dysfunction in Parkinson's disease |
| 000A62 |
Fabrizio Stocchi [Italie] ; Laura Vacca [Italie] ; Marcella Valente [Italie] ; Stefano Ruggieri [Italie] | Sleep disorders in Parkinson's disease |
| 000A63 |
Rosemary Basson [Canada] | Sex and idiopathic Parkinson's disease |
| 000A64 |
Vijay Dhawan [États-Unis] ; David Eidelberg [États-Unis] | SPECT imaging in Parkinson's disease |
| 000A65 |
Pierre J. Blanchet [Canada] ; Frédéric Calon [Canada] ; Marc Morissette [Canada] ; Martin Goulet [Canada] ; Richard Grondin [Canada] ; Daniel Levesque [Canada] ; Paul J. Bedard [Canada] ; Thérèse Di Paolo [Canada] | Regulation of dopamine receptors and motor behavior following pulsatile and continuous dopaminergic replacement strategies in the MPTP primate model |
| 000A66 |
Erik Ch. Wolters [Pays-Bas] | Psychiatric complications in the treatment of Parkinson's disease |
| 000A67 |
P. Ashby [Canada] ; G. Paradiso [Canada] ; J. A. Saint-Cyr [Canada] ; R. Chen [Canada] ; A. E. Lang [Canada] ; A. M. Lozano [Canada] | Potentials recorded at the scalp by stimulation near the human subthalamic nucleus |
| 000A68 |
Andreas Hartmann [France] ; Etienne C. Hirsch [France] | Parkinson's disease: The apoptosis hypothesis revisited |
| 000A69 |
Andres M. Lozano [Canada] ; Anthony E. Lang [Canada] | Pallidotomy for Parkinson's disease |
| 000A70 |
Ahmed Alkhani [Canada] ; Andres M. Lozano [Canada] | Pallidotomy for Parkinson disease : a review of contemporary literature |
| 000A71 |
Doris J. Doudet [Canada] | PET studies in the MPTP model of Parkinson's disease |
| 000A72 |
Amos D. Korczyn [Israël] | Neuropsychiatric manifestations in Parkinson's disease |
| 000A73 |
A. Jon Stoessl [Canada] | Neurochemical and neuroreceptor imaging with PET in Parkinson's disease |
| 000A74 |
Thomas B. Freeman [États-Unis] ; Allison Willing [États-Unis] ; Tanya Zigova [États-Unis] ; Paul R. Sanberg [États-Unis] ; Robert A. Hauser [États-Unis] | Neural transplantation in Parkinson's disease |
| 000A75 |
Peter Riederer [Allemagne] ; Heinz Reichmann [Allemagne] ; Bernd Janetzky [Allemagne] ; Jeswinder Sian [Allemagne] ; Klaus-Peter Lesch [Allemagne] ; Klaus W. Lange [Allemagne] ; K. L. Double [Allemagne] ; Toshiharu Nagatsu [Japon] ; Manfred Gerlach [Allemagne] | Neural degeneration in Parkinson's disease |
| 000A76 |
M. Fukuda [États-Unis] ; M. J. Mentis [États-Unis] ; Y. Ma [États-Unis] ; V. Dhawan [États-Unis] ; A. Antonini [États-Unis] ; A. E. Lang [Canada] ; A. M. Lozano [Canada] ; J. Hammerstad [États-Unis] ; K. Lyons [États-Unis] ; W. C. Koller [États-Unis] ; J. R. Moeller [États-Unis] ; D. Eidelberg [États-Unis] | Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A pet study of resting-state glucose metabolism |
| 000A77 |
Edith V. Sullivan [États-Unis] ; Paula K. Shear [États-Unis] ; Maria Stein [États-Unis] ; Rosemary Fama [États-Unis] ; Deborah A. Cahn-Weiner [États-Unis] ; Robert B. Zipursky [Canada] ; Adolf Pfefferbaum [États-Unis] | Motor sequencing deficits in schizophrenia: a comparison with Parkinson's disease |
| 000A78 |
Doris J. Doudet [Canada] | Monitoring disease progression in Parkinson's disease |
| 000A79 |
Thomas Gasser [Allemagne] | Molecular genetics of Parkinson's disease |
| 000A80 |
Richard Camicioli [États-Unis, Canada] ; Eric Lea [États-Unis] ; John G. Nutt [États-Unis] ; Gary Sexton [États-Unis] ; Barry S. Oken [États-Unis] | Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: A pilot study |
| 000A82 |
W. R. Wayne Martin [Canada] | Magnetic resonance imaging and spectroscopy in Parkinson's disease |
| 000A83 |
A. Y. Alemdar [Canada] ; K. A. Baker [Canada] ; D. Sadi [Canada] ; V. C. Mcalister [Canada] ; I. Mendez [Canada] | Liposomal tacrolimus administered systemically and within the donor cell suspension improves xenograft survival in hemiparkinsonian rats |
| 000A84 |
Ron Levy [Canada] ; Anthony E. Lang [Canada] ; Jonathan O. Dostrovsky [Canada] ; Peter Pahapill [États-Unis] ; John Romas [Canada] ; Jean Saint-Cyr [Canada] ; William D. Hutchison [Canada] ; Andres M. Lozano [Canada] | Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms |
| 000A85 |
Evian Gordon [Australie] | Integrative psychophysiology |
| 000A86 |
K. Tieu [Canada] ; P. C. Ashe [Canada] ; D. M. Zuo [Canada] ; P. H. Yu [Canada] | Inhibition of 6-hydroxydopamine-induced p53 expression and survival of neuroblastoma cells following interaction with astrocytes |
| 000A87 |
M. Guttman [Canada] ; D. Stewart [Canada] ; D. Hussey [Canada] ; A. Wilson [Canada] ; S. Houle [Canada] ; S. Kish [Canada] | Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD |
| 000A88 |
Patrick L. Mcgeer [Canada] ; Koji Yasojima [Canada] ; Edith G. Mcgeer [Canada] | Inflammation in Parkinson's disease |
| 000A89 |
Mahyar Etminan [Canada] ; Ali Samii [États-Unis] ; Bahi Takkouche [Espagne] ; Paula A. Rochon [Canada] | Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials |
| 000A90 |
Hitoshi Shinotoh [Japon] ; Hiroki Namba [Japon] ; Mika Yamaguchi [Japon] ; Kiyoshi Fukushi [Japon] ; Shin-Ichiro Nagatsuka [Japon] ; Masaomi Iyo [Japon] ; Masato Asahina [Japon] ; Takamichi Hattori [Japon] ; Shuji Tanada [Japon] ; Toshiaki Irie [Japon] | In vivo mapping of brain cholinergic function in Parkinson's disease and progressive supranuclear palsy |
| 000A91 |
Toshiya Murai [Canada, Allemagne] ; Ulrich Müller ; Katja Werheid ; Dietlind Sorger ; Mike Reuter ; Thomas Becker ; D. Yves Von Cramon ; Henryk Barthel | In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinson's Disease |
| 000A92 |
Ole Isacson [États-Unis] ; Craig Van Horne [États-Unis] ; James M. Schumacher [États-Unis] ; Anna-Liisa Brownell [États-Unis] | Improved surgical cell therapy in Parkinson's disease: Physiological basis and new transplantation methodology |
| 000A93 |
Robert Chen [Canada] ; SAMEER KUMAR [Canada] ; Rami R. Garg [Canada] ; Anthony E. Lang [Canada] | Impairment of motor cortex activation and deactivation in Parkinson's disease |
| 000A94 |
Caterina Breitenstein [Allemagne, États-Unis, Canada] ; Diana Van Lancker [États-Unis] ; Irene Daum [Allemagne] ; Cheryl H. Waters [États-Unis] | Impaired perception of vocal emotions in Parkinson's disease : Influence of speech time processing and executive functioning |
| 000A95 |
Kirk A. Frey [États-Unis] ; Robert A. Koeppe ; Michael R. Kilbourn | Imaging the vesicular monoamine transporter |
| 000A97 |
Kevin St. P. Mcnaught [Royaume-Uni] ; Moonhee Lee [Royaume-Uni] ; Dong-Hoon Hyun [Royaume-Uni] ; Peter Jenner [Royaume-Uni] | Glial cells and abnormal protein handling in the pathogenesis of Parkinson's disease |
| 000A98 |
A. L. Destefano [États-Unis] ; L. I. Golbe [États-Unis] ; M. H. Mark [États-Unis] ; A. M. Lazzarini [États-Unis] ; N. E. Maher [États-Unis] ; M. Saint-Hilaire [États-Unis] ; R. G. Feldman [États-Unis] ; M. Guttman [États-Unis] ; R. L. Watts [États-Unis] ; O. Suchowersky [Canada] ; A. L. Lafontaine [Canada] ; N. Labelle [Canada] ; M. F. Lew [États-Unis] ; C. H. Waters [États-Unis] ; J. H. Growdon [États-Unis] ; C. Singer [États-Unis] ; L. J. Currie [États-Unis] ; G. F. Wooten [États-Unis] ; P. Vieregge [Allemagne] ; P. P. Pramstaller [Italie] ; C. Klein [Allemagne] ; J. P. Hubble [États-Unis] ; M. Stacy [États-Unis] ; E. Montgomery [États-Unis] ; M. E. Macdonald [États-Unis] ; J. F. Gusella [États-Unis] ; R. H. Myers [États-Unis] | Genome-wide scan for Parkinson's disease: The genePD Study |
| 000A99 |
Nir Giladi [Israël] | Gait disturbances in advanced stages of Parkinson's disease |
| 000B00 |
David B. Ramsden [Royaume-Uni] ; Richard B. Parsons [Royaume-Uni] ; Shu-Leong Ho [Hong Kong] ; TAO XIE [États-Unis] ; Rosemary Hope Waring [Royaume-Uni] ; Adrian Charles Williams [Hong Kong] | Further studies in xenobiotic metabolism and Parkinson's disease |
| 000B01 |
Masafumi Fukuda [États-Unis] ; Marc Mentis [États-Unis] ; Maria Felice Ghilardi [États-Unis] ; Vijay Dhawan [États-Unis] ; Angelo Antonini [États-Unis] ; John Hammerstad [États-Unis] ; Andres M. Lozano [Canada] ; Anthony Lang [Canada] ; Kelly Lyons [États-Unis] ; William Koller [États-Unis] ; Claude Ghez [États-Unis] ; David Eidelberg [États-Unis] | Functional correlates of pallidal stimulation for Parkinson's Disease |
| 000B03 |
John G. Nutt [États-Unis] | Fluctuations in response to treatment for Parkinson's disease |
| 000B04 |
Yoshikuni Mizuno [Japon] ; Nobutaka Hattori [Japon] ; Tohru Kitada [Japon] ; Hiroto Matsumine [Japon] ; Hideo Mori [Japon] ; Hideki Shimura [Japon] ; Shinichiro Kubo [Japon] ; Hirokazu Kobayashi [Japon] ; Shuichi Asakawa [Japon] ; Shinsei Minoshima [Japon] ; Nobuyoshi Shimizu [Japon] | Familial Parkinson's disease: α-Synuclein and parkin |
| 000B05 |
Zbigniew K. Wszolek [États-Unis] ; Ryan J. Uitti [États-Unis] ; Katerina Markopoulou [États-Unis] | Familial Parkinson's disease and related conditions: Clinical genetics |
| 000B06 |
André Parent [Canada] ; Martine Cossette [Canada] | Extrastriatal dopamine and Parkinson's disease |
| 000B07 |
Raul De La Fuente-Fernandez [Canada] ; Thomas J. Ruth [Canada] ; Vesna Sossi [Canada] ; Michael Schulzer [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Expectation and dopamine release: Mechanism of the placebo effect in Parkinson's disease |
| 000B09 |
W. Maruyama [Japon] ; A. A. Boulton [Canada] ; B. A. Davis [Canada] ; P. Dostert [France] ; M. Naoi [Japon] | Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells : Suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine |
| 000B10 |
Poornima K. Tekumalla [États-Unis] ; Frédéric Calon [Canada] ; Zia Rahman [États-Unis] ; Sam Birdi [Canada] ; Ali H. Rajput [Canada] ; Oleh Hornykiewicz [Canada, Autriche] ; Therese Di Paolo [Canada] ; Paul J. Bedard [Canada] ; Eric J. Nestler [États-Unis] | Elevated levels of ΔFosB and RGS9 in striatum in Parkinson's disease |
| 000B11 |
B. M. Ross [Canada] ; N. Mamalias [Canada] ; A. Moszczynska [Canada] ; A. H. Rajput [Canada] ; S. J. Kish [Canada] | Elevated activity of phospholipid biosynthetic enzymes in substantia nigra of patients with Parkinson's disease |
| 000B12 |
Robert Chen [Canada] ; Rami R. Garg [Canada] ; Andres M. Lozano [Canada] ; Anthony E. Lang [Canada] | Effects of internal globus pallidus stimulation on motor cortex excitability |
| 000B13 |
ABDALLAH HADJ TAHAR [Canada] ; Anna Ekesbo [Suède] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Kjell A. Svensson [États-Unis] ; Joakim Tedroff [Suède] ; Paul J. Bedard [Canada] | Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys |
| 000B15 |
Moussa B. H. Youdim [Israël] ; Edna Grünblatt [Israël] ; Yona Levites-Royak [Israël] ; Silvia Mandel [Israël] | Drugs to prevent cell death in Parkinson's disease: Neuroprotection against oxidative stress and inflammatory gene expression |
| 000B16 |
Oleh Hornykiewicz [Autriche] | Dopamine and Parkinson's disease: A personal view of the past, the present, and the future |
| 000B17 |
Olivier Rascol [France] ; Joaquim J. Ferreira [Portugal] ; Claire Thalamas [France] ; Monique Galitsky [France] ; Jean-Louis Montastruc [France] | Dopamine agonists: Their role in the management of Parkinson's disease |
| 000B18 |
Y. R. Wu [Taïwan] ; R. Levy [Canada] ; P. Ashby [Canada] ; R. R. Tasker [Canada] ; J. O. Dostrovsky [Canada] | Does stimulation of the GPi control dyskinesia by activating inhibitory axons? |
| 000B19 |
Robert Jr Laforce [Canada] ; Julien Doyon [Canada] | Distinct contribution of the striatum and cerebellum to motor learning |
| 000B20 |
Eric R. Marcotte [Canada] ; Anita Chugh [Canada] ; Cia Barlas [Canada] ; Ram K. Mishra [Canada] | Differential regulation of striatal G protein levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration in C57 BL/6 mice |
| 000B21 |
Wolfgang H. Oertel [Allemagne] ; Günter U. Höglinger [Allemagne] ; Tommaso Caraceni [Italie] ; F. Girotti [Italie] ; Tobias Eichhorn [Allemagne] ; Annika E. Spottke [Allemagne] ; Jürgen C. Krieg [Allemagne] ; Werner Poewe [Autriche] | Depression in Parkinson's disease: An update |
| 000B22 |
Susan L. Mitchell [Canada] ; Kenneth Rockwood [Canada] | Defining parkinsonism in the Canadian Study of Health and Aging |
| 000B24 |
Alim-Louis Benabid [France] ; Adnan Koudsie [France] ; Abdelhamid Benazzouz [France] ; Brigitte Piallat [France] ; Paul Krack [Allemagne] ; Patricia Limousin-Dowsey [Royaume-Uni] ; Jean Francois Lebas [France] ; Pierre Pollak [France] | Deep brain stimulation for Parkinson's disease |
| 000B26 |
Oksana Suchowersky [États-Unis, Canada] ; Peter Bailey ; E. Pourcher ; Lynne Bulger ; Giovanni Facciponte | Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD |
| 000B27 |
Michael Schulzer [Canada] | Common pitfalls in the interpretation of statistical tests in the measurement of quality of life in Parkinson's disease |
| 000B28 |
Lüder Deecke [Autriche] | Clinical neurophysiology of Parkinson's disease: Bereitschaftspotential and contingent negative variation |
| 000B29 |
David J. Brooks [Royaume-Uni] | Cerebral blood flow activation studies in Parkinson's disease |
| 000B30 |
A. H. V. Schapira [Royaume-Uni] | Causes of neuronal death in Parkinson's disease |
| 000B31 |
Heikki Ter V Inen [Finlande] ; Urpo Rinne [Finlande] ; Ariel Gordin [Finlande] | Catechol-O-methyltransferase inhibitors in Parkinson's disease |
| 000B32 |
Raul De La Fuente-Fernandez [Canada] ; Jian-Qiang Lu [Canada] ; Vesna Sossi [Canada] ; Salma Jivan [Canada] ; Michael Schulzer [Canada] ; James E. Holden [États-Unis] ; Chong S. Lee [Canada] ; Thomas J. Ruth [Canada] ; Donald B. Calne [Canada] ; A. Jon Stoessl [Canada] | Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease : PET evidence of increased dopamine turnover |
| 000B33 |
Marco Scarselli [Italie] ; Marianna Armogida [Italie] ; Carla Pardini [Italie] ; Serena Chiacchio [Italie] ; Giovanni U. Corsini [Italie] | Apomorphine: A novel effect for an old compound |
| 000B34 |
Raul De La Fuente-Fernandez [Canada] ; Andrew S. Lim [Canada] ; Vesna Sossi [Canada] ; James E. Holden [États-Unis] ; Donald B. Calne [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Apomorphine-induced changes in synaptic dopamine levels : Positron emission tomography evidence for presynaptic inhibition |
| 000B35 |
Lana Depatie [Canada] ; Samarthji Lal [Canada] | Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? |
| 000B36 |
Daniel S. Sa [Canada] ; Shitij Kapur [Canada] ; Anthony E. Lang [Canada] | Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis |
| 000B37 |
Kjell Fuxe [Suède] ; Ingrid Strömberg [Suède] ; Patrizia Popoli [Italie] ; Roberto Rimondini-Giorgini [Suède] ; Maria Torvinen [Suède] ; Sven O. Ögren [Suède] ; Rafael Franco [Espagne] ; Luigi F. Agnati [Italie] ; Sergi Ferre [Suède] | Adenosine receptors and Parkinson's disease: Relevance of antagonistic adenosine and dopamine receptor interactions in the striatum |
| 000B39 |
Mitsuo Takahashi [Japon] ; Tatsuo Yamada [Japon] | A possible role of influenza A virus infection for Parkinson's disease |
| 000B40 |
Connie Marras [Canada] ; Anthony E. Lang [Canada] ; LEE CYN ANG [Canada] ; Jcm Zijlmans [Royaume-Uni] ; G. K. Wenning [Autriche] | 69-year-old man with gait disturbance and parkinsonism |
| 000B43 |
R. Kumar [Canada] ; A. E. Lang [Canada] ; M. C. Rodriguez-Oroz [Espagne] ; A. M. Lozano [Canada] ; P. Limousin [France] ; P. Pollak [France] ; A. L. Benabid [France] ; J. Guridi [Espagne] ; E. Ramos [Espagne] ; C. Van Der Linden [Belgique] ; A. Vandewalle [Belgique] ; J. Caemaert [Belgique] ; E. Lannoo [Belgique] ; D. Van Den Abbeele [Belgique] ; G. Vingerhoets [Belgique] ; M. Wolters [Belgique] ; J. A. Obeso [Espagne] | eep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease |
| 000B44 |
Y. L. Xue [République populaire de Chine] ; Z. F. Wang [République populaire de Chine] ; D. G. Zhong [République populaire de Chine] ; X. Cui [République populaire de Chine] ; X. J. Li [République populaire de Chine] ; X. J. Ma [République populaire de Chine] ; L. N. Wang [République populaire de Chine] ; K. Zhu [République populaire de Chine] ; A. M. Sun [Canada] | Xenotransplantation of microencapsulated bovine chromaffin cells into hemiparkinsonian monkeys |
| 000B45 |
H. Poizner [États-Unis] ; A. G. Feldman [Canada] ; M. F. Levin [Canada] ; M. B. Berkinblit [États-Unis, Russie] ; W. A. Hening [États-Unis] ; A. Patel [États-Unis] ; S. V. Adamovich [États-Unis, Russie] | The timing of arm-trunk coordination is deficient and vision-dependent in Parkinson's patients during reaching movements |
| 000B46 |
D. J. Chong [Canada] ; O. Suchowersky [Canada] ; C. Szumlanski [États-Unis] ; R. M. Weinshilboum [États-Unis] ; R. Brant [Canada] ; N. R. C. Campbell [Canada] | The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's Disease |
| 000B47 |
P. A. Pahapill [Canada] ; A. M. Lozano [Canada] | The pedunculopontine nucleus and Parkinson's disease |
| 000B48 |
Joseph Jankovic [États-Unis] ; A. H. Rajput [Canada] ; M. P. Mcdermott [États-Unis] ; D. P. Perl [États-Unis] | The evolution of diagnosis in early Parkinson Disease |
| 000B49 |
Hong Y. Choi [Canada] ; Jin H. Song [Canada] ; Dong K. Park [Corée du Sud] ; Gregory M. Ross [Canada] | The effects of ascorbic acid on dopamine-induced death of PC12 cells are dependent on exposure kinetics |
| 000B52 |
J. Guridi [Espagne] ; M. C. Rodriguez-Oroz [Espagne] ; A. M. Lozano [Canada] ; E. Moro [Italie] ; A. Albanese [Italie] ; B. Nuttin [Belgique] ; J. Gybels [Belgique] ; E. Ramos [Espagne] ; J. A. Obeso [Espagne] | Targeting the basal ganglia for deep brain stimulation in Parkinson's disease |
| 000B53 |
ABDALLAH HADJ TAHAR [Canada] ; Laurent Gregoire [Canada] ; Evelyne Bangassoro [Canada] ; Paul J. Bedard [Canada] | Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys |
| 000B54 |
A. E. Lang [Canada] ; LANGSTON ; RASCOL ; BROTCHIE ; BENABID ; MELAMED ; BONUCELLI ; OLANOW ; OBESO ; GIMENEZ-ROLDAN ; RAJPUT ; FAHN ; NUTT ; BROOKS ; CHASE | Surgery for levodopa-induced dyskinesias. Discussion |
| 000B55 |
A. E. Lang [Canada] | Surgery for Parkinson disease : A critical evaluation of the state of the art |
| 000B56 |
I. Mendez [Canada] ; K. A. Baker [Canada] ; M. Hong [Canada] | Simultaneous intrastriatal and intranigral grafting (double grafts) in the rat model of Parkinson's disease |
| 000B57 |
E. F. Field [Canada] ; I. Q. Whishaw [Canada] ; S. M. Pellis [Canada] | Sex differences in catalepsy : evidence for hormone-dependent postural mechanisms in haloperidol-treated rats |
| 000B58 |
Erich Mohr [Canada] ; Tilak Mendis [Canada] ; Kathleen Hildebrand [Canada] ; Peter Paul De Deyn [Belgique] | Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial |
| 000B59 |
W. J. Lombardi [États-Unis, Canada] ; R. E. Gross [États-Unis, Canada] ; L. L. Trepanier [Canada] ; A. E. Lang [Canada] ; A. M. Lozano [Canada] ; J. A. Saint-Cyr [Canada] | Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: Support for the existence of cognitive circuits in the human pallidum |
| 000B60 |
M. Goulet [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; S. Maltais [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of Parkinsonian-Monkeys |
| 000B62 |
C. R. Honey [Canada] ; M. O. K. Obochi ; HAO SHEN ; P. Margaron ; S. Yip ; J. G. Levy | Reduced xenograft rejection in rat striatum after pretransplant photodynamic therapy of murine neural xenografts |
| 000B63 |
Andis Klegeris [Canada] ; Patrick L. Mcgeer [Canada] | R-(-)-deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition |
| 000B65 |
M. Filion [Canada] ; OBESO ; BENABID ; OLANOW ; LANG ; HIRSCH ; NUTT | Physiologic basis of dyskinesia. Discussion |
| 000B66 |
B. J. Snow [Canada] ; F. J. G. Vingerhoets [Canada] ; J. W. Langston [États-Unis] ; J. W. Tetrud [États-Unis] ; V. Sossi [Canada] ; D. B. Calne [Canada] | Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism |
| 000B67 |
Duong P. Huynh [États-Unis] ; Daniel R. Scoles [États-Unis] ; Trang H. Ho [États-Unis] ; Marc R. Del Bigio [Canada] ; Stefan-M. Pulst [États-Unis] | Parkin is associated with actin filaments in neuronal and nonneural cells |
| 000B68 |
M. Grandbois [Canada] ; M. Morissette [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice |
| 000B69 |
André Parent [Canada] ; Fumi Sato [Canada] ; YING WU [Canada] ; Julie Gauthier [Canada] ; Martin Levesque [Canada] ; Martin Parent [Canada] | Organization of the basal ganglia : the importance of axonal collateralization |
| 000B70 |
P. E. Radau [États-Unis, Canada, Allemagne] ; R. Linke ; P. J. Slomka ; K. Tatsch | Optimization of automated quantification of 123I-IBZM uptake in the striatum applied to parkinsonism |
| 000B71 |
R. De La Fuente-Fernandez [Canada] ; A. Kishore [Canada] ; D. B. Calne [Canada] ; T. J. Ruth [Canada] ; A. J. Stoessl [Canada] | Nigrostriatal dopamine system and motor lateralization |
| 000B73 |
L. L. Trepanier [Canada] ; R. Kumar [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] ; J. A. Saint-Cyr [Canada] | Neuropsychological outcome of GPI pallidotomy and GPI or STN deep brain stimulation in Parkinson's disease |
| 000B74 |
Jean A. Saint-Cyr [Canada] ; Lisa L. Trepanier [Canada] ; Rajeev Kumar [États-Unis] ; Andres M. Lozano [Canada] ; A. E. Lang [Canada] | Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease |
| 000B75 |
Jean A. Saint-Cyr [Canada] ; Lisa L. Trepanier [Canada] | Neuropsychologic assessment of patients for movement disorder surgery |
| 000B76 |
P. Ashby [Canada] ; J. C. Rothwell [Royaume-Uni] | Neurophysiologic aspects of deep brain stimulation |
| 000B77 |
A. M. Lozano [Canada] ; A. E. Lang [Canada] ; R. Levy [Canada] ; W. Hutchison [Canada] ; J. Dostrovsky [Canada] | Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine |
| 000B78 |
I. Mendez [Canada] ; M. Hong ; S. Smith ; A. Dagher ; J. Desrosiers | Neural transplantation cannula and microinjector system : experimental and clinical experience : Technical note |
| 000B79 |
X. Lu [Canada] ; G. Bing [États-Unis] ; T. Hagg [Canada] | Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats |
| 000B80 |
J. Woulfe [Canada] ; H. Hoogendoorn [Canada] ; M. Tarnopolsky [Canada] ; D. G. Munoz [Canada, Espagne] | Monoclonal antibodies against Epstein-Barr virus cross-react with α-synuclein in human brain |
| 000B81 |
F. Calon [Canada] ; R. Grondin [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; P. J. Blanchet [Canada] ; T. T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Molecular basis of levodopa-induced dyskinesias |
| 000B82 |
M. N. Linhares [Canada] ; R. R. Tasker [Canada] ; R. A. E. Bakay ; K. J. Burchiel ; P. J. Kelly | Microelectrode-guided thalamotomy for Parkinson's Disease. Commentary |
| 000B83 |
J. Fine [Canada] ; J. Duff [Canada] ; R. Chen [Canada] ; W. Hutchison [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] | Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease |
| 000B84 |
P. K. Pal [Canada] ; A. Samii [Canada] ; A. Kishore [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; S. Yardley [Canada] ; I. M. Turnbull [Canada] ; D. B. Calne [Canada] | Long term outcome of unilateral pallidotomy : Follow up of 15 patients for 3 years |
| 000B85 |
Ida Tonolli [France] ; Roselyne Aurenty [France] ; Robert George Lee [France, Canada] ; Francois Viallet [France] ; Jean Massion [France] | Lateral leg raising in patients with Parkinson's disease : Influence of equilibrium constraint |
| 000B86 |
K. A. Baker [Canada] ; M. Hong [Canada] ; D. Sadi [Canada] ; I. Mendez [Canada] | Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease |
| 000B88 |
C. S. Lee [Canada] ; A. Samii [Canada] ; V. Sossi [Canada] ; T. J. Ruth [Canada] ; M. Schulzer [Canada] ; J. E. Holden [États-Unis] ; J. Wudel [Canada] ; P. K. Pal [Canada] ; R. De La Fuente-Fernandez [Canada] ; D. B. Calne [Canada] ; A. J. Stoessl [Canada] | In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease |
| 000B89 |
Maria C. Yang [Canada] ; Allan J. Mclean [Canada] ; Laurent P. Rivory [Australie] ; David G. Le Couteur [Canada] | Hepafic disposition of neurotoxins and pesticides |
| 000B91 |
C. Duval [Canada] ; M. Panisset [Canada] ; G. Bertrand [Canada] ; A. F. Sadikot [Canada] | Evidence that ventrolateral thalamotomy may eliminate the supraspinal component of both pathological and physiological tremors |
| 000B92 |
R. De La Fuente-Fernandez [Canada] ; P. K. Pal [Canada] ; F. J. G. Vingerhoets [Canada] ; A. Kishore [Canada] ; M. Schulzer [Canada] ; E. K. Mak [Canada] ; T. J. Ruth [Canada] ; B. J. Snow [Canada] ; D. B. Calne [Canada] ; A. J. Stoessl [Canada] | Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations |
| 000B93 |
I. Mendez [Canada] ; A. Dagher ; M. Hong ; A. Hebb ; P. Gaudet ; A. Law ; S. Weerasinghe ; D. King ; J. Desrosiers ; S. Darvesh ; T. Acorn ; H. Robertson | Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease : Report of two cases and technical considerations |
| 000B94 |
C. S. Lee [Canada] ; M. A. Cenci [Suède] ; M. Schulzer [Canada] ; A. Björklund [Suède] | Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease |
| 000B96 |
M. Cyr [Canada] ; F. Calon [Canada] ; M. Morissette [Canada] ; M. Grandbois [Canada] ; S. Callier [Canada, France] ; T. Di Paolo [Canada] | Drugs with estrogen-like potency and brain activity : Potential therapeutic application for the CNS |
| 000B97 |
Frédéric Calon [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; Pierre J. Blanchet [Canada] ; Marc Morissette [Canada] ; Richard Grondin [Canada] ; Martin Goulet [Canada] ; Jean-Pierre Doucet [Canada] ; George S. Robertson [Canada] ; Eric Nestler [États-Unis] ; Thérèse Di Paolo [Canada] ; Paul J. Bedard [Canada] | Dopamine-receptor stimulation : biobehavioral and biochemical consequences |
| 000B98 |
Lucie Godbout [Canada] ; Julien Doyon [Canada] | Defective representation of knowledge in Parkinson's disease: Evidence from a script-production task |
| 000B99 |
K. Kumar [Canada] ; M. Kelly [Canada] ; C. Toth [Canada] | Deep brain stimulation of the ventral intermediate nucleus of the thalamus for control of tremors in Parkinson's disease and essential tremor |
| 000C02 |
C. S. Kubu [Canada] ; G. M. Grace ; A. G. Parrent | Cognitive outcome following pallidotomy : the influence of side of surgery and age of patient at disease onset |
| 000C03 |
P. K. Pal [Canada] ; D. B. Calne [Canada] ; S. Calne [Canada] ; J. K. C. Tsui [Canada] | Botulinum toxin A as treatment for drooling saliva in PD |
| 000C06 |
T. J. Hudzik [États-Unis] ; A. Howell [États-Unis] ; K. Payza [Canada] ; A. J. Cross [États-Unis] | Antiparkinson potential of δ-opioid receptor agonists |
| 000C07 |
ABDALLAH HADJ TAHAR [Canada] ; N. Belanger [Canada] ; E. Bangassoro [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Antidyskinetic effect of JL-18, a clozapine analog, in parkinsonian monkeys |
| 000C08 |
Christopher Dromey [Canada] ; Rajeev Kumar [Canada] ; Anthony E. Lang [Canada] ; Andres M. Lozano [Canada] | An investigation of the effects of subthalamic nucleus stimulation on acoustic measures of voice |
| 000C09 |
C. R. Honey [Canada] ; R. A. Nugent [Canada] | A prospective randomized comparison of CT and MRI pre-operative localization for pallidotomy |
| 000C11 |
O. Monchi [Canada] ; J. G. Taylor [Royaume-Uni] ; A. Dagher [Canada] | A neural model of working memory processes in normal subjects, Parkinson's disease and schizophrenia for fMRI design and predictions |
| 000C12 |
O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada] | A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa |
| 000C13 |
F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | 125I-CGP 64213 binding to GABAB receptors in the brain of monkeys : Effect of MPTP and dopaminomimetic treatments |
| 000C14 |
H. Barthel [Allemagne] ; U. Müller [Allemagne] ; T. W Chter [Allemagne] ; P. Slomka [Canada] ; C. Dannenberg [Allemagne] ; T. Murai [Allemagne] ; T. Kahn [Allemagne] ; P. Georgi [Allemagne] | Multimodale SPECT- und MRT-Bilddatenanalyse zur Verbesserung der Diagnostik des idiopathischen Parkinson-Syndroms : Radiologische Diagnostik und Nuklearmedizin |
| 000C15 |
M. Panisset [Canada] | Syndromes extra-pyramidaux chez la personnes âgées |
| 000C16 |
R. E. Gross [Canada] ; W. J. Lombardi ; W. D. Hutchison ; S. Narula ; J. A. Saint-Cyr ; J. O. Dostrovsky ; R. R. Tasker ; A. E. Lang ; A. M. Lozano | Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease : anatomical, physiological, and technical factors that determine lesion distribution |
| 000C17 |
C. R. Honey [Canada] ; A. J. Stoessl [Canada] ; J. K. C. Tsui [Canada] ; M. Schulzer [Canada] ; D. B. Calne [Canada] | Unilateral pallidotomy for reduction of parkinsonian pain |
| 000C18 |
K. E. Norman [Canada] ; R. Edwards [Canada] ; C. Duval [Canada] ; S. Patenaude [Canada] ; A. Beuter [Canada] | Two-dimensional geometry and electromyography of spontaneous and imitated Parkinsonian wrist tremor |
| 000C19 |
D. A. Grimes [Canada] ; A. E. Lang | Treatment of early Parkinson's disease |
| 000C20 |
K. E. Norman [Canada] ; R. Edwards [Canada] ; A. Beuter [Canada] | The measurement of tremor using a velocity transducer : Comparison to simultaneous recordings using transducers of displacement, acceleration and muscle activity |
| 000C21 |
J. Gauthier [Canada] ; M. Parent [Canada] ; M. Levesque [Canada] ; A. Parent [Canada] | The axonal arborization of single nigrostriatal neurons in rats |
| 000C22 |
V. Fraïle [Canada] ; H. Cohen [Canada] | Temporal control of voicing in Parkinson's disease and tardive dyskinesia speech |
| 000C23 |
M. C. Evans [États-Unis] ; A. Pradhan [Canada] ; S. Venkatraman [États-Unis] ; W. H. Ojala [États-Unis] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Synthesis and dopamine receptor modulating activity of novel peptidomimetics of L-prolyl-L-leucyl-glycinamide featuring α, α-disubstituted amino acids |
| 000C24 |
Juan Fernandez-Ruiz [États-Unis] ; Doris Doudet [Canada] ; Thomas G. Aigner [États-Unis] | Spatial memory improvement by levodopa in parkinsonian MPTP-treated monkeys |
| 000C26 |
M. Grossman [États-Unis] | Sentence processing in Parkinson's disease |
| 000C27 |
M. Ichise [Canada] ; Y. J. Kim [Canada] ; J. R. Ballinger [Canada] ; D. Vines [Canada] ; S. S. Erami [Canada] ; F. Tanaka [Canada] ; A. E. Lang [Canada] | SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD |
| 000C28 |
D. E. Hobson [Canada] ; E. Pourcher [Canada] ; W. R. W. Martin [Canada] | Ropinirole and pramipexole, the new agonists |
| 000C29 |
R. E. Gross [Canada] ; W. J. Lombardi [Canada] ; A. E. Lang [Canada] ; J. Duff [Canada] ; W. D. Hutchison [Canada] ; J. A. Saint-Cyr [Canada] ; R. R. Tasker [Canada] ; A. M. Lozano [Canada] | Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease |
| 000C30 |
A. Samii [Canada] ; I. M. Turnbull [Canada] ; A. Kishore [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; S. Yardley [Canada] ; D. B. Calne [Canada] | Reassessment of unilateral pallidotomy in Parkinson's disease: A 2-year follow-up study |
| 000C31 |
P. J. Blanchet [Canada] | Rationale for use of dopamine agonists in Parkinson's disease : Review of ergot derivatives |
| 000C32 |
Nicolaas Paul L. G. Verhoeff [Canada] | Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders |
| 000C33 |
A. F. Miranda [Canada] ; M. A. Sutton [Canada] ; R. J. Beninger [Canada] ; K. Jhamandas [Canada] ; R. J. Boegman [Canada] | Quinolinic acid lesion of the nigrostriatal pathway : effect on turning behaviour and protection by elevation of endogenous kynurenic acid in rattus norvegicus |
| 000C36 |
A. E. Lang [Canada] ; J. Duff [Canada] ; J. A. Saint-Cyr [Canada] ; L. Trepanier [Canada] ; R. E. Gross [Canada] ; W. Lombardi [Canada] ; E. Montgomery [États-Unis] ; W. Hutchinson [Canada] ; A. M. Lozano [Canada] | Posteroventral medial pallidotomy in Parkinson's disease |
| 000C37 |
K. Kitani [Japon] ; S. Kanai [Japon] ; G. O. Ivy [Canada] ; M. C. Carrillo [Argentine] | Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl : a possible antioxidant strategy |
| 000C38 |
M. Guttman [Canada] ; O. Suchowersky [Canada] | Parkinson's disease management : Towards a new paradigm |
| 000C39 |
D. B. King [Canada] | Parkinson's disease : Levodopa complications |
| 000C40 |
A. Samii [Canada] ; K. Markopoulou [États-Unis] ; Z. K. Wszolek [États-Unis] ; V. Sossi [Canada] ; T. Dobko [Canada] ; E. Mak [Canada] ; D. B. Calne [Canada] ; A. J. Stoessl [Canada] | PET studies of parkinsonism associated with mutation in the α-synuclein gene |
| 000C42 |
J. K. C. Tsui [Canada] ; D. B. Calne [Canada] ; YUE WANG [Canada] ; M. Schulzer [Canada] ; S. A. Marion [Canada] | Occupational risk factors in Parkinson's disease |
| 000C43 |
C. Honey [Canada] ; R. E. Gross [Canada] ; A. M. Lozano [Canada] | New developments in the surgery for Parkinson's disease |
| 000C44 |
P. Ashby [Canada] ; Y. J. Kim [Canada] ; R. Kumar [Canada] ; A. E. Lang [Canada] ; A. M. Lozano [Canada] | Neurophysiological effects of stimulation through electrodes in the human subthalamic nucleus |
| 000C46 |
H. M. Schipper [Canada] ; L. Bernier [Canada] ; K. Mehindate [Canada] ; D. Frankel [Canada] | Mitochondrial iron sequestration in dopamine-challenged astroglia : Role of heme oxygenase-1 and the permeability transition pore |
| 000C47 |
T. Mendis [Canada] ; O. Suchowersky [Canada] ; A. Lang [Canada] ; S. Gauthier [Canada] | Management of Parkinson's disease : A review of current and new therapies |
| 000C48 |
R. A. Hauser [États-Unis] ; T. B. Freeman [États-Unis] ; B. J. Snow [Canada] ; M. Nauert [États-Unis] ; L. Gauger [États-Unis] ; J. H. Kordower [États-Unis] ; C. W. Olanow [États-Unis] | Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease |
| 000C49 |
G. G. Brown [États-Unis, Canada] ; C. Mcdonald [Canada] ; K. Spicer [États-Unis] | Lexical priming on Neely's (1977) paradigm in Parkinson's disease : Where do we stand? |
| 000C51 |
R. Edwards [Canada] ; A. Beuter [Canada] | Indexes for identification of abnormal tremor using computer tremor evaluation systems |
| 000C52 |
A. Richter [Allemagne] ; U. Ebert [Allemagne] ; J. N. Nobrega [Canada] ; J. J. Vallbacka [Canada] ; M. Fedrowitz [Allemagne] ; W. Löscher [Allemagne] | Immunohistochemical and neurochemical studies on nigral and striatal functions in the circling (ci) rat, a genetic animal model with spontaneous rotational behavior |
| 000C53 |
G. D. Muir [Canada] ; I. Q. Whishaw [Canada] | Ground reaction forces in locomoting hemi-parkinsonian rats : a definitive test for impairments and compensations |
| 000C54 |
M. Ichise [Canada] ; Y. J. Kim ; S. S. Erami ; J. R. Ballinger ; D. Vines ; F. Tanaka ; A. E. Lang | Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-β-CIT SPECT data |
| 000C56 |
T. Inoue [Canada, Japon] ; J. Tsui [Canada] ; N. Wong [Canada] ; SHIN YI WONG [Canada] ; F. Suzuki [Japon] ; YIN NAM KWOK [Canada] | Expression of glial cell line-derived neurotrophic factor and its mRNA in the nigrostriatal pathway following MPTP treatment |
| 000C57 |
G. Flores [Mexique, Canada] ; J. J. Liang [Mexique, Canada] ; A. Sierra [Mexique] ; D. Martinez-Fong [Mexique] ; R. Quirion [Mexique, Canada] ; J. Aceves [Mexique] ; L. K. Srivastava [Mexique] | Expression of dopamine receptors in the subthalamic nucleus of the rat : Characterization using reverse transcriptase-polymerase chain reaction and autoradiography |
| 000C58 |
A. J. Stoessl [Canada] | Etiology of Parkinson's disease |
| 000C59 |
T. A. Reader [Canada] ; K. M. Dewar [Canada] | Effects of denervation and hyperinnervation on dopamine and serotonin systems in the rat neostriatum : implications for human Parkinson's disease |
| 000C60 |
V. D. Doan [Canada] ; R. Grondin [Canada] ; ABDALLAH HADJ TAHAR [Canada] ; L. Gregoire [Canada] ; P. J. Bedard [Canada] | Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys |
| 000C61 |
B. E. Burbridge [Canada] ; J. K. Wallace [Canada] ; A. Rajput [Canada] ; L. Mcculloch [Canada] | Doppler ultrasonographic examination of the leg veins of patients with Parkinson disease |
| 000C62 |
R. Grondin [Canada] ; M. Goulet [Canada] ; M. Morissette [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958 |
| 000C63 |
A. J. Stoessl [Canada] ; J. Rivest [Canada] | Differential diagnosis of Parkinsonism |
| 000C64 |
E. M. Khalil [États-Unis] ; W. H. Ojala [États-Unis] ; A. Pradhan [Canada] ; V. D. Nair [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of spiro bicyclic peptidomimetics of L-prolyl-L-leucyl-glycinamide |
| 000C65 |
R. Grondin [Canada] ; V. D. Doan ; L. Gregoire ; P. J. Bedard | D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys |
| 000C66 |
D. Frankel [Canada] ; H. M. Schipper [Canada] | Cysteamine pretreatment of the astroglial substratum (mitochondrial iron sequestration) enhances PC12 cell vulnerability to oxidative injury |
| 000C67 |
R. Kumar [Canada] ; A. M. Lozano [Canada] ; E. Sime [Canada] ; E. Halket [Canada] ; A. E. Lang [Canada] | Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation |
| 000C69 |
F. Calon [Canada] ; M. Morissette [Canada] ; M. Goulet [Canada] ; R. Grondin [Canada] ; P. J. Blanchet [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys : effects on basal ganglia GABAA/ benzodiazepine receptor complex and GABA content |
| 000C70 |
J. Rivest [Canada] ; C. L. Barclay [Canada] ; O. Suchowersky [Canada] | COMT inhibitors in Parkinson's disease |
| 000C71 |
M. Lauk [États-Unis, Allemagne] ; C. C. Chow [États-Unis] ; L. A. Lipsitz [États-Unis] ; S. L. Mitchell [États-Unis, Canada] ; J. J. Collins [États-Unis] | Assessing muscle stiffness from quiet stance in Parkinson's disease |
| 000C72 |
J. Kegl [Canada] ; H. Cohen [États-Unis] ; H. Poizner [États-Unis] | Articulatory consequences of Parkinson's disease : Perspectives from two modalities |
| 000C73 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; A. Hadj Tahar [Canada] ; L. Gregoire [Canada] ; A. Mori [Japon] ; H. Kase [Japon] | Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys |
| 000C75 |
M. A. Bedard [Canada] ; B. Pillon [France] ; B. Dubois [France] ; N. Duchesne [Canada] ; H. Masson [Canada] ; Yves Agid [France] | Acute and long-term administration of anticholinergics in Parkinson's disease : Specific effects on the subcortico-frontal syndrome |
| 000C77 |
T. L. Sourkes [Canada] | "Rational hope" in the early treatment of Parkinson's disease |
| 000C78 |
A. Hadjtahar [Canada] ; P. J. Bedard [Canada] | Comprendre et traiter les dyskinésies induites par la levodopa |
| 000C81 |
A. H. Rajput [Canada] ; W. Martin [Canada] ; M.-H. Saint-Hilaire [États-Unis] ; E. Dorflinger [États-Unis] ; S. Pedder [États-Unis] | Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon : A double-blind, placebo-controlled, multicenter trial |
| 000C82 |
M. J. Majsak [États-Unis] ; T. Kaminski [États-Unis] ; A. M. Gentile [États-Unis] ; J. R. Flanagan [Canada] | The reaching movements of patients with Parkinson's disease under self-determined maximal speed and visually cued conditions |
| 000C84 |
D. Knoke [Canada] ; A. E. Taylor [Canada] ; J. A. Saint-Cyr [Canada] | The differential effects of cueing on recall in Parkinson's disease and normal subjects |
| 000C85 |
R. West [Canada] ; G. Winocur [Canada] ; A.-M. Ergis [France] ; J. Saint-Cyr [Canada] | The contribution of impaired working memory monitoring to performance of the Self-Ordered Pointing Task in normal aging and Parkinson's disease |
| 000C87 |
J. Doyon [Canada] ; R. Jr Laforce [Canada] ; G. Bouchard [Canada] ; D. Gaudreau [Canada] ; J. Roy [Canada, États-Unis] ; M. Poirier [États-Unis] ; P. J. Bedard [États-Unis] ; F. Bedard [Canada] ; J.-P. Bouchard [États-Unis] | Role of the striatum, cerebellum and frontal lobes in the automatization of a repeated visuomotor sequence of movements |
| 000C88 |
Z. Uhrin [Canada] ; H. Stein [Canada] | Rheumatoid-like deformities in Parkinson's disease |
| 000C90 |
A. Samii [Canada] ; S. R. Letwin [Canada] ; D. B. Calne [Canada] | Prospects for new drug treatment in idiopathic parkinsonism |
| 000C91 |
A. E. Lang [Canada] ; A. M. Lozano [Canada] | Parkinson's disease: First of two parts |
| 000C92 |
A. E. Lang [Canada] ; A. M. Lozano [Canada] | Parkinson's disease : Second of two parts |
| 000C93 |
A. M. Lozano [Canada] ; A. E. Lang [Canada] ; W. D. Hutchison [Canada] | Pallidotomy for tremor |
| 000C94 |
R. Kumar [Canada] ; A. M. Lozano [Canada] ; E. Montgomery [États-Unis] ; A. E. Lang [Canada] | Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson's disease |
| 000C95 |
N. Galvez-Jimenez [Canada] ; A. Lozano [Canada] ; R. Tasker [Canada] ; J. Duff [Canada] ; W. Hutchison [Canada] ; A. E. Lang [Canada] | Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy |
| 000C96 |
L. L. Trepanier [Canada] ; J. A. Saint-Cyr [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] | Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease |
| 000C97 |
W. D. Hutchison [Canada] ; R. J. Allan [Canada] ; H. Opitz [Canada] ; R. Levy [Canada] ; J. O. Dostrovsky [Canada] ; A. E. Lang [Canada] ; A. M. Lozano [Canada] | Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease |
| 000C98 |
H. M. Schipper [Canada] ; A. Liberman [Canada] ; E. G. Stopa [États-Unis] | Neural heme oxygenase-1 expression in idiopathic Parkinson's disease |
| 000C99 |
V. P. Calabrese [Canada] ; K. A. Lloyd [Canada] ; P. Brancazio [Canada] ; E. Cefali [États-Unis] ; P. Martin [États-Unis] ; J. Jr Wall [États-Unis] ; D. Sica [États-Unis] | N-0923, a novel soluble dopamine D2 agonist in the treatment of parkinsonism |
| 000D00 |
A. M. Lozano [Canada] ; W. D. Hutchison [Canada] ; R. R. Tasker [Canada] ; A. E. Lang [Canada] ; F. Junn [Canada] ; J. O. Dostrovsky [Canada] | Microelectrode recordings define the ventral posteromedial pallidotomy target |
| 000D01 |
B. M. Ross [Canada] ; A. Moszczynska [Canada] ; J. Erlich [Canada] ; S. J. Kish [Canada] | Low activity of key phospholipid catabolic and anabolic enzymes in human substantia nigra : Possible implications for Parkinson's disease |
| 000D03 |
J. H. Carter [États-Unis] ; B. J. Stewart [États-Unis] ; P. G. Archbold [États-Unis] ; I. Inoue [États-Unis] ; J. Jaglin [États-Unis] ; M. Lannon [États-Unis] ; E. Rost-Ruffner [États-Unis] ; M. Tennis [États-Unis] ; M. P. Mcdermott [États-Unis] ; D. Amyot [Canada] ; R. Barter [États-Unis] ; L. Cornelius [États-Unis] ; C. Demong [Canada] ; J. Dobson [États-Unis] ; J. Duff [Canada] ; J. Erickson [États-Unis] ; N. Gardiner [États-Unis] ; L. Gauger [États-Unis] ; P. Gray [Canada] ; B. Kanigan [Canada] ; B. Kiryluk [États-Unis] ; P. Lewis [États-Unis] ; K. Mistura [États-Unis] ; T. Malapira [États-Unis] ; M. Pay [États-Unis] ; C. Sheldon [États-Unis] ; L. Winfield [États-Unis] ; K. Wolfington-Shallow [États-Unis] ; K. Zoog [États-Unis] | Living with a person who has Parkinson's disease : The spouse's perspective by stage of disease |
| 000D05 |
J. H. Growdon [États-Unis] ; K. Kieburtz [Canada] ; M. P. Mcdermott [Canada] ; M. Panisset [Canada] ; J. H. Friedman [États-Unis] | Levodopa improves motor function without impairing cognition in mild nondemented Parkinson's disease patients |
| 000D06 |
W. W. Martin [Canada] ; T. E. Roberts [Canada] ; F. Q. Ye [Canada] ; P. S. Allen [Canada] | Increased basal ganglia iron in striatonigral degeneration : In vivo estimation with magnetic resonance |
| 000D07 |
D. G. Walker [Canada] ; K. Terai [Canada] ; A. Matsuo [Canada] ; T. G. Beach [Canada] ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Immunohistochemical analyses of fibroblast growth factor receptor-1 in the human substantia nigra. Comparison between normal and Parkinson's disease cases |
| 000D08 |
P. Ashby [Canada] ; A. Strafella [Canada] ; J. O. Dostrovsky [Canada] ; A. Lozano [Canada] ; A. E. Lang [Canada] | Immediate motor effects of stimulation through electrodes implanted in the human globus pallidus |
| 000D09 |
M. D. Muenter [États-Unis] ; L. S. Forno [États-Unis] ; O. Hornykiewicz [Autriche] ; S. J. Kish [Canada] ; D. M. Maraganore [États-Unis] ; R. J. Caselli [États-Unis] ; H. Okazaki [États-Unis] ; F. M. Jr Howard [États-Unis] ; B. J. Snow [Australie] ; D. B. Calne [Canada] | Hereditary form of parkinsonism-dementia |
| 000D10 |
E. G. Campioni [Canada] ; J. N. Nobrega [Canada] ; M. V. Sefton [Canada] | HEMA/MMMA microcapsule implants in hemiparkinsonian rat brain : Biocompatibility assessment using [3H]PK11195 as a marker for gliosis |
| 000D11 |
FENGQINSI [Canada] ; G. M. Ross [Canada] ; S. H. Shin [Canada] | Glutathione protects PC12 cells from ascorbate- and dopamine-induced apoptosis |
| 000D12 |
P. L. Mcgeer [Canada] ; E. G. Mcgeer [Canada] | Glial cell reactions in neurodegenerative diseases : Pathophysiology and therapeutic interventions |
| 000D13 |
C. Apostolides [Canada] ; E. Sanford [Canada] ; M. Hong [Canada] ; I. Mendez [Canada] | Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells |
| 000D14 |
J. H. Kordower [États-Unis] ; T. B. Freeman [États-Unis] ; E.-Y. Chen [États-Unis] ; E. J. Mufson [États-Unis] ; P. R. Sanberg [États-Unis] ; R. A. Hauser [États-Unis] ; B. Snow [Canada] ; C. W. Olanow [États-Unis] | Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease |
| 000D16 |
D. G. Walker [Canada] ; T. G. Beach [Canada] ; REN XU [États-Unis] ; J. Lile [États-Unis] ; K. D. Beck [États-Unis] ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease |
| 000D17 |
C. L. Reed [États-Unis] ; I. M. Franks [Canada] | Evidence for movement preprogramming and on-line control in differentially impaired patients with Parkinson's disease |
| 000D18 |
V. Mehta [Canada] ; M. Hong [Canada] ; J. Spears [Canada] ; I. Mendez [Canada] | Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor |
| 000D19 |
R. Kumar [Canada] ; A. M. Lozano [Canada] ; Y. J. Kim [Canada] ; W. D. Hutchison [Canada] ; E. Sime [Canada] ; E. Halket [Canada] ; A. E. Lang [Canada] | Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson disease |
| 000D20 |
C. A. Shaw [Canada] ; J. S. Bains [Canada] | Did consumption of flour bleached by the agene process contribute to the incidence of neurological disease? |
| 000D21 |
R. R. Tasker [Canada] ; R. D. Penn [États-Unis] | Deep brain stimulation is preferable to thalamotomy for tremor suppression. Commentary |
| 000D22 |
S. J. Crocker [Canada] ; M. Morelli [Italie] ; N. Wigle [Canada] ; Y. Nakabeppu [Japon] ; G. S. Robertson [Canada] | D1-receptor-related priming is attenuated by antisense-meditated 'knockdown' of fosB expression |
| 000D23 |
M. Manford [Royaume-Uni] ; F. Andermann [Canada] | Complex visual hallucinations clinical and neurobiological insights |
| 000D25 |
M.-A. Bedard [Canada] ; F. El Massioui [France] ; C. Malapani [France] ; B. Dubois [France] ; B. Pillon [France] ; B. Renault [France] ; Yves Agid [France] | Attentional deficits in Parkinson's disease : Partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic α1 agonist |
| 000D27 |
D. P. Perl [États-Unis] ; C. W. Olanow [États-Unis] ; D. Calne [Canada] | Alzheimer's disease and Parkinson's disease : Distinct entities or extremes of a spectrum of neurodegeneration? |
| 000D30 |
A. M. Owen [Royaume-Uni] ; J. Doyon [Canada] ; A. Dagher [Canada] ; A. Sadikot [Canada] ; A. C. Evans [Canada] | Abnormal basal ganglia outflow in Parkinson's disease identified with PET : Disease identified with pet implications for higher cortical functions |
| 000D31 |
A. Takeda [États-Unis, Japon] ; M. Mallory [États-Unis] ; M. Sundsmo [États-Unis] ; W. Honer [Canada] ; L. Hansen [États-Unis] ; E. Masliah [États-Unis] | Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders |
| 000D32 |
T. Gasser [Allemagne] ; B. Müller-Myhsok [Allemagne] ; Z. K. Wszolek [États-Unis] ; R. Oehlmann [Allemagne] ; D. B. Calne [Canada] ; V. Bonifati [Italie] ; B. Bereznai [Allemagne] ; E. Fabrizio [Italie] ; P. Vieregge [Allemagne] ; R. D. Horstmann [Allemagne] | A susceptibility locus for Parkinson's disease maps to chromosome 2p13 |
| 000D34 |
G. Le Dorze [Canada] ; J. Ryalls [États-Unis] ; C. Brassard [Canada] ; N. Boulanger [Canada] ; D. Ratte [Canada] | A comparison of the prosodic characteristics of the speech of people with Parkinson's disease and Friedreich's ataxia with neurologically normal speakers |
| 000D35 |
| Le traitement neurochirurgical de la maladie de Parkinson et autres mouvements anormaux |
| 000D36 |
| Thalamotomie |
| 000D37 |
| Stimulation thalamique |
| 000D38 |
| Stimulation subthalamique |
| 000D39 |
| Stimulation pallidale |
| 000D40 |
| Pallidotomie |
| 000D42 |
| Indications et choix de la cible |
| 000D43 |
O. Rascol [France] ; N. Fabre [France] ; U. Sabatini [Italie] | Imagerie fonctionnelle |
| 000D44 |
| Greffes |
| 000D45 |
A. Destee [France] | Données séméiologiques et principes actuels du traitement médical |
| 000D47 |
A. Parent [Canada] ; F. Cicchetti [Canada] | Anatomie et physiopathologie des ganglions de la base |
| 000D48 |
M. Guttman [Canada] ; J. Burkholder [États-Unis] ; S. J. Kish [Canada] ; D. Hussey [États-Unis] ; A. Wilson [États-Unis] ; J. Dasilva [États-Unis] ; S. Houle [États-Unis] | [11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease : Implications for the symptomatic threshold |
| 000D49 |
F. J. G. Vingerhoets [Canada] ; M. Schulzer [Canada] ; D. B. Calne [Canada] ; B. J. Snow [Canada] | Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? |
| 000D50 |
A. H. Rajput [Canada] ; W. Martin [Canada] ; M.-H. Saint-Hilaire [États-Unis] ; E. Dorflinger [États-Unis] ; S. Pedder [États-Unis] | Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial |
| 000D53 |
I. H. Richard [États-Unis] ; R. Kurlan [États-Unis] ; C. Tanner [États-Unis] ; S. Factor [États-Unis] ; J. Hubble [États-Unis] ; O. Suchowersky [Canada] ; C. Waters [États-Unis] | Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease |
| 000D54 |
R. Edwards [Canada] ; A. Beuter [Canada] | Sensitivity and specificity of a portable system measuring postural tremor |
| 000D55 |
J. Doyon [Canada] ; D. Gaudreau [Canada] ; R. Jr Laforce [Canada] ; M. Castonguay [Canada] ; P. J. Bedard [Canada] ; F. Bedard [Canada] ; J.-P. Bouchard [Canada] | Role of the striatum, cerebellum, and frontal lobes in the learning of a visuomotor sequence |
| 000D56 |
D. Giaschi [Canada] ; A. Lang [Canada] ; D. Rean [Canada] | Reversible dissociation of sensitivity to dynamic stimuli in Parkinson's disease : is magnocellular function essential to reading motion-defined letters? |
| 000D57 |
N. Paquet [Canada] ; C. W. Y. Hui-Chan [Canada] | Responses to dynamic head-and-body tilts are enhanced in Parkinson's disease |
| 000D58 |
I. Mendez [Canada] ; M. Hong [Canada] | Reconstruction of the striato-nigro-striatal circuitry by simultaneous double dopaminergic grafts: a tracer study using fluorogold and horseradish peroxidase |
| 000D59 |
R. Levy [France] ; L.-N. Hazrati [Canada] ; M.-T. Herrero [France, Espagne] ; M. Vila [France] ; O.-K. Hassani [France] ; M. Mouroux [France] ; M. Ruberg [France] ; H. Asensi [Espagne] ; Yves Agid [France] ; J. Feger [France] ; J. A. Obeso [Espagne] ; A. Parent [Canada] ; E. C. Hirsch [France] | Re-evaluation of the functional anatomy of the basal ganglia in normal and Parkinsonian states |
| 000D61 |
A. F. Miranda [Canada] ; R. J. Boegman [Canada] ; R. J. Beninger [Canada] ; K. Jhamandas [Canada] | Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid |
| 000D62 |
R. Grondin [Canada] ; P. J. Bedard [Canada] ; D. R. Britton [États-Unis] ; K. Shiosaki [États-Unis] | Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929 : An acute study in parkinsonian levodopa-primed monkeys |
| 000D63 |
A. E. Lang [Canada] ; A. M. Lozano [Canada] ; E. Montgomery [États-Unis] ; J. Duff [Canada] ; R. Tasker [Canada] ; W. Hutchinson [Canada] | Posteroventral medial pallidotomy in advanced Parkinson's disease |
| 000D65 |
A. Strafella [Canada] ; P. Ashby ; A. Lozano ; A. E. Lang | Pallidotomy increases cortical inhibition in Parkinson's disease |
| 000D67 |
P. Caffarra [Italie] ; L. Riggio [Italie] ; L. Malvezzi [Italie] ; A. Scaglioni [Italie] ; M. Freedman [États-Unis, Canada] | Orienting of visual attention in Alzheimer's disease : Its implication in favor of the interhemispheric balance |
| 000D68 |
P. A. Rochon [Canada] ; J. H. Gurwitz [États-Unis] | Optimising drug treatment for elderly people : the prescribing cascade |
| 000D70 |
K. Markopoulou [États-Unis] ; K. W. Larsen [États-Unis] ; E. K. Wszolek [États-Unis] ; M. A. Denson [États-Unis] ; A. E. Lang [Canada] ; R. F. Pfeiffer [États-Unis] ; Z. K. Wszolek [États-Unis] | Olfactory dysfunction in familial parkinsonism |
| 000D71 |
J. S. Bains [Canada] ; C. A. Shaw [Canada] | Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death |
| 000D72 |
M. Mamelak [Canada] | Neurodegeneration, sleep, and cerebral energy metabolism : A testable hypothesis |
| 000D73 |
V. Mehta [Canada] ; J. Spears [Canada] ; I. Mendez [Canada] | Neural transplantation in Parkinson's disease |
| 000D74 |
A. M. Lozano [Canada] ; A. E. Lang [Canada] ; W. D. Hutchison [Canada] ; J. O. Dostrovsky [Canada] | Microelectrode recording-guided posteroventral pallidotomy in patients with Parkinson's disease |
| 000D75 |
A. E. Lang [Canada] ; A. Lozano [Canada] ; J. Duff [Canada] ; R. Tasker [Canada] ; J. Miyasaki ; N. Galvez-Jimenez ; W. Hutchison ; J. Dostrovsky | Medial pallidotomy in late-stage Parkinson's disease and striatonigral degeneration |
| 000D76 |
A. Prochazka [Canada] ; D. J. Bennett [Canada] ; M. J. Stephens [Canada] ; S. K. Patrick [Canada] ; R. Sears-Duru [Canada] ; T. Roberts [Canada] ; J. H. Jhamandas [Canada] | Measurement of rigidity in Parkinson's disease |
| 000D78 |
N. A. Tatton [Canada] ; S. J. Kish [Canada] | In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and Acridine Orange Staining |
| 000D79 |
I. Q. Whishaw [Canada] ; B. L. K. Coles [Canada] ; S. M. Pellis [Canada] ; E. I. Miklyaeva [Canada] | Impairments and compensation in mouth and limb use in free feeding after unilateral dopamine depletions in a rat analog of human Parkinson's disease |
| 000D80 |
W. D. Hutchison [Canada] ; A. M. Lozano [Canada] ; R. R. Tasker [Canada] ; A. E. Lang [Canada] ; J. O. Dostrovsky [Canada] | Identification and characterization of neurons with tremor-frequency activity in human globus pallidus |
| 000D81 |
W. Koller [États-Unis] ; R. Pahwa [États-Unis] ; K. Busenbark [États-Unis] ; J. Hubble [États-Unis] ; S. Wilkinson [États-Unis] ; A. Lang [Canada] ; P. Tuite [Canada] ; E. Sime [Canada] ; A. Lazano [Canada] ; R. Hauser [États-Unis] ; T. Malapira [États-Unis] ; D. Smith [États-Unis] ; D. Tarsy [États-Unis] ; E. Miyawaki [États-Unis] ; T. Norregaard [États-Unis] ; T. Kormos [États-Unis] ; C. W. Olanow [États-Unis] | High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor |
| 000D83 |
A. Kishore [Canada] ; I. M. Turnbull [Canada] ; B. J. Snow [Canada] ; R. De La Fuente-Fernandez [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; S. Yardley [Canada] ; D. B. Calne [Canada] | Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease: Six-month follow-up with additional 1-year observations |
| 000D84 |
N. Rajakumar [Canada] ; W. Rushlow [Canada] ; B. Rajakumar [Canada] ; C. C. G. Naus [Canada] ; A. J. Stoessl [Canada] ; B. A. Flumerfelt [Canada] | Effects of graft-derived dopaminergic innervation on the target neurons of patch and matrix compartments of the striatum |
| 000D85 |
D. J. Doudet [Canada] ; G. L. Y. Chan [Canada] ; J. E. Holden [États-Unis] ; K. S. Morrison [Canada] ; R. J. Wyatt [États-Unis] ; T. J. Ruth [Canada] | Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced Parkinsonism in monkeys |
| 000D86 |
W. D. Hutchison [Canada] ; R. Levy [Canada] ; J. O. Dostrovsky [Canada] ; A. M. Lozano [Canada] ; A. E. Lang [Canada] | Effects of apomorphine on globus pallidus neurons in parkinsonian patients |
| 000D90 |
M. Guttman [Canada] | Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease |
| 000D92 |
A. Rajput [États-Unis] ; A. Kishore [Canada] ; B. Snow [Canada] ; C. F. Bolton [Canada] ; A. H. Rajput [Canada] | Dopa-responsive, nonprogressive, juvenile parkinsonism : Report of a case |
| 000D93 |
P. W. Baures [États-Unis] ; W. H. Ojala [États-Unis] ; W. J. Costain [Canada] ; M. C. Ott [Canada] ; A. Pradhan [Canada] ; W. B. Gleason [États-Unis] ; R. K. Mishra [Canada] ; R. L. Johnson [États-Unis] | Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide |
| 000D94 |
M. Goulet [Canada] ; M. Morissette [Canada] ; F. Calon [Canada] ; P. J. Blanchet [Canada] ; P. Falardeau [Canada] ; P. J. Bedard [Canada] ; T. Di Paolo [Canada] | Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression : In situ hybridization histochemical analysis |
| 000D95 |
A. H. Rajput [Canada] ; M. E. Fenton [Canada] ; D. George [Canada] ; A. Rajput [États-Unis] ; W. Wilson [Canada] ; L. Mcculloch [Canada] | Concordance of common movement disorders among familial cases |
| 000D96 |
R. Kumar [Canada] ; A. E. Lang [Canada] | Coexistence of tics and parkinsonism : Evidence for non-dopaminergic mechanisms in tic pathogenesis |
| 000D98 |
M. Freedman [Canada] ; M. Oscar-Berman [États-Unis] | Breakdown of cross-modal function in dementia |
| 000E02 |
D. D. Newman [Canada] ; N. Rajakumar ; B. A. Flumerfelt ; A. J. Stoessl [Canada] | A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease |
| 000E05 |
R. J. Uitti [Canada] ; H. Shinotoh [Canada] ; M. Hayward [Canada] ; M. Schulzer [Canada] ; E. Mak [Canada] ; D. B. Calne [Canada] | "Familial Parkinson's disease": A case-control study of families |
| 000E06 |
| |
| 000E08 |
J. E. Graham [Canada] ; A. B. Mitnitski [Canada] ; A. J. Mogilner ; D. Gauvreau [Canada] ; K. Rockwood [Canada] | Symptoms and signs in dementia : Synergy and antagonism |
| 000E10 |
D. J. Martens [Canada] ; I. Q. Whishaw [Canada] ; E. I. Miklyaeva [Canada] ; S. M. Pellis [Canada] | Spatio-temporal impairments in limb and body movements during righting in an hemiparkinsonian rat analogue : relevance to axial apraxia in humans |
| 000E11 |
P. J. Blanchet [Canada] ; P. Allard [Canada] ; L. Gregoire [Canada] ; F. Tardif [Canada] ; P. J. Bedard [Canada] | Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients |
| 000E12 |
F. J. G. Vingerhoets [Canada] ; M. Schulzer ; T. J. Ruth ; J. E. Holden ; B. J. Snow | Reproducibility and discriminating ability of fluorine-18-6-fluoro-L-dopa PET in Parkinson's disease |
| 000E13 |
P. Sandor [Canada] ; A. E. Lang [Canada] ; S. Singal [Canada] ; C. Augus [Canada] | Remoxipride in the treatment of levodopa-induced psychosis |
| 000E14 |
N. Galvez-Jimenez [Canada] ; A. E. Lang [Canada] | Perioperative problems in Parkinson's disease and their management : Apomorphine with rectal domperidone |
| 000E16 |
W. G. Tatton [Canada] ; R. M. E. Chalmers-Redman [Canada] | Modulation of gene expression rather than monoamine oxidase inhibition : (-)-Deprenyl-related compounds in controlling neurodegeneration |
| 000E17 |
L. Wahl [Canada] ; C. Nahmias [Canada] | Modeling of fluorine-18-6-fluoro-L-Dopa in humans |
| 000E22 |
J.-J. Soghomonian [Canada] ; S. Pedneault [Canada] ; P. J. Blanchet [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | L-DOPA regulates glutamate decarboxylases mRNA levels in MPTP-treated monkeys |
| 000E23 |
D. Boismenu [Canada] ; O. Mamer [Canada] ; L. Ste-Marie [Canada] ; L. Vachon [Canada] ; J. Montgomery [Canada] | In vivo hydroxylation of the neurotoxin, 1-methyl-4-phenylpyridinium, and the effect of monoamine oxidase inhibitors : Electrospray-MS analysis of intra-striatal microdialysates |
| 000E24 |
D. Charbonneau [Canada] ; R. J. Riopelle [Canada] ; R. J. Beninger [Canada] | Impaired incentive learning in treated Parkinson's disease |
| 000E26 |
E. I. Miklyaeva [Canada] ; I. Q. Whishaw [Canada] | HemiParkinson analogue rats display active support in good limbs versus passive support in bad limbs on a skilled reaching task of variable height |
| 000E27 |
F. Q. Ye [Canada] ; W. R. M. Martin ; P. S. Allen [Canada] | Estimation of brain iron in vivo by means of the interecho time dependence of image contrast |
| 000E28 |
M. Goulet [Canada] ; R. Grondin ; P. J. Blanchet ; P. J. Bedard ; T. Di Paolo [Canada] | Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode to not correlate with changes of putaminal D1 receptors in drug-naive MPTP monkeys |
| 000E29 |
P. J. Blanchet [Canada] ; R. Grondin ; P. J. Bedard | Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates |
| 000E30 |
T. Roberts [Canada] ; U. De Boni ; M. V. Sefton [Canada] | Dopamine secretion by PC12 cells microencapsulated in a hydroxyethyl methacrylate-methyl methacrylate copolymer |
| 000E31 |
P. J. Blanchet [Canada] ; R. Grondin [Canada] ; P. J. Bedard [Canada] ; K. Shiosaki [États-Unis] ; D. R. Britton [États-Unis] | Dopamine D1 receptor desensitization profile in MPTP-lesioned primates |
| 000E33 |
J. M. Wilson [Canada] ; A. I. Levey [États-Unis] ; A. Rajput [Canada] ; L. Ang [Canada] ; M. Guttman [Canada] ; K. Shannak [Canada] ; H. B. Niznik [Canada] ; O. Hornykiewicz [Canada, Autriche] ; C. Pifl [Autriche] ; S. J. Kish [Canada] | Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease |
| 000E36 |
R. Grondin [Canada] ; M. Goulet [Canada] ; T. Di Paolo [Canada] ; P. J. Bedard [Canada] | Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates |
| 000E39 |
F. Q. Ye [Canada] ; P. S. Allen [Canada] ; W. R. W. Martin | Basal ganglia iron content in Parkinson's disease measured with magnetic resonance |
| 000E40 |
B. P. Connop [Canada] ; R. J. Boegman [Canada] ; R. J. Beninger ; K. Jhamandas [Canada] | Attenuation of malonate-induced degeneration of the nigrostriatal pathway by inhibitors of nitric oxide synthase |
| 000E41 |
M. D. Berry [Canada] ; A. V. Juorio [Canada] ; X.-M. Li [Canada] ; A. A. Boulton [Canada] | Aromatic L-amino acid decarboxylase : A neglected and misunderstood enzyme |
| 000E42 |
B. J. Knowlton [États-Unis] ; J. A. Mangels [Canada, États-Unis] ; L. R. Squire [États-Unis] | A neostriatal habit learning system in humans |
| 000E43 |
AGDU'L-MISSAGH GHADIRIAN [Canada] ; L. Annable ; M.-C. Belanger ; G. Chouinard | A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients |
| 000E44 |
M.-A. Bedard [Canada] ; M. Panisset | Neurochimie des troubles cognitifs dans la maladie de Parkinson |
| 000E45 |
L. J. Easdown [Canada] ; M. J. Tessler ; J. Minuk | Upper airway involvement in Parkinson's disease resulting in postoperative respiratory failure |
| 000E48 |
J.-A. St-Pierre [Canada] ; P. J. Bedard | Systemic administration of the NMDA receptor antagonist MK-801 potentiates circling induced by intrastriatal microinjection of dopamine |
| 000E49 |
XIAO-HUI ZHONG [Canada] ; J. W. Haycock ; K. Shannak [Canada] ; Y. Robitaille ; J. Fratkin ; A. H. Koeppen ; O. Hornykiewicz [Canada] ; S. J. Kish [Canada] | Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy |
| 000E50 |
A. E. Lang [Canada] ; P. Sandor ; J. Duff [Canada] | Remoxipride in Parkinson's disease : differential response in patients with dyskinesias fluctuations versus psychosis |
| 000E52 |
H. Kuwabara [Canada] ; P. Cumming ; Y. Yasuhara ; G. C. Leger ; M. Guttman ; M. Diksic ; A. C. Evans ; A. Gjedde | Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease |
| 000E55 |
R. G. Lee [Canada] ; I. Tonolli [France] ; F. Viallet [France] ; R. Aurenty [France] ; J. Massion [France] | Preparatory postural adjustments in Parkinsonian patients with postural instability |
| 000E58 |
F. Calon [Canada] ; M. Goulet [Canada] ; P. J. Blanchet ; J. C. Martel [Canada] ; M. F. Piercey ; P. J. Bedard ; T. Di Paolo [Canada] | Levodopa or D2 agonist induced dyskinesia in MPTP monkeys : correlation with changes in dopamine and GABAA receptors in the striatopallidal complex |
| 000E59 |
E. Mohr [Canada] ; T. Mendis ; J. D. Grimes | Late cognitive changes in Parkinson's disease with an emphasis on dementia |
| 000E61 |
E. I. Miklyaeva [Canada] ; D. J. Martens ; I. Q. Whishaw | Impairments and compensatory adjustment in spontaneous movement after unilateral dopamine depletion in rats |
| 000E62 |
A. E. Lang [Canada] | Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism : the spectrum of hemiparkinsonism-hemiatrophy syndrome |
| 000E63 |
A. M. W. Penn [Canada] ; T. Roberts [Canada] ; J. Hodder [Canada] ; P. S. Allen ; G. Zhu ; W. R. W. Martin [Canada] | Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle |
| 000E64 |
S. Chaturvedi [Canada] ; T. Stbye ; A. J. Stoessl [Canada] ; H. Merskey ; V. Hachinski [Canada] | Environmental exposures in elderly Canadians with Parkinson's disease |
| 000E65 |
K. M. Semchuk [Canada] ; E. J. Love | Effects of agricultural work and other proxy-derived case-control data on Parkinson's disease risk estimates |
| 000E66 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; R. Markstein ; P. J. Bedard ; T. Di Paolo [Canada] | Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys : regional changes of brain dopamine receptors |
| 000E67 |
C. Thiffault [Canada] ; N. Aumont ; R. Quirion [Canada] ; J. Poirier | Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain |
| 000E68 |
A. M. Lozano [Canada] ; A. E. Lang ; N. Galvez-Jimenez ; J. Miyasaki ; J. Duff ; W. D. Hutchinson ; J. O. Dostrovsky | Effect of GPi pallidotomy on motor function in Parkinson's disease |
| 000E69 |
P. J. Bedard [Canada] ; B. Gomez-Mancilla [Canada] ; P. Blanchet [Canada] ; R. Grondin [Canada] ; T. Dipaolo [Canada] ; SETHY ; PIERCEY ; CHASE ; WISE ; PERLMUTTER ; RANHOSKY | Dopamine-receptor families and the treatment of Parkinson's disease. Discussion |
| 000E70 |
P. Chagnon [Canada] ; C. Betard ; Y. Robitaille ; A. Cholette ; D. Gauvreau | Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases |
| 000E72 |
P. J. Bedard [Canada] | D-1 receptor in neurology and psychiatry : an overview : The role of D-1 dopamine receptors in neurology and psychiatry |
| 000E73 |
G. M. Ross [Canada] ; B. E. Mccarry ; R. K. Mishra [Canada] | Covalent affinity labeling of brain catecholamine-absorbing proteins using a high-specific-activity substituted tetrahydronaphthalene |
| 000E75 |
O. Suchowersky [Canada] ; S. Furtado ; G. Rohs | Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease |
| 000E76 |
J. A. Saint-Cyr [Canada] ; A. E. Taylor ; K. Nicholson | Behavior and the basal ganglia |
| 000E77 |
M.-G. Martinoli [Canada] ; J. Q. Trojanowski ; M. L. Schmidt ; S. E. Arnold ; T. M. Fujiwara ; V. M.-Y. Lee ; H. Hurtig ; J.-P. Julien [Canada] ; C. Clark | Association of apolipoprotein ε4 allele and neuropathologic findings in patients with dementia |
| 000E78 |
J. S. Parboosingh [Canada] ; M. Rousseau [Canada] ; F. Rogan ; Z. Amit ; H. Chertkow ; W. G. Johnson ; F. Manganaro ; H. N. Schipper ; T. J. Curran ; J. Stoessl ; G. A. Rouleau [Canada] | Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease |
| 000E79 |
C. Nahmias [Canada] ; L. Wahl ; R. Chirakal ; G. Firnau ; E. S. Garnett | A probe for intracerebral aromatic amino-acid decarboxylase activity : distribution and kinetics of [18F]6-fluoro-L-m-tyrosine in the human brain |
| 000E81 |
XUDONG WANG [Canada] ; F. Manganaro ; H. M. Schipper | A cellular stress model for the sequestration of redox-active glial in the aging and degenerating nervous system |
| 000E82 |
| |
| 000E83 |
M. Filion [Canada] ; L. Tremblay ; M. Matsumura ; H. Richard | Focalisation dynamique de la convergence informationnelle dans les noyaux gris centraux |
| 000E84 |
G. L. Trick [Canada] ; B. Kaskie ; S. B. Steinman | Visual impairment in Parkinson's disease : deficits in orientation and motion discrimination |
| 000E85 |
M. C. Tierney [Canada] ; A. Nores ; W. G. Snow ; R. H. Fisher ; M. L. Zorzitto ; D. W. Reid | Use of the Rey Auditory Verbal Learning Test in differentiating normal aging from Alzheimer's and Parkinson's dementia |
| 000E86 |
A. Beuter [Canada] ; A. De Geoffroy [Canada] ; P. Cordo | The measurement of tremor using simple laser systems |
| 000E88 |
E. Scarr [Canada] ; D. M. Wingerchuk ; A. V. Juorio ; I. A. Paterson | The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions |
| 000E91 |
J. P. Hammerstad [Canada] ; K. Elliott ; E. Mak ; M. Schulzer ; S. Calne ; D. B. Calne | Tendon jerks in Parkinson's disease |
| 000E92 |
T. Mendis [Canada] ; E. Mohr [Canada] ; A. George ; I. N. Rusk [Canada] ; P. Gray ; J. D. Grimes | Symptomatic relief from treatment-induced psychosis in Parkinson's disease: an open-label pilot study with remoxipride |
| 000E93 |
M.-C. Asselin [Canada] ; J.-J. Soghomonian ; P.-Y. Côte ; A. Parent | Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys |
| 000E94 |
I. Tooyama [Canada] ; E. G. Mcgeer [Canada] ; T. Kawamata [Canada] ; H. Kimura ; P. L. Mcgeer [Canada] | Retention of basic fibroblast growth factor immunoreactivity in dopaminergic neurons of the substantia nigra during normal aging in humans contrasts with loss in Parkinson's disease |
| 000E95 |
FU-LIN WANG [Canada] ; K. M. Semchuk ; E. J. Love | Reliability of environmental and occupational exposure data provided by surrogate respondents in a case-control study of Parkinson's disease |
| 000E96 |
FU-LIN WANG [Canada] ; K. M. Semchuk ; E. J. Love | Reliability of environmental and occupational exposure data provided by surrogate respondents in a case-control study of Parkinson's disease |
| 000E97 |
R. K. Mosewich [Canada] ; A. H. Rajput [Canada] ; A. Shuaib [Canada] ; B. Rozdilsky ; L. Ang | Pulmonary embolism: an under-recognized yet frequent cause of death in Parkinsonism |
| 000E98 |
B. P. Connop [Canada] ; N. G. Rolfe ; R. J. Boegman [Canada] ; K. Jhamandas [Canada] ; R. J. Beninger | Potentiation of NMDA-mediated toxicity on nigrostriatal neurons by a low dose of 7-nitro indazole |
| 000E99 |
F. J. G. Vingerhoets [Canada] ; B. J. Snow [Canada] ; J. W. Tetrud ; J. W. Langston ; M. Schulzer [Canada] ; D. B. Calne [Canada] | Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions |
| 000F00 |
P. H. Yu [Canada] | Pharmacological and clinical implications of MAO-B inhibitors |
| 000F03 |
K. Shannak [Canada] ; A. Rajput ; B. Rozdilsky ; S. Kish [Canada] ; J. Gilbert ; O. Hornykiewicz [Canada] | Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus : observations in Parkinson's disease and normal subjects |
| 000F05 |
D. B. Calne [Canada] ; N.-S. Chu ; C.-C. Huang ; C.-S. Lu ; W. Olanow | Manganism and idiopathic parkinsonism : similarities and differences |
| 000F06 |
F. J. G. Vingerhoets [Canada] ; B. J. Snow ; C. S. Lee ; M. Schulzer ; E. Mak ; D. B. Calne | Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic Parkinsonism |
| 000F07 |
H. Cohen [Canada] ; S. Bouchard ; P. Scherzer ; H. Whitaker | Language and verbal reasoning in Parkinson's disease |
| 000F08 |
D. B. Calne [Canada] | Is idiopathic parkinsonism the consequence of an event or a process ? |
| 000F09 |
O. Yasuhara [Canada] ; T. Kawamata ; Y. Aimi ; E. G. Mcgeer ; P. L. Mcgeer | Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases |
| 000F10 |
P. J. Blanchet [Canada] ; R. Boucher [Canada] ; P. J. Bedard | Excitotoxic lateral pallidotomy does not relieve L-DOPA-induced dyskinesia in MPTP parkinsonian monkeys |
| 000F13 |
W. D. Hutchison [Canada] ; A. M. Lozano ; K. D. Davis [Canada] ; J. A. Saint-Cyr ; A. E. Lang ; J. O. Dostrovsky | Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients |
| 000F14 |
A. Beuter [Canada] ; D. Mergler [Canada] ; A. De Geoffroy [Canada] ; L. Carriere [Canada] ; S. Belanger [Canada] ; L. Varghese [Canada] ; J. Sreekumar [Canada] ; S. Gauthier | Diadochokinesimetry : a study of patients with Parkinson's disease and manganese exposed workers |
| 000F15 |
M. Huberman [Canada] ; M. Moscovitch ; M. Freedman [Canada] | Comparison of patients with Alzheimer's and Parkinson's disease on different explicit and implicit tests of memory |
| 000F18 |
C. Hertzman [Canada] ; M. Wiens ; B. Snow ; S. Kelly ; D. Calne | A case-control study of Parkinson's disease in a horticultural region of British Columbia |
| 000F19 |
D. B. Calne [Canada] | Treatment of Parkinson's disease |
| 000F21 |
S. Weissenborn [Canada] | The effect of using a two-step verbal cue to a visual target above eye level on the Parkinsonian gait : a case study |
| 000F22 |
A. Gjedde [Canada] ; G. C. Leger ; P. Cumming ; Y. Yasuhara ; A. C. Evans ; M. Guttman ; H. Kuwabara | Striatal L-DOPA decarboxylase activity in Parkinson's disease in vivo : implications for the regulation of dopamine synthesis |
| 000F26 |
M. S. Pollanen [Canada] ; D. W. Dickson ; C. Bergeron | Pathology and biology of the Lewy body |
| 000F27 |
R. J. Uitti [Canada] ; D. B. Calne | Pathogenesis of idiopathic parkinsonism |
| 000F28 |
K. M. Semchuk [Canada] ; E. J. Love [Canada] ; R. G. Lee | Parkinson's disease : a test of the multifactorial etiologic hypothesis |
| 000F33 |
D. S. Borrett [Canada] ; T. H. Yeap ; H. C. Kwan | Neural networks and Parkinson's disease |
| 000F34 |
E. A. Roy [Canada] ; J. Saint-Cyr ; A. Taylor ; A. Lang | Movement sequencing disorders in Parkinson's disease |
| 000F35 |
J. C. Chen [Canada] ; P. A. Hardy ; W. Kucharczyk [Canada] ; M. Clauberg ; J. G. Joshi ; A. Vourlas [Canada] ; MADHU DHAR ; R. M. Henkelman | MR of human postmortem brain tissue : correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease |
| 000F36 |
M. Takada [Canada] ; T. Sugimoto ; T. Hattori [Canada] | MPTP neurotoxicity to cerebellar Purkinje cells in mice |
| 000F37 |
I. Tooyama [Canada] ; T. Kawamata [Canada] ; D. Walker [Canada] ; T. Yamada [Canada] ; K. Hanai ; H. Kimura ; M. Iwane ; K. Igarashi ; E. G. Mcgeer [Canada] ; P. L. Mcgeer [Canada] | Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease |
| 000F39 |
B. J. Snow [Canada] ; I. Tooyama ; E. G. Mcgeer [Canada] ; T. Yamada ; D. B. Calne [Canada] ; H. Takahashi [Canada] ; H. Kimura | Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels |
| 000F40 |
A. Beuter [Canada] ; J. Belair ; C. Labrie | Feedback and delays in neurological diseases: a modeling study using dynamical systems |
| 000F42 |
A. H. Rajput [Canada] | Environmental causation of Parkinson's disease |
| 000F44 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; C. Gagnon ; T. Di Paolo ; R. Markstein ; P. J. Bedard | Effect of adding the D1 agonist CY 208-243 to chronic bromocriptine treatment. I: Evaluation of motor parameters in relation to striatal catecholamine content and dopamine receptors |
| 000F46 |
B. D. Pate [Canada] ; T. Kawamata ; T. Yamada ; E. G. Mcgeer [Canada] ; K. A. Hewitt [Canada] ; B. J. Snow [Canada] ; T. J. Ruth [Canada] ; D. B. Calne [Canada] | Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices |
| 000F49 |
R. W. Lam [Canada] | Chronic schizophrenia and idiopathic Parkinson's disease |
| 000F50 |
C. Gagnon [Canada] ; B. Gomez-Mancilla ; P. J. Bedard ; T. Di Paolo [Canada] | Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors |
| 000F51 |
R. Quirion [Canada] | Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release |
| 000F52 |
A. P. Sen [Canada] ; P. Boksa ; R. Quirion | Brain calcium channel related dihydropyridine and phenylalkylamine binding sites in Alzheimer's, Parkinson's and Huntington's diseases |
| 000F54 |
K. Mizukawa [Canada] ; E. G. Mcgeer ; P. L. Mcgeer | Autoradiographic study on dopamine uptake sites and their correlation with dopamine levels and their striata from patients with Parkinson disease, alzheimer disease, and neurologically normal controls |
| 000F55 |
J. Poirier [Canada] ; C. Thiffault | Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease ? |
| 000F56 |
A. H. Rajput [Canada] ; B. Rozdilsky ; A. Rajput | Alzheimer's disease and idiopathic Parkinson's disease coexistence |
| 000F57 |
M. Guttman [Canada] ; G. Leger ; A. Reches ; A. Evans ; H. Kuwabara ; J. M. Cedarbaum ; A. Gjedde | Administration of the new COMT inhibitor OR-611 increases striatal uptake of fluorodopa |
| 000F59 |
L. Rioux [Canada] ; C. Gagnon ; D. P. Gaudin [Canada] ; T. Di Paolo ; P. J. Bedard [Canada] | A fetal nigral graft prevents behavioral supersensitivity associated with repeated injections of L-dopa in 6-OHDA rats. Correlation with D1 and D2 receptors |
| 000F60 |
H. Hoshi [Canada] ; H. Kuwabara ; G. Leger ; P. Cumming ; M. Guttman ; A. Gjedde | 6-[18F]fluoro-L-DOPA metabolism in living human brain : a comparison of six analytical methods |
| 000F61 |
| 3 rd Canadian conference on neurodegenerative diseases, L'Estérel PQ, April 4-6, 1991 |
| 000F63 |
A. Beuter [Canada] ; L. Carriere ; B. Mcfayden ; S. Gauthier | The organization of stepping in patients with Parkinson's disease : bradykinesia or discoordination ? |
| 000F64 |
D. B. Calne [Canada] | The nature of Pakinson's disease |
| 000F65 |
D. B. Calne [Canada] | The free radical hypothesis in idiopathic Parkinsonism : evidence against it |
| 000F66 |
G. Le Dorze [Canada] ; L. Dionne ; J. Ryalls ; M. Julien ; L. Quellet | The effects of speech and language therapy for a case of dysarthria associated with Parkinson's disease |
| 000F67 |
J. Starkes [Canada] ; C. Riach ; B. Clarke | The effect of eye closure on postural sway : converging evidence from children and a Parkinson patient |
| 000F68 |
M. Schulzer [Canada] ; E. Mark ; D. B. Calne | The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic |
| 000F70 |
H. A. Robertson [Canada] ; M. R. Peterson ; G. G. Worth | Synergistic and persistent interaction between the D2 agonist, bromocriptine, and the D1 selective agonist, CY 208-243 |
| 000F73 |
R. Chen [Canada] ; P. Ashby ; A. E. Lang | Stimulus-sensitive myoclonus in akinetic-rigid syndromes |
| 000F74 |
J. Kalra [Canada] ; A. H. Rajput ; S. V. Mantha ; K. Prasad | Serum antioxidant enzyme activity in Parkinson's disease |
| 000F77 |
G. L.-Y. Chan [Canada] ; K. Scott Morrison ; J. E. Holden ; T. J. Ruth | Plasma L-[18F]6-Fluorodopa input function : a simplified method |
| 000F78 |
L. C. Doering [Canada] | Peripheral nerve segments promote consistent long-term survival of adrenal medulla transplants in the brain |
| 000F79 |
A. Tabatabaei [Canada] ; T. L. Perry ; S. Hansen ; C. Krieger | Partial protective effect of MK-4801 on MPTP-induced reduction of striatal dopamine in mice |
| 000F80 |
K. M. Semchuk [Canada] ; E. J. Love ; R. G. Lee | Parkinson's disease and exposure to agricultural work and pesticide chemicals |
| 000F81 |
J. Kalra [Canada] ; A. H. Rajput ; S. V. Mantha ; A. K. Chaudhary ; KAILASH PRASAD | Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease |
| 000F82 |
E. Mohr [Canada] ; U. M. Mann ; R. S. Miletich ; M. Sampson ; T. E. Godberg ; J. D. Grimes ; T. N. Chase | Neuropsychological and glucose metabolic profiles in asymmetric Parkinson's disease |
| 000F83 |
T. Yamada [Canada] ; P. L. Mcgeer ; E. G. Mcgeer | Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins |
| 000F85 |
B. Lavoie [Canada] ; P.-Y. Cote ; A. Parent | Immunohistochemical study of the basal ganglia in normal and Parkinsonian monkeys |
| 000F88 |
E. Pourcher [Canada] ; B. Gomez-Mancilla ; P. J. Bedard | Ethosuximide and tremor in Parkinson's disease : a pilot study |
| 000F89 |
B. Gomez-Mancilla [Canada] ; J.-F. Latulippe ; R. Boucher ; P. J. Bedard | Effect of ethosuximide on rest tremor in the MPTP monkey model |
| 000F90 |
S. Pare [Canada] ; S. I. Barr ; S. E. Ross | Effect of daytime protein restriction on nutrient intakes of free-living Parkinson's disease patients |
| 000F91 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys |
| 000F92 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of Parkinsonism |
| 000F93 |
M. Guttman [Canada] | Dopamine receptors in Parkinson's disease |
| 000F94 |
M. S. Pollanen [Canada] ; C. Bergeron ; L. Weyer | Detergent-insoluble cortical lewy body fibrils share epitopes with neurofilament and τ |
| 000F95 |
J. L. Cummings [Canada] | Depression and Parkinson's disease : a review |
| 000F97 |
M. L. Paul [Canada] ; A. M. Graybiel ; J.-C. David ; H. A. Robertson [Canada] | D1-like and D2-like dopamine receptors synergistically actitave rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease |
| 000F98 |
D. B. Calne [Canada] ; B. J. Snow ; C. Lee | Criteria for diagnosing Parkinson's disease |
| 000F99 |
I. Aubert [Canada] ; D. M. Araujo ; D. Cecyre ; Y. Robitaille ; S. Gauthier ; R. Quirion | Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's diseases |
| 001000 |
R. F. Peppard [Canada] ; R. Wayne Martin [Canada] ; G. D. Carr ; E. Grochowski ; M. Schulzer [Canada] ; M. Guttman [Canada] ; P. L. Mcgeer ; A. G. Phillips ; J. K. C. Tsui [Canada] ; D. B. Calne [Canada] | Cerebral glucose metabolism in Parkinson's disease with and without dementia |
| 001001 |
B. Lach [Canada] ; D. Grimes ; B. Benoit ; A. Minkiewicz-Janda | Caudate nucleus pathology in Parkinson's disease : ultrastructural and biochemical findings in biopsy material |
| 001002 |
S. G. Adams [Canada] ; A. E. Lang | Can the Lombard effect be used to improve low voice intensity in Parkinson's disease? |
| 001004 |
E. G. Mcgeer [Canada] ; E. A. Singh | Angiotensin-converting enzyme in cortisal tissue in Alzheimer's and some other neurological diseases |
| 001007 |
S. J. Kish [Canada] ; K. Shannak ; A. Rajput ; J. H. N. Deck ; O. Hornykiewicz | Aging produces a specific pattern of striatal dopamine loss : implications for the etiology of idopathic Parkinson's disease |
| 001008 |
A. J. Flint [Canada] ; S. E. Black ; I. Campbell-Taylor ; G. F. Gailey ; C. Levinton | Acoustic analysis in the differentiation of Parkinson's disease and major depression |
| 001010 |
M. Cordes [Canada] ; B. J. Snow ; H. Takahashi ; P. Schofield ; S. Cooper ; V. Sossi ; S. Morrison ; D. B. Calne | L-18F-DOPA-PET bei Parkinson-Plus-Syndromen zum Nachweis einer gestörten präsynaptischen dopaminergen Funktion |
| 001011 |
S. Bagley [Canada] ; B. Kelly ; N. Tunnicliffe ; G. I. Turnbull ; J. M. Walker | The effect of visual cues on the gait of independently mobile Parkinson's disease patients |
| 001012 |
H. B. Niznik ; E. F. Fogel ; F. F. Fassos ; P. Seeman | The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus |
| 001013 |
R. Rivest ; S. St-Pierre ; F. B. Jolicoeur | Structure-activity studies of neurotensin on muscular rigidity and tremors induced by 6-hydroxydopamine lesions in the posterolateral hypothalamus of the rat |
| 001015 |
W. G. Tatton [Canada] ; C. E. Greenwood | Rescue of dying neurons : a new action for deprenyl in MPTP parkinsonism |
| 001017 |
M. H. Bhatt ; B. J. Snow ; W. R. Wayne Martin ; B. D. Pate ; D. B. Calne | Positron emission tomography suggests that the rate of progression of idiopthic parkinsonism is slow |
| 001018 |
K. M. Semchuk [Canada] ; E. J. Love ; R. G. Lee | Parkinson's disease and exposure to rural environmental factors : a population based case-control study |
| 001019 |
J. A. Jesberger ; J. S. Richardson | Oxygen free radicals and brain dysfunction |
| 001020 |
A. H. Rajput [Canada] ; B. Rozdilsky ; L. Ang | Occurrence of resting tremor in Parkinson's disease |
| 001021 |
D. B. Calne [Canada] | Neurotoxins and degeneration in the central nervous system |
| 001024 |
J. C. S. Furtado [Canada] ; M. F. Mazurek | MPTP-induced neurotoxicity and the quest for a preventative therapy for Parkinson's disease |
| 001026 |
F. B. Jolicoeur [Canada] ; R. Rivest ; A. Drumheller | Hypokinesia, rigidity, and tremor induced by hypothalamic 6-OHDA lesions in the rat |
| 001028 |
J. Poirier [Canada] ; S. Kogan ; S. Gauthier | Environment, genetics and idiopathic Parkinson's disease |
| 001029 |
M. Filion ; L. Tremblay ; P. J. Bedard | Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism |
| 001030 |
B. Gomez-Mancilla [Canada] ; R. Boucher ; P. J. Bedard | Effect of clonidine and atropine on rest tremor in the MPTP monkey model of parkinsonism |
| 001031 |
B. Gomez-Mancilla [Canada] ; P. J. Bedard | Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-DOPA in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys |
| 001032 |
O. S. Kofman [Canada] | Deprenyl : protective vs. symptomatic effect |
| 001033 |
D. B. Calne ; M. J. Zigmond | Compensatory mechanisms in degenerative neurologic diseases : insights from Parkinsonism |
| 001037 |
F. B. Jolicoeur ; R. Rivest ; S. St.-Pierre ; A. Drumheller | Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats |
| 001038 |
E. Keller [Canada] ; P. Vigneux ; M. Laframboise | Acoustic analysis of neurologically impaired speech |
| 001039 |
A. H. Rajput [Canada] ; B. Rozdilsky ; A. Rajput | Accuracy of clinical diagnosis in Parkinsonism―A prospective study |
| 001040 |
M. Filion ; L. Tremblay | Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism |
| 001041 |
J. Zayed ; P. Andre ; J. C. Panisset ; S. Ducic ; G. Campanella ; M. Roy ; G. Kennedy ; C. Delisle | Contamination environnementale par les métaux et maladie de Parkinson |
| 001042 |
A. J. Lewis ; M. J. Gawel | diffuse lewy body disease with dementia and oculomotor dysfunction |
| 001043 |
S. J. Kish ; L. M. Distefano ; S. Dozic ; Y. Robitaille ; A. Rajput ; J. H. N. Deck ; O. Hornykiewicz | [3H]vesamicol binding in human brain cholinergic deficiency disorders |
| 001045 |
A. Fine | Transplantation of adrenal tissue into the central nervous system |
| 001048 |
N. R. C. Campbell ; D. Rankine ; A. E. Goodridge ; B. B. Hasinoff ; M. Kara | Sinemet-ferrous sulphate interaction in patients with Parkinson's disease |
| 001050 |
M. H. Bhatt ; B. J. Snow ; W. R. W. Martin ; S. Cooper ; D. B. Calne | Positron emission tomography in Shy-Drager syndrome |
| 001052 |
C. Hertzman [Canada] ; M. Wiens ; D. Bowering ; B. Snow ; D. Calne | Parkinson's disease: a case-control study of occupational and environmental risk factors |
| 001053 |
M. Freedman | Object alternation and orbitofrontal system dysfunction in Alzheimer's and Parkinson's disease |
| 001054 |
D. Pare ; R. Curro'Dossi ; M. Steriade | Neuronal basis of the Parkinsonian resting tremor : a hypothesis and its implications for treatment |
| 001055 |
E. R. Vriezen [Canada] ; M. Moscovitch | Memory for temporal order and conditional associative-learning in patients with Parkinson's disease |
| 001056 |
A. E. Taylor ; J. A. Saint-Cyr ; A. E. Lang | Memory and learning in early Parkinson's disease : evidence for a frontal lobe syndrome |
| 001058 |
M. Guttman ; H. C. Fibiger ; A. Jakubovic ; D. B. Calne | Intracarotid 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration: biochemical and behavioral observations in a primate model of hemiparkinsonism |
| 001060 |
R. Turcotte ; C. Godin ; R. Duchesne ; A. Jodoin | Hip fractures and Parkinson's disease : a clinical review of 94 fractures treated surgically |
| 001061 |
L. W. Svenson | Geographic distribution of deaths due to Parkinson's disease in Canada : 1979-1986 |
| 001062 |
J. Zayed ; S. Ducic ; G. Companella ; J. C. Panisset ; P. Andre ; H. Masson ; M. Roy | Facteurs environnementaux dans l'étiologie de la maladie de Parkinson |
| 001063 |
C. Rouillard ; P. J. Bedard ; T. Di Paolo | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393 |
| 001064 |
C. Gagnon ; P. J. Bedard ; T. Di Paolo | Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists |
| 001065 |
R. T. Ross | Drug-induced Parkinsonism and other movement disorders |
| 001067 |
P. Seeman ; H. B. Niznik | Dopamine receptors and transporters in Parkinson's disease and schizophrenia |
| 001069 |
A. Beuter [Canada] ; J. G. Milton ; C. Labrie ; L. Glass ; S. Gauthier | Delayed visual feedback and movement control in Parkinson's disease |
| 001070 |
J. K. C. Tsui ; R. F. Peppard ; K. C. Petruk ; G. Allen ; R. S. Burns ; D. B. Calne | Decreased efficay of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants |
| 001071 |
C. Harnois ; T. Di Paolo | Decreased dopamine in the retinas of patients with Parkinson's disease |
| 001072 |
R. F. Peppard ; W. R. W. Martin ; C. M. Clark ; G. D. Carr ; P. L. Mcgeer ; D. B. Calne | Cortical glucose metabolism in Parkinson's and Alzheimer's disease |
| 001073 |
T. Yamada ; H. Akiyama ; P. L. Mcgeer | Complement-activated oligodendroglia : a new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d |
| 001074 |
E. C. Wolters ; T. A. Hurwitz ; E. Mak ; P. Teal ; F. R. Peppard ; R. Remick ; S. Calne ; D. B. Calne | Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis |
| 001075 |
A. E. Lang ; D. E. Riley ; L. Vachon ; X. Lataste | CQA 206-291 in Parkinson's disease : an acute single escalating dosage study |
| 001078 |
D. B. Calne | Is «Parkinson's disease» one disease? |
| 001081 |
VOON WEE YONG ; M. Guttman ; S. U. Kim ; D. B. Calne ; I. Turnbull ; K. Watabe ; R. W. W. Tomlinson | Transplantation of human sympathetic neurons and adrenal chromaffin cells into parkinsonian monkeys: no reversal of clinical symptoms |
| 001082 |
J. K. Tsui ; S. Ross ; K. Poulin ; J. Douglas ; D. Postnikoff ; S. Calne ; W. Woodward ; D. B. Calne | The effect of dietary protein on the efficacy of L-dopa: a double-blind study |
| 001083 |
M. Freedman ; M. Oscar-Berman | Spatial and visual learning deficits in Alzheimer's and Parkinson's disease |
| 001084 |
W. G. Vincken ; C. M. Darauay ; M. G. Cosio | Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease |
| 001085 |
L. Tremblay ; M. Filion ; P. J. Bedard | Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism |
| 001086 |
R. J. Uitti ; A. H. Rajput ; B. Rozdilsky ; M. Bickis ; T. Wollin ; W. K. Yuen | Regional metal concentrations in Parkinson1s disease, other chronic neurological diseases, and control brains |
| 001087 |
E. C. Wolters ; C.-C. Huang ; C. Clark ; R. F. Peppard ; J. Okada ; N.-S. Chu ; M. J. Adam ; T. J. Ruth ; D. Li ; D. B. Calne | Positron emission tomography in manganese intoxication |
| 001089 |
A. H. Rajput ; R. J. Uitti ; S. Sudhakar ; B. Rozdilsky | Parkinsonism and neurofibrillary tangle pathology in pigmented nuclei |
| 001090 |
M. Guttman ; R. S. Burns ; W. R. W. Martin ; R. F. Peppard ; M. J. Adam ; T. J. Ruth ; G. Allen ; R. A. Parker ; N. B. Tulipan ; D. B. Calne | PET studies of Parkinsonian patients treated with autologous adrenal implants |
| 001091 |
H. Teravainen ; J. K. C. Tsui ; E. Mak ; D. B. Calne | Optimal indices for testing parkinsonian rigidity |
| 001093 |
G. S. Robertson ; D. G. Herrera ; M. Dragunow ; H. A. Robertson | L-DOPA activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra |
| 001094 |
D. Riley ; A. E. Lang ; R. D. G. Blair ; A. Birnbaum ; B. Reid | Frozen shoulder and other shoulder disturbances in Parkinson's disease |
| 001096 |
P. J. Bedard ; R. Boucher | Effect of D1 receptor stimulation in normal and MPTP monkeys |
| 001097 |
C. Harnois ; G. Marcotte ; T. Di Paolo | Different sensitivities to MPTP toxicity in primate nigrostriatal and retinal dopaminergic systems: electrophysiological and biochemical evidence |
| 001098 |
S. M. Schnider ; R. H. Kwong ; F. A. Lenz ; H. C. Kwan | Detection of feedback in the central nervous system using system identification techniques |
| 001099 |
J. G. Milton ; A. Longtin ; A. Beuter ; M. C. Mackey ; L. Glass | Complex dynamics and bifurcations in neurology |
| 001100 |
E. C. Wolters ; T. A. Hurwitz ; R. F. Peppard ; D. B. Calne | Clozapine: an antipsychotic agent in Parkinson's disease? |
| 001103 |
T. A. Cox ; J. V. Mcdarby ; L. Lavine ; J. C. Steele ; D. B. Calne | A retinopathy on Guam with high prevalence in Lytico-Bodig |
| 001104 |
J. K. C. Tsui ; E. C. Wolters ; R. F. Peppard ; D. B. Calne | A double-blind, placebo-controlled, dose-ranging study to investigate the safety and efficacy of CY 208-243 in patients with Parkinson's disease |
| 001105 |
S. J. Kish ; K. Shannak ; O. Hornykiewicz | Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications |
| 001106 |
T. A. Hurwitz ; D. B. Calne ; K. Waterman | Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy |
| 001108 |
T. L. Perry ; K. Jones ; S. Hansen | Tetrahydroisoquinoline lacks dopaminergic nigrostriatal neurotoxicity in mice |
| 001110 |
F. A. Lenz ; R. R. Tasker ; H. C. Kwan ; S. Schnider ; R. Kwong ; Y. Murayama ; J. O. Dostrovsky ; J. T. Murphy | Single unit analysis of the human ventral thalamic nuclear group: correlation of thalamic "tremor cells" with the 3-6 Hz component of Parkinsonian tremor |
| 001112 |
M. Pisa | Regional specialization of motor functions in the rat striatum: implications for the treatment of parkinsonism |
| 001113 |
P. L. Mcgeer ; S. Itagaki ; B. E. Boyes ; E. G. Mcgeer | Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains |
| 001114 |
P. L. Mcgeer ; S. Itagaki ; H. Akiyama ; E. G. Mcgeer | Rate of cell death in parkinsonism indicates active neuropathological process |
| 001115 |
J. A. Saint-Cyr ; A. E. Taylor ; A. E. Lang | Procedural learning and neostriatal dysfunction in man |
| 001116 |
J. D. Grimes ; M. N. Hassan ; J. H. Thakar | Prevention of progression of Parkinson's disease with antioxidative therapy |
| 001117 |
D. Riley ; A. E. Lang | Practical application of a low-protein diet for Parkinson's disease |
| 001120 |
M. W. Rogers ; C. W. Y. Chan | Motor planning is impaired in Parkinson's disease |
| 001121 |
D. B. Calne ; A. J. Lees | Late progression of post encephalitic Parkinson's syndrome |
| 001122 |
A. E. Taylor ; J. A. Saint-Cyr ; A. E. Lang | Idiopathic Parkinson's disease: revised concepts of cognitive and affective status |
| 001123 |
M. N. Hassan ; J. H. Thakar | Dopamine receptors in Parkinson's disease |
| 001124 |
J. J. Gilbert ; S. J. Kish ; LI-JAN CHANG ; C. Morito ; K. Shannak ; O. Hornykiewicz | Dementia, parkinsonism, and motor neuron disease: neurochemical and neuropathological correlates |
| 001126 |
P. Falardeau ; S. Bouchard ; P. J. Bedard ; R. Boucher ; T. Di Paolo | Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2dopamine agonists in MPTP monkeys |
| 001127 |
J. P. Hunter ; P. Ashby ; A. E. Lang | Afferent contributing to the exaggerated long latency reflex response to electrical stimulation in Parkinson's disease |
| 001128 |
R. J. Riopelle | Adrenal medulla autografts in Parkinson's disease: a proposed mechanism of action |
| 001129 |
M. Filion ; L. Tremblay ; P. J. Bedard | Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys |
| 001130 |
E. C. Wolters ; J. C. Kebabian ; M. Guttman ; E. Mak ; B. D. Pate ; D. B. Calne | A new device for the quantitative assessment of dopaminergic drug effects in unilateral MPTP-lesioned monkeys |
| 001131 |
T. L. Perry ; K. Jones ; S. Hansen ; R. A. Wall | 2-Phenylpyridine and 3-phenylpyridine, constituents of tea, are unlikely to cause idiopathic Parkinson's disease |
| 001132 |
J. H. Thakar ; M. N. Hassan ; J. D. Grimes | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), its metabolite cyperquat (MPP+) and energy transduction in mitochondria from rat striatum and liver |
| 001134 |
E. Keller | Mesures ultrasoniques des mouvements du dos de la langue en production de la parole: aspects cliniques |
| 001135 |
T. L. Perry ; VOON WEE YONG ; S. Hansen ; K. Jones ; C. Bergeron ; J. G. Foulks ; J. M. Wright | α-Tocopherol and β-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 001137 |
M. Freedman ; M. Oscar-Berman | Tactile discrimination learning deficits in Alzheimer's and Parkinson's diseases |
| 001138 |
J. A. Sharpe ; W. A. Fletcher ; A. E. Lang ; D. H. Zackon | Smooth pursuit during dose-related on-off fluctuations in Parkinson's disease |
| 001139 |
A. A. F. Sima ; G. Hoag ; B. Rozdilsky | Shy-Drager syndrome: the transitional variant |
| 001141 |
M. M. Finkelstein ; G. M. Liss | Selection bias in occupational case-control studies that use death registries to select subjects: a discussion and demonstration |
| 001142 |
A. E. Lang | Restless legs syndrome and Parkinson's disease: insights into pathophysiology |
| 001144 |
A. E. Taylor ; J. A. Saint-Cyr ; A. E. Lang | Parkinson's disease: cognitive changes in relation to treatment response |
| 001145 |
D. Regan ; C. Maxner | Orientation-selective visual loss in patients with Parkinson's disease |
| 001146 |
A. E. Lang | Manipulating the dopaminergic system in Parkinson's disease |
| 001147 |
H. A. Robertson ; G. S. Robertson | Hypothesis. Combined L-dopa and bromocriptine therapy for Parkinson's disease: a proposed mechanism of action |
| 001148 |
S. Calne ; B. Schoenberg ; W. Martin ; R. J. Uitti ; P. Spencer ; D. B. Calne | Familial Parkinson's disease: possible role of environmental factors |
| 001149 |
T. L. Perry ; S. Hansen ; K. Jones | Exposure to cigarette smoke does not decrease the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice |
| 001150 |
J. Poirier ; A. Barbeau | Erythrocyte antioxidant activity in human patients with Parkinson's disease |
| 001153 |
J. M. Radke ; P. Cumming ; S. R. Vincent | Effects of MPTP poisoning on central somatostatin and substance P levels in the mouse |
| 001154 |
A. Barbeau ; M. Roy ; G. Bernier ; G. Campanella ; S. Paris | Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas |
| 001156 |
J. D. S. Mckean ; P. B. R. Allen ; L. J. Filipow ; J. D. R. Miller | CT guided functional stereotaxic surgery |
| 001157 |
D. Kimura ; A. Hahn ; H. J. M. Barnett | Attentional and perseverative impairment in two cases of familial fatal Parkinsonism with cortical sparing |
| 001158 |
A. E. Lang ; K. Johnson | Akathisia in idiopathic Parkinson's disease |
| 001159 |
I. Libman ; M. J. Gawel ; R. J. Riopelle ; S. Bouchard | A comparison of bromocriptine (Parlodel®) and levodopa-carbidopa (Sinemet®) for treatment of "De Novö Parkinson's disease patients |
| 001160 |
A. H. Rajput ; K. P. Offord ; C. M. Beard ; L. T. Kurland | A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease |
| 001161 |
T. L. Perry ; K. Jones ; S. Hansen ; R. A. Wall | 4-phenylpyridine and three other analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lack dopaminergic nigrostriatal neurotoxicity in mice and marmosets |
| 001162 |
| Proceedings/Systems approach in Vision. Workshop, Amsterdam, 26-29 August 1984 |
| 001164 |
H. Teravainen ; L. Forgach ; M. Hietanen ; M. Schulzer ; B. Schoenberg ; D. B. Calne | The age of onset of Parkinson's disease: etiological implications |
| 001167 |
C. B. Bozek ; O. Suchowersky ; S. Purves ; S. Calne ; D. B. Calne | Sinemet in Parkinson's disease: efficacy with and without food |
| 001168 |
M. Freedman ; M. Oscar-Berman | Selective delayed response deficits in Parkinson's and Alzheimer's disease |
| 001170 |
T. L. Perry ; VOON WEE YONG ; R. A. Wall ; K. Jones | Paraquat and two endogenous analogues of the neurotoxic substance N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine do not damage dopaminergic nigrostriatal neurons in the mouse |
| 001171 |
T. Di Paolo ; P. Bedard ; M. Daigle ; R. Boucher | Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys |
| 001172 |
J. H. Moss ; D. E. Stewart | Iatrogenic Parkinsonism in Huntington's chorea |
| 001173 |
H. Kamo ; S. U. Kim ; P. L. Mcgeer ; D. H. Shin | Functional recovery in a rat model of Parkinson's disease following transplantation of cultured human sympathetic neurons |
| 001174 |
A. E. Taylor ; J. A. Saint-Cyr ; A. E. Lang | Frontal lobe dysfunction in Parkinson's disease |
| 001175 |
J. Kish ; A. Rajput ; J. Gilbert ; B. Rozdilsky ; L.-J. Chang ; K. Shannak ; O. Hornykiewicz | Elevated γ-aminobutyric acid level in striatal but not extrastriatal brain regions in Parkinson's disease: correlation with striatal dopamine loss |
| 001176 |
E. Lau ; K. Waterman ; R. Glover ; M. Schulzer ; D. B. Calne | Effect of antacid on levodopa therapy |
| 001177 |
A. H. Rajput ; R. J. Uitti ; W. Stern ; W. Laverty | Early onset Parkinson's disease in Saskatchewan-environmental considerations for etiology |
| 001178 |
M. Guttman ; P. Seeman ; G. P. Reynolds ; P. Riederer ; K. Jellinger ; W. W. Tourtellotte | Dopamine D2 receptor density remains constant in treated Parkinson's disease |
| 001180 |
C. W. Y. Chan | Could parkinsonian akinesia be attributable to a disturbance in the motor preparatory process? |
| 001184 |
P. J. Bedard ; T. Di Paolo ; P. Falardeau ; R. Boucher | Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys. Correlation with [3H]spiperone binding |
| 001185 |
D. B. Calne ; E. Mcgeer ; A. Eisen ; P. Spencer | Alzheimer's disease, Parkinson's disease, and motoneurone disease: abiotropic interaction between ageing and environment? |
| 001186 |
W. R. W. Martin | Positron emission tomography in movement disorders |
| 001187 |
K. S. Polyzoidis ; J. D. Mc Queen ; A. H. Rajput ; D. J. Mac Fadyen | Parkinsonism as a manifestation of brain tumor |
| 001188 |
R. J. Uitti ; A. H. Rajput ; E. M. Ashenhurst ; B. Rozdilsky | Cyanide-induced parkinsonism: a clinicopathologic report |
| 001189 |
C. J. Gibson ; M. Logue ; J. H. Growdon | CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease |
| 001192 |
D. Regan ; D. Neima | Visual fatigue and visual evoked potentials in multiple sclerosis, glaucoma, ocular hypertension and Parkinson's disease |
| 001193 |
T. A. Larsen ; R. Newman ; P. Lewitt ; D. B. Calne | Severity of Parkinsońs disease and the dosage of bromocriptine |
| 001194 |
D. Regan ; D. Neima | Low-contrast letter charts in early diabetic retinopaphy, ocular hypertension, glaucoma, and Parkinson's disease |
| 001195 |
A. H. Rajput ; K. P. Offord ; C. M. Beard ; L. T. Kurland | Epidemiology of Parkinsonism: incidence, classification, and mortality |
| 001196 |
A. H. Rajput ; W. Stern ; W. H. Laverty | Chronic low-dose levodopa therapy in Parkinsońs disease: an argument for delaying levodopa therapy |
| 001197 |
W. G. Tatton ; W. Bedingham ; M. C. Verrier ; R. D. G. Blair | Characteristic alterations in responses to imposed wrist displacements in parkinsonian rigidity and dystonia musculorum deformans |
| 001198 |
J. D. Grimes ; D. B. King ; O. S. Kofman ; P. Molina-Negro ; A. F. Wilson ; S. Bouchard | Bromocriptine in the management of end of dose deterioration in Parkinson's disease |
